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The Role Of The Central Glp-1 System In Cocaine-Seeking Behavior
Abstract
Cocaine use disorder continues be a significant public health concern with no available FDA-approved
pharmacotherapies despite decades of research focused on treatment and the neurobiological
mechanisms underlying drug addiction. Thus, there remains a critical need for conceptually innovative
approaches toward identifying new medications to treat this disease. Current preclinical literature show
that analogs of the neuroendocrine hormone glucagon-like peptide-1 (GLP-1) have promising clinical
potential, as GLP-1 receptor (GLP-1R) activation reduces the rewarding and reinforcing effects of cocaine
in animal models of drug addiction. To expand our knowledge of the neural circuitry and neurobiological
mechanisms that underly the effects of GLP-1 on cocaine addiction, the research presented in this
doctoral dissertation studies the role of the central GLP-1 system in regulating the reinstatement of
cocaine-seeking behavior, an animal model of relapse. In Chapter 2, I establish that the GLP-1R agonist
exendin-4 reduces cocaine seeking at doses that do not cause adverse side effects and acts on GLP-1Rs
in the ventral tegmental area (VTA). Second, I show that the endogenous central GLP-1 system is
dynamically changed by cocaine self-administration and abstinence. Chapter 3 demonstrates that GLP-1R
activation in the nucleus accumbens (NAc) was sufficient to reduce cocaine seeking. To determine the
effects of NAc GLP-1R activation on neuronal excitability in cocaine-experienced rats, electrophysiological
studies were conducted and found that exendin-4 increased the intrinsic excitability of NAc medium spiny
neurons. Chapter 4 continues to investigate the mechanism of exendin-4 to reduce cocaine seeking and
the involvement of GLP-1R signaling in hindbrain nuclei. Administration of exendin-4 into the laterodorsal
tegmental nucleus (LDTg) was found to decrease cocaine seeking by activating GLP-1Rs on GABAergic
neurons that project to the VTA. Additionally, the ability of GLP-1-producing neurons in the nucleus tractus
solitarius (NTS) to reduce cocaine seeking was examined. Activation of NTS-to-LDTg projections
significantly attenuated cocaine seeking through a GLP-1-mediated mechanism without effecting food
intake or body weight in cocaine-experienced animals. Collectively, this dissertation broadens our
understanding of the neurobiological mechanisms that regulate cocaine seeking and also provides
further evidence for the use of GLP-1 system-targeted therapeutics for treating cocaine use disorder.
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ABSTRACT
THE ROLE OF THE CENTRAL GLP-1 SYSTEM IN COCAINE SEEKING BEHAVIOR
Nicole S. Hernandez
Heath D. Schmidt, Ph.D.

Cocaine use disorder continues be a significant public health concern with no available
FDA-approved pharmacotherapies despite decades of research focused on treatment and
the neurobiological mechanisms underlying drug addiction. Thus, there remains a critical
need for conceptually innovative approaches toward identifying new medications to treat
this disease. Current preclinical literature show that analogs of the neuroendocrine
hormone glucagon-like peptide-1 (GLP-1) have promising clinical potential, as GLP-1
receptor (GLP-1R) activation reduces the rewarding and reinforcing effects of cocaine in
animal models of drug addiction. To expand our knowledge of the neural circuitry and
neurobiological mechanisms that underly the effects of GLP-1 on cocaine addiction, the
research presented in this doctoral dissertation studies the role of the central GLP-1
system in regulating the reinstatement of cocaine-seeking behavior, an animal model of
relapse. In Chapter 2, I establish that the GLP-1R agonist exendin-4 reduces cocaine
seeking at doses that do not cause adverse side effects and acts on GLP-1Rs in the
ventral tegmental area (VTA). Second, I show that the endogenous central GLP-1 system
is dynamically changed by cocaine self-administration and abstinence. Chapter 3
demonstrates that GLP-1R activation in the nucleus accumbens (NAc) was sufficient to
reduce cocaine seeking. To determine the effects of NAc GLP-1R activation on neuronal
excitability in cocaine-experienced rats, electrophysiological studies were conducted and
found that exendin-4 increased the intrinsic excitability of NAc medium spiny neurons.
Chapter 4 continues to investigate the mechanism of exendin-4 to reduce cocaine seeking
and the involvement of GLP-1R signaling in hindbrain nuclei. Administration of exendin-4
iv

into the laterodorsal tegmental nucleus (LDTg) was found to decrease cocaine seeking by
activating GLP-1Rs on GABAergic neurons that project to the VTA. Additionally, the ability
of GLP-1-producing neurons in the nucleus tractus solitarius (NTS) to reduce cocaine
seeking was examined. Activation of NTS-to-LDTg projections significantly attenuated
cocaine seeking through a GLP-1-mediated mechanism without effecting food intake or
body weight in cocaine-experienced animals. Collectively, this dissertation broadens our
understanding of the neurobiological mechanisms that regulate cocaine seeking and also
provides further evidence for the use of GLP-1 system-targeted therapeutics for treating
cocaine use disorder.
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CHAPTER 1: Introduction

Cocaine: A Brief History
Cocaine is derived from the leaves of Erythroxylum coca, a plant that is native to South
America. The leaves of the coca plant have been utilized for thousands of years by native
peoples of the South American region. When the leaves are chewed or brewed for tea,
the effects cause a reduction in appetite and create a mild stimulant effect that reverses
fatigue. However, the power of the coca plant was left largely unexplored in the
Western/European world until cocaine was isolated in 1860 by German scientist Albert
Niemann (Gootenberg, 2008; Goldstein et al., 2009). By the late 1800’s, cocaine was
widely used in medical practice as an anesthetic and in commercial products such as
wines and the famous soft drink, Coca-Cola. Due to an increased awareness of the
addictive properties of cocaine and opioids, the U.S. passed the Harrison Narcotics Act in
1914 which restricted and regulated their distribution (Gootenberg, 2008; Goldstein et al.,
2009). By the 1920’s, the use of cocaine declined but with illegalization, the illicit cocaine
market started to emerge. The demand for cocaine made a rapid resurgence in the 1970’s
with the help of the counterculture movement and the rise of large-scale illegal drug
trafficking. Cocaine use continued to skyrocket into the 1980’s and 1990’s with Americans
spending about 38 billion dollars on cocaine each year (Gootenberg, 2008; Goldstein et
al., 2009). Although cocaine use is not at the same level today as it once was before the
2000’s, cocaine remains the 3rd highest abused illicit drug after marijuana and prescription
opioids and continues to be a significant public health concern (NSDUH, 2018).
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Cocaine Use Disorder
In the United States, approximately 5.9 million Americans (2.2% of the population) aged
12 years or older reported having used cocaine in the past year (NSDUH, 2018). Recent
epidemiological data indicate that the prevalence of cocaine use is increasing (Hughes,
2016). For example, ~2% of all young adults (18-25 years of age) were classified as
current users of cocaine in 2017, the highest rate reported for this age group in the past
10 years (NSDUH, 2018). One hallmark of cocaine use disorder is the high rate of relapse
following detoxification (O'Brien, 1997; Dackis and O'Brien, 2001). Unfortunately, there
are no FDA-approved medications to treat cocaine craving-induced relapse despite
decades of focused preclinical and clinical research that have advanced our
understanding of the anatomical, neurochemical and molecular bases of drug addiction
(O'Brien, 1997; Pierce et al., 2012). Thus, there is a clear need for innovative research
aimed at identifying novel neurobiological mechanisms underlying cocaine addiction and
new therapeutic drug targets to treat this disease.

Animal Models of Cocaine Use Disorder
Preclinical studies utilizing rodent models of addiction-like behaviors are critical towards
identifying molecular substrates that could serve as targets for novel pharmacotherapies
aimed at preventing or reducing relapse in human cocaine addicts. Cocaine craving and
relapse of drug-taking behavior in abstinent human addicts are precipitated by three major
stimuli: stressful life events, re-exposure to environmental cues previously associated with
drug taking, and re-exposure to the previously self-administered drug itself (de Wit and
Stewart, 1981; Jaffe et al., 1989; O'Brien et al., 1992; Sinha et al., 1999). Craving-induced
relapse of drug taking/seeking in humans is typically modeled in laboratory animals as
follows: after a period of drug self-administration and the subsequent extinction of the
drug-reinforced operant behavior, the ability of stress exposure, drug-associated stimuli,
2

or re-exposure to the drug itself to reinstate drug-seeking behavior is assessed (Shalev et
al., 2002; Shaham et al., 2003; Mantsch et al., 2016). For example, after extinction of
cocaine self-administration, administration of relatively low doses of cocaine reinstate
operant responding in the absence of drug reinforcement in both non-human primates and
rodents (Gerber and Stretch, 1975; de Wit and Stewart, 1981; Spealman et al., 1999;
Anderson et al., 2003). As the most commonly used animal model of relapse, the
reinstatement model has proven invaluable for elucidating the neural circuits and
neurobiological mechanisms underlying cocaine-seeking behavior (Schmidt et al., 2005;
Schmidt and Pierce, 2010).

Neurocircuitry Mediating the Rewarding and Reinforcing Efficacy of Cocaine
Cocaine functions, in part, as a non-selective biogenic amine transporter inhibitor that
binds to and inhibits dopamine, serotonin and norepinephrine transporters (Ritz et al.,
1990). Biogenic amine transporters are directly coupled to transmembrane Na +/Clgradients and convey neurotransmitters from the extracellular space into the presynaptic
nerve terminal (Elliott and Beveridge, 2005). Indeed, the primary mechanism by which
dopamine, serotonin and norepinephrine signaling is inactivated in the brain is through
high-affinity transporter-mediated uptake (Elliott and Beveridge, 2005). Thus, cocaine’s
main pharmacological mechanism of action in the brain is to increase extracellular
concentrations of dopamine, norepinephrine and serotonin resulting in enhanced
transmission of these biogenic amines.

Drugs of abuse including cocaine produce their reinforcing effects through actions in the
mesolimbic reward system, a circuit of functionally and anatomically interconnected nuclei
that are responsible for the influence of motivational, emotional, contextual and affective
information on behavior (Pierce and Kumaresan, 2006; Schmidt and Pierce, 2010). Limbic
3

nuclei, including the amygdala, hippocampus, and medial prefrontal cortex (mPFC), send
major glutamatergic projections to the nucleus accumbens (NAc), which functions as a
hub integrating this information with midbrain dopamine innervation that encodes
motivational information pertaining to the rewarding and reinforcing properties of drugs of
abuse (Kelley, 2004). The NAc is broadly divided into two main subregions, the shell and
core (Zahm, 1999). The NAc sends segregated efferent GABAergic projections to the
ventral pallidum and ventral tegmental area (VTA)/substantia nigra (Groenewegen et al.,
1999; Zahm, 1999). Both the ventral pallidum and VTA, in turn send GABAergic efferent
projections to the medial dorsal thalamus. Glutamatergic projections from the medial
dorsal thalamus to the mPFC close this limbic circuit (Alexander and Crutcher, 1990;
Kalivas and Nakamura, 1999; Groenewegen and Uylings, 2000). Dopaminergic neurons
in the VTA innervate the NAc, amygdala, hippocampus, mPFC, and ventral pallidum, and
changes in dopaminergic transmission play a critical role in modulating the flow of
information through the mesolimbic reward system (Wise, 2002; Jay, 2003; Feltenstein
and See, 2008; Bromberg-Martin et al., 2010). Thus, excitatory input from cortical and
subcortical structures to the NAc is filtered and integrated by dopamine-mediated
mechanisms, thereby shaping information output to the basal ganglia (Schmidt and
Pierce, 2010).

Midbrain dopamine neurons exhibit distinctive firing patterns including occasional, highfrequency trains of action potentials known as bursts (Grace and Bunney, 1984; Marinelli
et al., 2006). Bursts of action potentials from midbrain dopamine neurons and their
associated release of dopamine in target nuclei are collectively termed “phasic” dopamine
signaling (Hsu et al., 2018). Phasic burst firing of midbrain dopamine neurons and
subsequent phasic release of dopamine in the NAc are key neurophysiological
mechanisms that implicate mesolimbic dopamine signaling as critical for goal-directed
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behaviors including drug reinforcement (Roitman et al., 2004; Cheer et al., 2007; Day et
al., 2007; Tsai et al., 2009; Schultz, 2013; Sulzer et al., 2016). Phasic mesolimbic
dopamine signaling is thought to reinforce learned associations between predictive stimuli
and primary reward (Schultz, 2007, 2013). Based on a large literature examining reward
prediction error, phasic dopamine is commonly referred to as a “teaching” signal that
functionally regulates motivational aspects of behavior (Hollerman and Schultz, 1998;
Schultz, 2016; Hsu et al., 2018). Phasic dopamine signaling is also believed to play an
important role in the incentive-sensitization theory of addiction (for further review, please
see Robinson and Berridge, 1993; Berridge, 2012; Berridge and Robinson, 2016).

The reinforcing effects of cocaine are primarily dependent upon activation of the
mesolimbic dopamine system (Wise, 1996; Pierce and Kumaresan, 2006; Schmidt and
Pierce, 2006b). Dopaminergic projections from the VTA to limbic nuclei including the NAc
play a critical role in cocaine self-administration and the reinstatement of cocaine-seeking
behavior (Schmidt et al., 2005; Pierce and Kumaresan, 2006; Schmidt et al., 2006;
Schmidt and Pierce, 2006b, a). Additionally, recent studies have begun to examine how
the mesolimbic dopamine system is modulated by downstream nuclei. For example,
regions such as the lateral septum, laterodorsal tegmental nucleus (LDTg), habenula, and
lateral hypothalamus project to the VTA and regulate cocaine-mediated behaviors by
modulating dopamine transmission in midbrain and forebrain nuclei (Schmidt et al., 2009;
Aston-Jones et al., 2010; Sartor and Aston-Jones, 2012; Sotomayor-Zarate et al., 2013;
Lammel et al., 2014; Zapata et al., 2017; Lopez et al., 2018).

In addition to regulating drug craving and relapse, the mesolimbic dopamine system also
plays an important role in regulating the hedonic value of food and consequently behaviors
directed towards the consumption of food (Wise, 2006; Narayanan et al., 2010; Kenny,
5

2011a; DiLeone et al., 2012). Moreover, the neurobiological mechanisms underlying food
intake and drug seeking overlap to a degree (Kenny, 2011b). For example, neuropeptidemediated signaling in the VTA plays a key role in modulating mesolimbic dopamine
transmission and the rewarding properties of both food and drugs of abuse (Kenny, 2011b;
DiLeone et al., 2012). These findings suggest that the same biochemical and molecular
mechanisms that play a role in the control of food intake may also influence voluntary drug
taking and seeking. Indeed, the idea that shared neural mechanisms regulating both food
intake and drug seeking has informed basic science approaches toward identifying novel
pharmacotherapies for drug addiction.

Metabolic Factors Regulate the Mesolimbic Reward System and Food Intake
Identifying endogenous modulators of the mesolimbic reward system may provide new
targets for drug discovery programs aimed at developing novel medications to treat
obesity and substance use disorders (DiLeone et al., 2012; Volkow et al., 2017). Over the
last two decades, it has become clear that peripheral and central homeostatic regulators
of hunger, satiety and body weight interact with and influence the mesolimbic reward
system (Kenny, 2011b; Grill and Hayes, 2012; Williams and Elmquist, 2012). These
metabolic factors regulate the mesolimbic reward system directly by stimulating or
inhibiting VTA dopamine neurons through cognate receptors or indirectly through
downstream nuclei projecting to the VTA (Figlewicz et al., 2003; Hommel et al., 2006;
Skibicka et al., 2011; Alhadeff et al., 2012; Labouebe et al., 2013). Indeed, metabolic
factors such as insulin, leptin, glucagon-like peptide-1, and amylin inhibit VTA dopamine
neurons and decrease food intake (Wang et al., 2015; Volkow et al., 2017). Furthermore,
central administration of both leptin and insulin are known to decrease striatal dopamine
release as well as act directly on dopamine neurons to regulate food intake (McCaleb and
Myers, 1979; Krugel et al., 2003; Hommel et al., 2006; Figlewicz et al., 2007). In contrast,
6

the feeding hormone ghrelin promotes ad libitum food intake through actions on ghrelin
receptors expressed in the VTA and NAc (Naleid et al., 2005; Abizaid et al., 2006). The
effects of ghrelin on mesolimbic dopamine signaling and food intake, however, are
complex. For example, infusions of ghrelin directly into the VTA, but not the NAc, increase
food motivated behaviors (i.e. operant responding for food) adding further complexity to
how the mesoaccumbens dopamine system integrates feeding signals (Skibicka et al.,
2011; Skibicka et al., 2012; Skibicka et al., 2013). These divergent effects may be due to
poly-synaptic connections between feeding-relevant nuclei as infusions of ghrelin directly
into the lateral hypothalamus, but not VTA, potentiate phasic dopamine release in the NAc
in response to food reward and food-predictive cues (Cone et al., 2014; Cone et al., 2015).
Based on their ability to modulate the mesolimbic reward system, it has been hypothesized
that metabolic factors may regulate non-drug motivated behaviors including addiction-like
phenotypes (Hayes and Schmidt, 2016; Jerlhag, 2018).

Glucagon-like Peptide-1 (GLP-1)
Glucagon-like peptide-1 (GLP-1) is an incretin hormone and satiation factor that is
released predominantly from L cells of the small intestine and neurons in the nucleus
tractus solitarius (NTS) of the caudal brainstem (Baggio and Drucker, 2007; Holst, 2007;
Grill and Hayes, 2012). GLP-1 is the primary posttranslational product of the
preproglucagon (PPG) gene (Han et al., 1986; Larsen et al., 1997). PPG-expressing
neurons in the NTS are the primary central source of GLP-1 and these neurons project to
many midbrain and forebrain areas including those implicated in goal-directed behaviors
(e.g., VTA and NAc) (Merchenthaler et al., 1999; Rinaman, 2010; Alhadeff et al., 2012).
Peripheral GLP-1 has a relatively short plasma half-life of ~2 minutes in both humans and
rodents as it is rapidly degraded by the enzyme dipeptidyl peptidase-IV (DPP-IV), which
is highly expressed in tissue compartments throughout the body including the central
7

nervous system (Deacon et al., 1995a; Deacon et al., 1995b; Kieffer et al., 1995; Mentlein,
1999). The GLP-1 receptor (GLP-1R) is a G-protein coupled receptor that is expressed on
both pre- and post-synaptic sites throughout the brain (Merchenthaler et al., 1999; Holst,
2007; Hayes et al., 2011b). The GLP-1R couples to different G proteins, including Gs, Gq,
and Gi subunits, that stimulate or inhibit intra-cellular second messenger systems
(Montrose-Rafizadeh et al., 1999; Hallbrink et al., 2001; Fletcher et al., 2016). However,
most intra-cellular signaling is initiated predominately by Gs subunits (Fletcher et al.,
2016). Studies have shown that activation of GLP-1Rs increases intracellular calcium
levels and activity of downstream signaling molecules such as adenylate cyclase,
phospholipase C (PLC), protein kinase A (PKA), protein kinase C (PKC), phosphoinositide
3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) (Holst, 2007; Hayes et al.,
2011b; Rupprecht et al., 2013).

GLP-1 plays an important role in energy homeostasis and food intake in both humans
(Gutzwiller et al., 1999a; Gutzwiller et al., 1999b) and animal models (Turton et al., 1996;
Barrera et al., 2011). Activation of GLP-1Rs produces a number of physiological
responses including increased insulin secretion from pancreatic -cells, inhibition of
gastric emptying and reduced food intake (Holst, 2007; Lovshin and Drucker, 2009;
Ruttimann et al., 2009; Hayes et al., 2010; Kanoski et al., 2011). With regard to energy
homeostasis, GLP-1R agonists reduce food intake, in part, by activating central GLP-1Rs
(Kanoski et al., 2011; Secher et al., 2014; Sisley et al., 2014). Based on their ability to
regulate blood glucose levels, food intake and body weight, GLP-1R agonists are FDAapproved for the treatment of type II diabetes mellitus (Lovshin and Drucker, 2009) and
obesity (Shukla et al., 2015).
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Of interest to the drug addiction field is a body of research showing that GLP-1R activation
influences the hedonic value of palatable food by direct modulation of the mesolimbic
reward system (Williams and Elmquist, 2012). GLP-1-producing neurons in the NTS send
monosynaptic projections to the VTA and NAc and direct infusions of GLP-1R agonists
into these brain regions have been shown to reduce consumption of palatable food (Schick
et al., 2003; Dossat et al., 2011; Hayes et al., 2011b; Alhadeff et al., 2012; Williams and
Elmquist, 2012; Mietlicki-Baase et al., 2013). Interestingly, some of these studies identified
intra-cranial doses of GLP-1R agonists that selectively reduced intake of palatable food
but not intake of normal chow (Alhadeff et al., 2012; Mietlicki-Baase et al., 2013). These
findings indicate that activation of GLP-1Rs in the mesolimbic reward system selectively
modulates the hedonic value of food and not homeostatic feeding (Hayes and Schmidt,
2016). Given that the reinforcing effects of drugs of abuse, including cocaine, are
regulated by neural circuits that include the VTA and NAc, these findings suggest that
central GLP-1R signaling may also reduce non-feeding motivated behaviors including
drug taking and seeking.

GLP-1Rs in Animal Models of Cocaine Use Disorder
Emerging evidence indicates that GLP-1Rs play an important role in preclinical models of
substance use disorder and that systemic administration of GLP-1R agonists reduces the
rewarding and reinforcing effects of drugs of abuse, including cocaine (Skibicka, 2013;
Engel and Jerlhag, 2014; Hernandez and Schmidt, 2019). For example, peripheral
administration of the GLP-1R agonist exendin-4 (Ex-4) attenuates cocaine conditioned
place preference (CPP) and self-administration in mice and decreases in cocaine-evoked
dopamine release in the NAc (Egecioglu et al., 2013b; Graham et al., 2013; Sorensen et
al., 2015). Additionally, work from our lab has shown that activation of GLP-1Rs in the
VTA decreases cocaine self-administration in rats (Schmidt et al., 2016). However, the
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central mechanisms that mediate the ability of Ex-4 to reduce cocaine-mediated behaviors
are largely unknown. Furthermore, no studies have previously explored the role of the
GLP-1 system to regulate animal models of relapse such as the reinstatement of cocaineseeking behavior. Thus, this dissertation aims to investigate: 1) the ability of Ex-4 to
attenuate the reinstatement of cocaine-seeking behavior and the potential mechanisms
behind this effect; 2) the role of GLP-1Rs in mesolimbic reward nuclei and endogenous
GLP-1 system to regulate cocaine seeking.

The Laterodorsal Tegmental Nucleus (LDTg)
Expanding our knowledge of the circuitry that encompasses the mesolimbic reward
system is crucial for understanding the mechanisms that underly cocaine-mediated
behaviors and how central GLP-1Rs play a role in this system. The LDTg is a hindbrain
nucleus that is a part of the mesopontine tegmentum and is known for its role in arousal
and motivated behaviors (Steriade et al., 1990; Maskos, 2008). The LDTg receives inputs
from the prefrontal cortex, lateral hypothalamus, lateral habenula, interpeduncular
nucleus, VTA, substantia nigra pars compacta, parabrachial nucleus, and NTS (Satoh and
Fibiger, 1986; Cornwall et al., 1990). The LDTg sends projections to the prefrontal cortex,
hippocampus, lateral septum, thalamic nuclei, lateral habenula, lateral hypothalamus,
substantia nigra pars compacta, VTA, interpeduncular nucleus, dorsal and medial raphe,
pedunculopontine tegmental nucleus, parabrachial nucleus, and the NTS (Satoh and
Fibiger, 1986; Cornwall et al., 1990). The neurons in the LDTg are made up of cholinergic,
glutamatergic and GABAergic subtypes. Studies quantifying these cell types in the LDTg
have shown that 40-46% of LDTg neurons are GABAergic expressing glutamic acid
decarboxylase (GAD), 31-38% are glutamatergic neurons expressing the vesicular
glutamate transporter (vGlut2), and ~22% are cholinergic neurons expressing choline
acetyltransferase (ChAT) (Wang and Morales, 2009; Luquin et al., 2018). These are
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primarily distinct neuronal populations as studies have reported very minimal coexpression within these subtypes in the LDTg (Wang and Morales, 2009; Luquin et al.,
2018).

Although GABAergic neurons are the major cell type in the LDTg, the literature regarding
LDTg neurons in reward has focused primarily on the cholinergic and glutamatergic
neurons. The LDTg along with the pedunculopontine tegmental nucleus is the primary
source of cholinergic input into the VTA (Oakman et al., 1995; Mena-Segovia et al., 2008;
Holmstrand and Sesack, 2011). LDTg cholinergic and glutamatergic neurons synapse
directly onto VTA dopamine neurons and studies have shown that these projections are
essential for dopamine burst firing (Omelchenko and Sesack, 2005; Lodge and Grace,
2006; Dautan et al., 2016). Additionally, optogenetic stimulation of LDTg cholinergic or
glutamatergic projections to the VTA induces conditioned place preference (CPP)
providing further evidence that these pathways drive reward (Lammel et al., 2012; Xiao et
al., 2016; Steidl et al., 2017). Moreover LDTg neurons synapse on to VTA-to-NAc
projecting dopamine neurons and LDTg stimulation elicits dopamine release in the NAc
which is blocked by intra-VTA acetylcholine receptor antagonists (Forster and Blaha,
2000; Lammel et al., 2012). Although it is clear that the excitatory LDTg projections to the
VTA promotes reward-related mechanisms and behaviors, there is a paucity of studies
examining LDTg GABAergic neurons in motivated behaviors.

Studies have shown that the excitatory neurons in the LDTg promote both drug-related
and food-driven behaviors (Omelchenko and Sesack, 2005; Lodge and Grace, 2006;
Schmidt et al., 2009; Dickson et al., 2010; Shabani et al., 2010; Dickson et al., 2011;
Jerlhag et al., 2012; Lammel et al., 2012; Shinohara et al., 2014; Steidl et al., 2015; Steidl
et al., 2017). Lesion studies have shown that the LDTg is necessary for the motor
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activating effects of drugs of abuse and increases the latency to self-administer cocaine
(Blaha et al., 1996; Laviolette et al., 2000; Forster et al., 2002; Alderson et al., 2005; Dobbs
and Cunningham, 2014; Steidl et al., 2015). In addition, cocaine exposure increases
presynaptic glutamate release onto LDTg cholinergic neurons and facilitates LDTg
stimulation-induced dopamine release to the NAc (Lester et al., 2010; Kurosawa et al.,
2013). Moreover, pharmacological inhibition of excitatory signaling in the LDTg attenuates
cocaine-mediated behaviors (Schmidt et al., 2009; Shabani et al., 2010; Shinohara et al.,
2014). Specifically, our lab has shown that delivery of a glutamate receptor antagonist in
the LDTg attenuates cocaine priming-induced reinstatement of drug seeking (Schmidt et
al., 2009). While these findings clearly indicate that the LDTg plays an important role in
cocaine-mediated behaviors, the neurobiological mechanisms in the LDTg that function to
regulate drug-seeking behavior must be investigated.

The LDTg expresses receptors for a variety of metabolic hormones, including GLP-1,
amylin, ghrelin, oxytocin, orexin and PYY (Sexton et al., 1994; Merchenthaler et al., 1999;
Parker and Herzog, 1999; Greco and Shiromani, 2001; Gould and Zingg, 2003; Dickson
et al., 2011; Cabral et al., 2013; Reiner et al., 2017; Reiner et al., 2018), some of which
have been studied in the context of motivated behavior. For example, ghrelin
administration into the LDTg increases acetylcholine release in the VTA, resulting in
dopamine release in the NAc and consumption of food (Jerlhag et al., 2007; Dickson et
al., 2010; Dickson et al., 2011; Jerlhag et al., 2012). Alternatively, amylin receptor
activation in the LDTg reduces food intake and the motivation to self-administer highly
palatable foods (Reiner et al., 2017). Additionally, amylin receptors are expressed on
LDTg GABA neurons and the intake suppressive effects of amylin receptor activation are
dependent on GABAergic signaling in the LDTg (Reiner et al., 2017). These findings
suggest that LDTg GABA neurons may act to reduce motivated behaviors. GLP-1Rs in
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the LDTg have also been shown to play an important role in energy balance regulation.
Administration of Ex-4 into the LDTg causes a reduction in cumulative chow intake and
body weight without any effects on nausea/malaise (Reiner et al., 2018). In addition to
exogenously regulating food intake, endogenous GLP-1 signaling in the LDTg also acts
to reduce feeding behaviors. GLP-1-producing neurons from the NTS project directly to
the LDTg and delivery of the GLP-1R antagonist in the LDTg results in an increase in
chow intake and body weight. However, the cell types in the LDTg that mediate the effects
of GLP-1R activation on feeding are unknown. Overall, these data strongly suggest that
GLP-1R signaling in the LDTg may also play an important role in cocaine-seeking
behavior.

The Nucleus Tractus Solitarius (NTS)
The NTS is a brainstem region and an important nucleus in the control of energy balance.
The NTS expresses receptors for a wide variety of peripherally- and centrally-derived
peptides and neurotransmitters which process vagal nerve-mediated gastrointestinal (GI)
satiation factors in addition to blood-borne energy status signals (Grill and Hayes, 2009,
2012). During the ingestion of food, the GI tract releases a number of gut peptides and
neurotransmitters into the bloodstream and on vagal sensory afferents that synapse to the
NTS (Grill and Hayes, 2009, 2012). In turn, the NTS sends projections to a variety of
hindbrain and forebrain areas to control feeding behavior and other aspects of energy
balance control (Grill and Hayes, 2009, 2012). Neurons from the caudal region of the NTS
project to vagal efferent neurons of the dorsal motor nucleus to control for parasympathetic
GI responses including insulin secretion and gastric emptying (Grill and Hayes, 2012). In
addition, they send projections to nuclei within the hindbrain and hypothalamus to control
neuroendocrine and sympathetic efferent responses related to energy expenditure. NTS
neurons from the rostral region project to the parvocellular reticular formation to control
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ingestive consummatory responses (i.e., licking, chewing, swallowing) and project to the
parabrachial nucleus to regulate neuroendocrine responses (Grill and Hayes, 2012).

The caudal portion of the NTS has a heterogenous cell population which include PPGexpressing neurons that project locally within the NTS and throughout the brain to provide
the primary source of central GLP-1 (Rinaman, 2010; Dossat et al., 2011; Alhadeff et al.,
2012; Kanoski et al., 2016; Holt et al., 2019). More recent literature has examined the role
of NTS GLP-1 signaling in regulating non-homeostatic feeding and motivated behaviors.
Viral-mediated knockdown of PPG mRNA expression in the NTS produces hyperphagia
and exacerbates high fat diet-induced obesity, suggesting that a reduction of GLP-1 in the
NTS increases the rewarding value of food (Barrera et al., 2011). Additionally, NTS GLP1R activation has been shown to decrease CPP and intake of palatable foods, and
attenuate progressive ratio responding for sucrose (Alhadeff and Grill, 2014; Richard et
al., 2015). Furthermore, chronic knockdown of NTS GLP-1Rs results in increased chow
intake and meal size as well as increased operant responding for sucrose (Alhadeff et al.,
2016). Moreover, NTS GLP-1-producing neurons have been shown to project to a wide
variety of brain regions that are involved in reward (Figure 1.1) such as the VTA, NAc and
LDTg (Rinaman, 2010; Alhadeff et al., 2012; Reiner et al., 2018). Overall, these studies
suggest that the NTS may regulate motivated behaviors through its projections to the
mesolimbic reward system. However, examination of these circuits in regulating drugmediated behaviors needs to be established.

The NTS has been shown to be modulated by the effects of cocaine. Previous studies
show that acute cocaine exposure increases neuronal activity in the NTS (Grabus et al.,
2004; Zahm et al., 2010; Buffalari and Rinaman, 2014). Our lab expanded these findings
to show that cocaine self-administration increases c-Fos expression in GLP-1-producing
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neurons in the NTS (Schmidt et al., 2016). These data suggest that cocaine-induced
activation of NTS GLP-1-producing neurons may result in increased GLP-1 release in
midbrain and forebrain areas. The mechanisms by which cocaine activates NTS GLP-1producing neurons are not clear but may involve increased corticosterone signaling in the
hindbrain. Since cocaine taking increases plasma and central corticosterone levels
(Goeders and Guerin, 1996; Galici et al., 2000; Mantsch et al., 2000; You et al., 2018) and
peripheral administration of corticosterone increases activation of NTS GLP-1-producing
neurons (Schmidt et al., 2016), it is possible and likely that cocaine self-administration
increases activation of GLP-1-producing neurons in the NTS through a corticosteronemediated mechanism of action. Indeed, administration of corticosterone directly into the
4th ventricle attenuates cocaine self-administration and these effects are blocked by
pharmacological inhibition of GLP-1Rs in the VTA (Schmidt et al., 2016). Taken together,
these findings suggest that the endogenous central GLP-1 system and NTS circuits may
play an important role in regulating cocaine-seeking behavior.

Overview of Dissertation
The current literature thus far suggests that activation of central GLP-1Rs are an important
mechanism to reduce cocaine-mediated behaviors. Therefore, the GLP-1 system may
serve as a novel target for treating cocaine-induced craving and relapse. Due to this
clinical relevance, it is important to characterize the specific circuits, nuclei and cell types
that are activated by GLP-1 and its FDA-approved analogs to regulate addiction-like
behaviors. Thus, this dissertation will investigate the role of GLP-1Rs in three mesolimbic
reward nuclei, the VTA, NAc and LDTg, in cocaine seeking and the mechanisms by which
the GLP-1R agonist Ex-4 decreases cocaine-seeking behavior. This dissertation also aims
to understand how cocaine affects the central GLP-1 system and the role of GLP-1producing NTS circuits in cocaine seeking.
15

Figures

Figure 1.1 NTS PPG neurons innervate nuclei within the mesolimbic reward system
PPG = preproglucagon, LDTg = laterodorsal tegmental nucleus, VTA = ventral tegmental
area, LH = lateral hypothalamus, LS = lateral septum, Amy = amygdala, NAc = nucleus
accumbens.
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Abstract
Novel molecular targets are needed to develop new medications for the treatment of
cocaine addiction. Here, we investigated a role for glucagon-like peptide-1 (GLP-1)
receptors in the reinstatement of cocaine-seeking behavior, an animal model of relapse.
We showed that peripheral administration of the GLP-1 receptor (GLP-1R) agonist
exendin-4 (Ex-4) dose-dependently reduced cocaine seeking in rats at doses that did not
affect ad libitum food intake, meal patterns or body weight. We also demonstrated that
systemic Ex-4 penetrated the brain where it putatively bound receptors on both neurons
and astrocytes in the ventral tegmental area (VTA). The effects of systemic Ex-4 on
cocaine reinstatement were attenuated in rats pretreated with intra-VTA infusions of the
GLP-1R antagonist exendin-(9-39), indicating that the suppressive effects of systemic Ex4 on cocaine seeking were due, in part, to activation of GLP-1Rs in the VTA. Consistent
with these effects, infusions of Ex-4 directly into the VTA reduced cocaine seeking. Finally,
extinction following cocaine self-administration was associated with decreased
preproglucagon mRNA expression in the caudal brainstem. Thus, our study demonstrated
a novel role for GLP-1Rs in the reinstatement of cocaine-seeking behavior and identified
behaviorally-relevant doses of a GLP-1R agonist that selectively reduced cocaine seeking
and did not produce adverse effects.
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Introduction
One hallmark of cocaine addiction is the high rate of relapse to compulsive drug use during
periods of abstinence (Leshner, 1997). Indeed, the most difficult aspect of treating cocaine
addiction is preventing relapse (O'Brien, 1997). Unfortunately, there are currently no
effective FDA-approved treatments for cocaine relapse, which continues to be a significant
public health concern. Thus, there is a clear need to identify and develop novel
pharmacotherapies for cocaine addiction.

Glucagon-like peptide-1 (GLP-1) is an incretin hormone and neuropeptide that is produced
peripherally by intestinal L cells and centrally by preproglucagon (PPG) neurons within the
nucleus tractus solitarius (NTS) of the caudal brainstem (Holst, 2007; Grill and Hayes,
2012). GLP-1 receptor (GLP-1R) ligands are FDA-approved for treating type II diabetes
mellitus and obesity based on their ability to increase insulin production and reduce food
intake (Lovshin and Drucker, 2009; Pi-Sunyer et al., 2015; Shukla et al., 2015; Tella and
Rendell, 2015). In addition, a growing literature indicates that peripheral administration of
GLP-1R agonists attenuates drug-associated behavioral responses including cocaineinduced conditioned place preference (CPP) and the locomotor-activating effects of
cocaine (Skibicka, 2013; Engel and Jerlhag, 2014; Hayes and Schmidt, 2016). However,
no studies to date have examined the efficacy of GLP-1R agonists to reduce the
reinstatement of cocaine-seeking behavior, an animal model of relapse (Shaham et al.,
2003; Epstein et al., 2006).

GLP-1Rs are expressed throughout the brain including the ventral tegmental area (VTA),
a nucleus known to play a critical role in cocaine-seeking behavior (Goke et al., 1995;
Merchenthaler et al., 1999; Schmidt et al., 2005). Our lab recently identified a novel role
for central GLP-1Rs in cocaine self-administration in rats (Schmidt et al., 2016).
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Specifically, we found that activation of GLP-1Rs in the VTA attenuates cocaine selfadministration (Schmidt et al., 2016). While these results suggest that GLP-1Rs may
represent a novel target for cocaine addiction pharmacotherapies, the role of central GLP1 signaling in cocaine seeking is unknown.

The present study had four main goals: 1) to assess the ability of systemic injections of
the GLP-1R agonist exendin-4 (Ex-4) to attenuate the reinstatement of drug-seeking
behavior elicited by an acute priming injection of cocaine or re-exposure to conditioned
cues previously associated with cocaine self-administration; 2) to determine if the effects
of systemic Ex-4 on cocaine seeking are due, in part, to activation of GLP-1Rs in the VTA;
3) to investigate the effects of direct activation of VTA GLP-1Rs on cocaine seeking; and
4) to characterize the effects of cocaine self-administration and subsequent extinction on
GLP-1R mRNA expression in the VTA and PPG mRNA expression in the NTS. Our
findings support the hypothesis that GLP-1R activation is sufficient to attenuate the
reinstatement of cocaine-seeking behavior. Moreover, we identified doses of the GLP-1R
agonist Ex-4 that significantly attenuated cocaine seeking and did not produce adverse
malaise-like effects or reduce feeding behaviors. These results indicate a novel role for
central GLP-1Rs in cocaine-seeking behavior and suggest that pharmacotherapies
targeting GLP-1Rs may represent novel approaches for treating cocaine relapse.
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Materials and Methods
Animals and housing
Male Sprague-Dawley rats (Rattus norvegicus) weighing 225-250 g were obtained from
Taconic Laboratories. Rats were individually housed with food and water available ad
libitum in their home cages. A 12/12 hr light/dark cycle was used with the lights on at 7:00
a.m. All experimental procedures were performed during the light cycle. The experimental
protocols were consistent with the guidelines issued by the U.S. National Institutes of
Health and were approved by the University of Pennsylvania’s Institutional Animal Care
and Use Committee.

Drugs
Cocaine was obtained from the National Institute on Drug Abuse (Rockville, MD) and
dissolved in bacteriostatic 0.9% saline. Ex-4 and exendin-(9-39) were purchased from the
American Peptide Company (Sunnyvale, CA) and were dissolved in artificial cerebrospinal
fluid (aCSF; Harvard Apparatus, Holliston, MA). Fluoro-Ex-4 was purchased from
AnaSpec (Fremont, CA) and dissolved in bacteriostatic 0.9% saline. The doses and time
course of administration for each of the aforementioned pharmacological compounds were
based on the following systemic and intra-cranial microinjection experiments in rats: Ex-4
(Alhadeff et al., 2012; Schmidt et al., 2016), exendin-(9-39) (Alhadeff et al., 2012; Schmidt
et al., 2016) and fluoro-Ex-4 (Kanoski et al., 2012; Reiner et al., 2016).

Surgery
Rats were handled daily and allowed one week to acclimate to their home cages upon
arrival. Prior to surgery, rats were anesthetized with 80 mg/kg ketamine (Midwest
Veterinary Supply, Valley Forge, PA) and 12 mg/kg xylazine (Sigma-Aldrich/RBI, St. Louis,
MO). An indwelling catheter (SAI Infusion Technologies, Lake Villa, IL) was inserted into
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the right jugular vein and sutured in place. The catheter was routed to a mesh backmount
that was implanted subcutaneously above the shoulder blades. To prevent infection and
maintain patency, catheters were flushed daily with 0.2 ml of the antibiotic Timentin (0.93
mg/ml; Fisher, Pittsburgh, PA) dissolved in heparinized 0.9% saline (Butler Schein, Dublin,
OH). When not in use, catheters were sealed with plastic obturators.

After catheter insertion, some rats were then immediately mounted in a stereotaxic
apparatus (Kopf Instruments, CA) and implanted with cannulae for intra-cranial
microinjections. Bilateral guide cannulae (26 gauge; 16 mm; Plastics One, Roanoke, VA)
were implanted 2mm dorsal to the VTA and cemented in place by affixing dental acrylic to
stainless steel screws secured in the skull. The coordinates for the ventral ends of the
guide cannulae, relative to bregma according to the atlas of Paxinos and Watson (1997),
were as follows: -5.8 mm A/P, ±0.5 mm M/L, and -6.6 mm D/V. An obturator (33 gauge;
Plastics One) was inserted into each guide cannula to prevent occlusion.

Cocaine self-administration, extinction and reinstatement of cocaine seeking
Rats were allowed 7 days to recover from surgery before behavioral testing commenced.
Initially, rats were placed in operant conditioning chambers and allowed to lever-press for
intravenous infusions of cocaine (0.25 mg/kg/infusion, infused over a 5 s period) on a
fixed-ratio 1 (FR1) schedule of reinforcement. Rats were allowed to self-administer a
maximum of 30 injections per 120 min operant session. Once a rat achieved at least 20
infusions of cocaine in a single daily operant session under the FR1 schedule, the subject
was switched to a fixed-ratio 5 (FR5) schedule of reinforcement. The maximum number
of injections was again limited to 30 per daily self-administration session under the FR5
schedule. For both FR1 and FR5 schedules, a 20 s time-out period followed each cocaine
infusion, during which time active lever responses were tabulated but had no scheduled
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consequences. Responses made on the inactive lever, which had no scheduled
consequences, were also recorded during both the FR1 and FR5 training sessions.
Following 21 days of daily cocaine self-administration sessions, drug-taking behavior was
extinguished by replacing the cocaine solution with 0.9% saline. Daily extinction sessions
continued until responding on the active lever was <15% of the total active lever responses
completed on the last day of cocaine self-administration. Typically, it took ~7 days for rats
to meet this criterion. Once cocaine self-administration was extinguished, rats entered the
reinstatement phase of the experiment. During reinstatement test sessions, satisfaction of
the response requirement (i.e., five presses on the active lever) resulted in an infusion of
saline rather than cocaine. Using a between-sessions reinstatement procedure, each
reinstatement test session was followed by extinction sessions until responding was again
<15% of the total active lever responses completed on the last day of cocaine selfadministration. Generally, 1–2 days of extinction were necessary to reach extinction
criterion between reinstatement test sessions.

Cue-induced reinstatement of cocaine-seeking behavior was tested in a separate cohort
of rats. The same self-administration procedure was used as described above with the
addition of contingent light cues. Each cocaine infusion was associated with concurrent
illumination of a cue light located directly above the active lever for 5 s. Following 21 days
of cocaine self-administration sessions, drug-taking behavior was extinguished by
replacing the cocaine solution with saline and turning off the drug-paired cue light. Once
cocaine self-administration was extinguished (operationally defined as <15% of the total
active lever responses completed on the last day of cocaine self-administration), rats
entered the reinstatement phase of the experiment and the ability of the cue light to
reinstate drug-seeking behavior was assessed. During reinstatement test sessions, every
5th lever press resulted in an infusion of saline and illumination of the cue light previously
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paired with cocaine taking during the self-administration phase of the experiment. The
effects of systemic vehicle and fluoro-Ex-4 (0.2 µg/kg, i.p.) on cue-induced reinstatement
of cocaine-seeking behavior were tested using a counterbalanced, within-subjects design.

Cocaine Reinstatement
To determine if systemic administration of a GLP-1R agonist reduces cocaine seeking and
penetrates the brain, initial studies utilized the GLP-1R agonist Ex-4 tagged with
fluorescein (fluoro-Ex-4). In addition to binding GLP-1Rs in vitro and in vivo, fluoro-Ex-4
produces behavioral responses identical to unlabeled Ex-4 (Rajan et al., 2015; Reiner et
al., 2016). Once cocaine-taking behavior was extinguished, rats were pretreated with
vehicle or 3.0 µg/kg fluoro-Ex-4 (i.p.) one hour prior to an acute priming injection of cocaine
(10 mg/kg, i.p.). Rats were then placed immediately into the operant conditioning
chambers and a two-hour reinstatement test session commenced. Separate groups of
rats were used in the fluoro-Ex-4 dose-response study to identify doses that attenuate
cocaine reinstatement, and are not associated with adverse malaise-like effects (Hayes
et al., 2011a; Kanoski et al., 2012). In this experiment, rats were pretreated with vehicle,
0.01, 0.1, and 0.2 µg/kg fluoro-Ex-4 (i.p.) one hour prior to a 10 mg/kg priming injection of
cocaine and subsequent reinstatement test sessions. Using a within-subjects design, each
rat served as its own control and fluoro-Ex-4 doses were counterbalanced to avoid rank
order effects of drug treatment. Twenty-four hours after each treatment, rats were weighed
to confirm that 0.01, 0.1, and 0.2 µg/kg doses of fluoro-Ex-4 do not affect body weight.

To determine if the effects of peripherally administered Ex-4 on cocaine seeking are due,
in part, to activation of GLP-1Rs in the brain, the GLP-1R antagonist exendin-(9-39) was
microinjected into the VTA prior to systemic administration of fluoro-Ex-4. Obturators were
removed from the guide cannulae and 33 gauge stainless steel microinjectors (18mm;
24

2mm projection, Plastics One) were inserted. Using a within-subjects design, rats were
infused bilaterally with vehicle or 10 µg/100 nl exendin-(9-39) directly into the VTA.
Microinjectors were left in place for an additional one minute following infusions in order
to allow for diffusion of the drug solution away from the tips of the microinjectors. Rats
were then placed back in their home cages. Thirty minutes later rats received a systemic
injection of vehicle or 3.0 µg/kg fluoro-Ex-4 (i.p.)

Sucrose self-administration, extinction and reinstatement of sucrose seeking
Potential nonspecific rate-suppressing effects of intra-VTA Ex-4 were evaluated by
assessing the influence of Ex-4 on the reinstatement of sucrose-seeking behavior.
Separate cohorts of rats were trained initially to self-administer 45 mg sucrose pellets
(Research Diets, New Brunswick, NJ) on a FR1 schedule of reinforcement during daily
one hour operant sessions. Once rats achieved stable responding for sucrose (defined as
<20% variation in responding over 3 consecutive days) on the FR1 schedule of
reinforcement, the response requirement was increased to an FR5 schedule of
reinforcement. Rats were limited to 30 sucrose pellets within each daily operant session
and were restricted to ~20-25 g of lab chow (Harlan Teklad, Wilmington, DE) daily in their
home cages for the duration of the experiment. Water was available ad libitum in the home
cage.

After two weeks of sucrose-maintained responding on an FR5 schedule of reinforcement,
rats underwent an extinction phase where active lever pressing no longer resulted in
sucrose delivery. Once active lever responding decreased to <15% of the maximum
number of responses completed on the last day of sucrose self-administration, rats
proceeded to reinstatement testing. Ex-4 (0.005 and 0.05 µg/100 nl) and vehicle were
microinjected into the VTA 10 min prior to the beginning of the reinstatement test sessions.
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Using a within-subjects design, each animal served as its own control and doses were
counterbalanced across test sessions. The experimenter remotely administered one
sucrose pellet every two min for the first 10 min of the reinstatement session. A betweensession procedure was used so that each daily reinstatement test session was followed
by an extinction session the following day until responding was again <15% of the total
active lever responses maintained by sucrose.

Ad libitum food intake
To assess the effects of fluoro-Ex-4 on chow intake in cocaine-experienced rats, a
separate group of rats was housed in a custom-made automated feedometer during the
extinction and reinstatement phases of the experiment. Rats were housed individually in
hanging wire cages each with a small access hole leading to a food cup resting on an
electronic scale as we have described previously (Alhadeff et al., 2016; Reiner et al.,
2016). Each rat was pretreated with vehicle or fluoro-Ex-4 (0.1 or 0.2 μg/kg) one hour
prior to a cocaine priming-induced reinstatement test session. Rats were returned to the
feedometer immediately following the reinstatement session and given ad libitum access
to normal chow (Purina LabDiet 5001, Purina, St. Louis, MO). Chow intake and meal
patterns were quantified by measuring the weight of each food cup using computer
software (LabView) every 10 s for 24 h. Feeding measurements were recorded 1, 3, 6, 12
and 24 h post session (4, 6, 9, 15 and 27 h post infusion). Total body weight and water
intake were measured 24 h post session (27 h post infusion). Cumulative food intake and
meal patterns were analyzed, with a meal defined as ingestion of at least 0.25 g of food
with a minimum of 10 min between feeding bouts (Alhadeff et al., 2016; Reiner et al.,
2016).
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Verification of cannula placements
After completion of all VTA microinjection experiments, rats were given an overdose of
pentobarbital (100 mg/kg, i.p.). Brains were removed and drop fixed in 10% formalin.
Coronal sections (100 µm) were taken at the level of the VTA with a vibratome and
mounted on gelatin-coated slides. An individual blinded to behavioral responses verified
microinjection sites using light microscopy. Rats with cannula placements outside of the
VTA and/or excessive mechanical damage were excluded from subsequent data
analyses.

Immunohistochemistry
Rats pretreated with 0.2 or 3.0 µg/kg fluoro-Ex-4 (i.p.) were deeply anesthetized and
transcardially perfused with 0.1 M PBS, pH 7.4, followed with 4% formalin in 0.1 M PBS
immediately following their cocaine priming-induced reinstatement test session (i.e., three
hours post infusion). Once brains were removed, they were postfixed overnight in 4%
formalin in 0.1 M PBS and then cryoprotected in 20% sucrose in 0.1 M PBS at 4 oC for
three days. Coronal sections (30 µm) were then taken at the level of the VTA using a
cryostat (Leica 3050S; Leica Corp., Deerfield, IL). Brain sections were stored in 0.1 M
PBS at 4oC until processed.

Immunohistochemistry was performed on free-floating coronal sections containing the
VTA according to modified procedures from previously published studies (Reiner et al.,
2016; Schmidt et al., 2016). Briefly, sections were washed with 1% sodium borohydride
followed by 0.1 M PBS. Sections were then blocked in 0.1 M PBS containing 5% normal
donkey serum and 0.2% Triton-X for 1 h at room temperature. Sections were incubated in
primary antibodies overnight, and then, following a PBS rinse, they were incubated in
secondary antibodies for 2 h. The primary antibodies used were rabbit anti-NeuN (1:1000;
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ab177487, Abcam, Cambridge, UK), goat anti-GFAP (1:1000; ab53554, Abcam,
Cambridge, UK) and rabbit anti-tyrosine hydroxylase (1:1000; 2792; Cell Signaling,
Danvers, MA). Secondary antibodies were donkey anti-goat Alexa Fluor 594 (1:500),
donkey anti-rabbit Alexa Fluor 647 (1:500) and donkey anti-rabbit Alexa Fluor 594 (1:500)
from Jackson ImmunoResearch (West Grove, PA). Sections were then washed and
mounted onto glass slides and coverslipped using Vectashield (Vector Laboratories;
Burlingame, CA). Sections were visualized with a Leica SP5 X confocal microscope using
the 20x and 63x oil-immersion objectives along with 488, 594 and 633 nm laser lines.
Image z-stacks were captured with a 2–3x optical zoom at the 63x oil-immersion objective
with a step size of 0.5 μm.

Quantitative real-time PCR, cocaine self-administration and yoked saline controls
Separate rats underwent jugular catheterization as described above. Following a recovery
period, the rats were randomly assigned to one of two groups: cocaine-experimental or
yoked saline controls. Each rat allowed to respond for contingent cocaine infusions was
paired with a yoked rat that received infusions of saline. While lever pressing for the salineyoked rats had no scheduled consequences, these rats received the same number and
temporal pattern of infusions as self-administered by their paired cocaine-experimental
rat. Cocaine-experimental rats were allowed to lever press for intravenous cocaine
infusions on a FR1 schedule as described above for a total of 21 days.

To assess the effects of cocaine self-administration and extinction on expression of VTA
GLP-1Rs and PPG in the NTS, rats were sacrificed either immediately after the first
extinction session (Ext1) or following 7 consecutive days of extinction (Ext7). Brains were
collected and flash frozen in -20C isopentane and stored at -80C. Brains were
subsequently mounted on a cryostat (Leica 3050S; Leica Corp., Deerfield, IL) and coronal
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sections at the levels of the NTS and VTA were taken. Bilateral 1mm 3 micropunches of
the VTA and NTS were collected for quantitative real-time PCR to determine GLP-1R and
PPG expression, respectively. mRNA expression was quantified using Taqman gene
expression

kits

(GLP-1R:

Rn00562406_m1;

PPG:

Rn00562293_m1;

GAPDH:

Rn01775763_g1; ThermoFisher Scientific, Waltham, MA). qPCR was conducted using an
Eppendorf Mastercycler ep realplex2 and the comparative threshold cycle method was
used to quantify relative mRNA expression. Relative fold-expression of VTA GLP-1R and
NTS PPG transcripts at Ext1 and Ext7 were normalized to yoked saline controls and
GAPDH levels.

Statistics
For all cocaine and sucrose reinstatement experiments, the total mean active and inactive
lever responses were analyzed with two-way ANOVAs. Analyses of body weight and
feeding behaviors for the fluoro-Ex-4 dose-response experiment were conducted using
repeated measures one-way ANOVAs. Pairwise analyses were made using Bonferroni
post hoc tests (p<0.05). Changes in fold mRNA expression of VTA GLP-1Rs and NTS
PPG were analyzed using unpaired t-tests.
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Results
Systemic administration of a GLP-1R agonist dose-dependently attenuated cocaine
seeking in rats.
Total active and inactive lever responses (mean ± SEM) in rats pretreated with systemic
fluoro-Ex-4 (vehicle or 3.0 µg/kg, i.p.; n=10/treatment) prior to a cocaine priming-induced
reinstatement test session are shown in Figure 2.1A. These data were analyzed with a
two-way ANOVA, which revealed significant main effects of treatment [F(1,36)=28.63,
p<0.0001] and lever [F(1,36)=66.3, p<0.0001] as well as a significant interaction between
lever and treatment [F(1,36)=29.01, p<0.0001]. Subsequent pairwise analyses indicated
that active lever responses were significantly different between vehicle and 3.0 µg/kg
fluoro-Ex-4 (Bonferroni, p<0.05). No significant differences were found on inactive lever
responding between treatments.

While peripheral administration of 3.0 µg/kg fluoro-Ex-4 significantly attenuated cocaine
seeking, one could argue that the effects of fluoro-Ex-4 on drug seeking were due to
malaise-like effects as previous studies have shown that an acute injection of 3.0 µg/kg
Ex-4 produces a mild pica response and reduces food intake and body weight in rats
(Hayes et al., 2011a; Kanoski et al., 2012). Therefore, we aimed to identify doses of
systemic fluoro-Ex-4 that attenuated cocaine seeking and did not produce pica (Kanoski
et al., 2012) or reduce body weight. We assessed the ability of lower doses of fluoro-Ex4 (0, 0.01, 0.1, and 0.2 µg/kg, i.p.; n=16/treatment) to attenuate cocaine priming-induced
reinstatement of drug seeking behavior. Total active and inactive lever responses (mean
± SEM) from the reinstatement test sessions are shown in Figure 2.1B. These data were
analyzed with a two-way ANOVA, which revealed significant main effects of treatment
[F(3,120)=6.798, p<0.001] and lever [F(1,120)=98.85, p<0.0001] as well as a significant
lever x treatment interaction [F(3,120)=6.585, p<0.001]. Subsequent pairwise analyses
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indicated significant decreases between vehicle and 0.1 and 0.2 µg/kg fluoro-Ex-4 on
active lever responses (Bonferroni, p<0.05). No significant differences were found on
inactive lever responding between treatments. Body weight was measured 24 h after each
treatment to determine if peripheral fluoro-Ex-4 at these doses resulted in a reduction of
body weight. Mean body weight changes for each treatment are shown in Figure 2.1C.
There were no significant effects of fluoro-Ex-4 treatment on 24 h body weight in cocaineexperienced rats.

We also investigated the ability of low dose fluoro-Ex-4 to attenuate cue-induced
reinstatement of cocaine seeking. Consistent with the effects on cocaine priming-induced
reinstatement (Figure 2.1B), 0.2 µg/kg fluoro-Ex-4 pretreatment significantly reduced
reinstatement of drug-seeking behavior elicited by re-exposure to conditioned cues
previously associated with cocaine self-administration (Figure 2.1D).

Doses of systemic fluoro-Ex-4 that attenuated cocaine seeking had no effect on chow
intake, number of meals or meal size in cocaine-experienced rats.
To further evaluate potential adverse effects of systemic fluoro-Ex-4 on feeding behaviors
in cocaine-experienced rats, meal pattern analyses were performed on each
reinstatement test day. Meal pattern analyses began immediately after reinstatement test
sessions (i.e., three hours post fluoro-Ex-4 injection), a time point that coincides with
decreased food intake in rats treated with higher doses of Ex-4 (Kanoski et al., 2012).
Peripheral injections of fluoro-Ex-4 (0.1 and 0.2 µg/kg, i.p.) attenuated cocaine seeking in
separate cohorts of rats (n=7/treatment; data not shown but consistent with Figure 2.1B)
and had no effect on 24 h body weight gain (Figure 2.2A) similar to Figure 2.1C. Detailed
analyses of feeding patterns revealed no effect of fluoro-Ex-4 treatment on cumulative
chow intake (Figure 2.2B), number of meals (Figure 2.2C) and meal size (Figure 2.2D) at
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any time point. Taken together, these data demonstrated that fluoro-Ex-4 attenuated
cocaine seeking at doses (0.1 and 0.2 µg/kg) subthreshold for effects on ad libitum chow
intake.

Peripherally administered fluoro-Ex-4 penetrated the brain and was visualized in the VTA.
Immediately following the reinstatement test session, rats pretreated with a systemic
injection of 3.0 µg/kg fluoro-Ex-4 (Figure 2.1A) or 0.2 µg/kg fluoro-Ex-4 (Figure 2.1B) were
sacrificed and their brains removed to determine if fluoro-Ex-4 was present in the VTA
(Figures 2.3A & 2.3D). Coronal sections of the VTA were immunohistochemically
processed to label neurons and astroctyes. Confocal microscopy revealed co-localization
of fluoro-Ex-4 with both GFAP-positive astrocytes and NeuN-positive neurons in the VTA
(Figures 2.3B & 2.3E). Separate immunohistochemical analyses to evaluate if fluoro-Ex4 bound putative GLP-1Rs expressed on dopamine neurons in the VTA revealed that
fluoro-Ex-4 co-localized with tyrosine hydroxylase-positive neurons (Figures 2.3C & 2.3F).

Intra-VTA administration of the GLP-1R antagonist exendin-(9-39) prevented the ability of
peripheral fluoro-Ex-4 to attenuate cocaine seeking in rats.
Our immunohistochemistry findings suggested that the effects of peripheral fluoro-Ex-4 on
cocaine seeking are mediated, in part, by activation of GLP-1Rs in the VTA. To test this
hypothesis, the GLP-1R antagonist exendin-(9-39) (Ex-9; 10 µg/100nl) was administered
directly into the VTA prior to a systemic injection of fluoro-Ex-4 (3.0 µg/kg, i.p.) and a
cocaine priming-induced reinstatement test session. Using a within-subjects design, there
were

4

treatment

vehicle/peripheral

conditions

fluoro-Ex-4,

(intra-VTA
intra-VTA

vehicle/peripheral

Ex-9/peripheral

vehicle,

vehicle,

intra-VTA

intra-VTA

Ex-

9/peripheral fluoro-Ex-4; n=13/treatment). Total active lever responses (mean ± SEM) are
shown in Figure 2.3G. These data were analyzed with a two-way ANOVA which revealed
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significant main effects of systemic treatment [F(1,12)=18.06, p<0.01] and intra-VTA
treatment [F(1,12)=10.94, p<0.01] as well as a significant systemic treatment x intra-VTA
treatment interaction [F(1,12)=14.52, p<0.01]. Subsequent pairwise analyses indicated a
significant difference in total active lever responding between intra-VTA vehicle/peripheral
vehicle, intra-VTA Ex-9/peripheral vehicle, and intra-VTA Ex-9/peripheral fluoro-Ex-4
versus intra-VTA vehicle/peripheral fluoro-Ex-4 treated rats (Bonferroni, p<0.05). There
was no effect of treatment on total inactive lever responding (data not shown).
Corresponding microinjection sites in the VTA are shown in Figure 2.3H. Taken together,
these results suggested that the effects of peripheral fluoro-Ex-4 on the reinstatement of
cocaine-seeking behavior were due, in part, to activation of GLP-1Rs in the VTA.

Extinction following cocaine self-administration was associated with decreased PPG
mRNA expression in the NTS.
Using quantitative real-time PCR, we assessed the effects of cocaine self-administration
and subsequent extinction sessions on expression of GLP-1R mRNA transcripts in the
VTA and PPG mRNA transcripts in the NTS (Figure 2.4A). GLP-1R mRNA expression in
the VTA was not changed in cocaine-experienced rats following one (Ext1) and seven
(Ext7) days of extinction when compared to yoked saline controls (Figures 2.4B & 2.4C).
While PPG mRNA expression in the NTS was not altered in cocaine-experienced rats
following one day of extinction (Figure 2.4D), NTS PPG mRNA expression was
significantly decreased following seven days of extinction [t(14)=3.18, p<0.01;
n=8/treatment] (Figure 2.4E). These results indicated that extinction following cocaine selfadministration is associated with decreased endogenous PPG mRNA expression in the
NTS.
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Administration of Ex-4 directly into the VTA dose-dependently attenuated cocaine seeking
in rats.
To determine if increased activation of VTA GLP-1Rs during extinction is sufficient to
attenuate cocaine seeking, Ex-4 was infused directly into the VTA 10 minutes prior to a
cocaine priming-induced reinstatement test session. Total active and inactive lever
responses (mean ± SEM) in animals pretreated with Ex-4 (vehicle, 0.005 or 0.05 µg/100nl,
n=8/treatment) are shown in Figure 2.5A. These data were analyzed using a two-way
ANOVA, which revealed significant main effects of treatment [F(2,56)=6.735, p<0.01] and
lever [F(1,56)=75.37, p<0.001] as well as a significant treatment x lever interaction
[F(2,56)=6.828, p<0.01]. Subsequent pairwise analyses indicated that active lever
responses were significantly different between vehicle and 0.05 µg Ex-4 (Bonferroni,
p<0.05). No significant differences were found on inactive lever responding between
treatments. Microinjection sites corresponding to these experiments are shown in Figure
2.5B.

While intra-VTA administration of Ex-4 had no significant effect on inactive lever
responding, one could argue that responses were too low to assess the potential ratesuppressant effects of intra-VTA Ex-4 treatment. Total active and inactive lever responses
(mean ± SEM) are shown in Figure 2.5C for rats pretreated with intra-VTA Ex-4 prior to a
sucrose reinstatement test session. There were no effects of intra-VTA Ex-4 on sucrose
seeking. Infusion sites within the VTA for these experiments are depicted in Figure 2.5D.
Taken together with the cocaine reinstatement studies, these data indicated that activation
of VTA GLP-1Rs reduced cocaine seeking and that these effects were not due to deficits
in operant responding.
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Discussion
The present study identified a critical role for GLP-1Rs in drug-seeking behavior.
Specifically, we showed that systemically administered Ex-4 attenuated the reinstatement
of drug-seeking behavior elicited by both cocaine and conditioned cues. Importantly, we
identified doses of Ex-4 that selectively reduced cocaine seeking and did not affect food
intake or body weight. Moreover, these behaviorally-relevant doses of Ex-4 do not produce
nausea/malaise-like adverse effects in rodents (Kanoski et al., 2012) further highlighting
the selectivity of this behavioral response at these doses. We also showed that peripheral
Ex-4 was able to cross the blood brain barrier and putatively bind receptors expressed on
neurons and astrocytes in the VTA. Indeed, the suppressive effects of peripheral Ex-4 on
cocaine seeking were due, in part, to activation of central GLP-1Rs in the VTA. Moreover,
cocaine self-administration and subsequent extinction may reduce endogenous GLP-1
expression in the brain, as evidenced by a significant decrease in PPG mRNA expression
in the NTS following seven days of extinction, a time point that coincides with drug-seeking
behavior (Schmidt and Pierce, 2010; Schmidt et al., 2015b). Since the NTS sends direct
monosynaptic GLP-1-expressing efferent projections to the VTA (Alhadeff et al., 2012),
these results suggest that decreased endogenous GLP-1 release in midbrain areas
including the VTA may facilitate cocaine seeking. This hypothesis is supported by our data
indicating that infusions of Ex-4 directly into the VTA were sufficient to attenuate the
reinstatement of cocaine-seeking behavior. Collectively, these findings identify a novel
neural mechanism focused on central GLP-1Rs that could be targeted to prevent cocaine
craving-induced relapse.

GLP-1R agonists and cocaine addiction
A growing literature indicates that GLP-1Rs play an important role in addiction-like
behaviors and that systemic administration of GLP-1R agonists reduces the rewarding
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and reinforcing effects of drugs of abuse (Skibicka, 2013; Engel and Jerlhag, 2014; Hayes
and Schmidt, 2016). For example, peripheral administration of the GLP-1R agonist Ex-4
has been shown to attenuate cocaine-induced conditioned place preference (CPP) and
cocaine self-administration in mice (Egecioglu et al., 2013b; Graham et al., 2013;
Sorensen et al., 2015). Our findings expanded on these studies and identified an important
role for GLP-1Rs in an animal model of cocaine craving-induced relapse.

The present study also identified doses of peripheral Ex-4 that selectively attenuated
addiction-like behaviors and did not produce adverse effects commonly associated with
higher doses in rodents. Indeed, a significant limitation to interpreting results from previous
studies of peripheral Ex-4 in preclinical models of drug addiction is the exceedingly high
doses of Ex-4 tested. While previous studies have laid the foundation for our
understanding of the role of GLP-1 in drug addiction, the doses of peripheral Ex-4 used to
pretreat mice in these studies ranged from 3.0 to 100.0 µg/kg (Egecioglu et al., 2013b;
Graham et al., 2013; Sorensen et al., 2015). Doses of Ex-4 as low as 0.25 µg/kg have
been shown to produce malaise-like adverse effects in rats, which can confound
subsequent behavioral responses (Hayes et al., 2011a; Kanoski et al., 2012). Moreover,
nausea and malaise are common adverse effects associated with high doses of
peripherally administered GLP-1R agonists in humans (Buse et al., 2009). Since the doses
of Ex-4 shown to reduce cocaine CPP and self-administration are likely producing
malaise-like effects in mice, it is impossible to draw firm conclusions about the role of GLP1Rs in addiction-like behaviors from these previous studies. In contrast, we identified
systemic doses of Ex-4 as low as 0.1 and 0.2 µg/kg that were sufficient to attenuate
cocaine seeking in rats. Importantly, these doses were subthreshold for effects on feeding
behavior in cocaine-experienced rats (present findings) and do not produce malaise-like
effects in rats (Hayes et al., 2011a; Kanoski et al., 2012). The translational implications of
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these findings are profound in that they support potential therapeutic approaches toward
the specific use of GLP-1R agonists for the treatment of cocaine craving and relapse.

In addition to causing nausea and malaise-like effects, peripheral administration of Ex-4
at doses as low as 0.25 µg/kg have been shown to significantly decrease food intake and
body weight in rats (Hayes et al., 2011a; Kanoski et al., 2012). These findings further
confound prior studies that examined the effects of Ex-4 on drug-mediated behaviors
because they indicate that doses of Ex-4 greater than 0.25 µg/kg reduce motivated
behaviors generally and not drug reinforcement specifically. Furthermore, reductions in ad
libitum food intake and body weight limit the therapeutic potential of GLP-1R agonists for
use in human addicts. Our novel findings clearly identified doses of Ex-4 (0.1 and 0.2
µg/kg) that selectively attenuated cocaine seeking and did not affect ad libitum food intake,
meal patterns or body weight in cocaine-experienced rats. These data support selective
effects of a peripherally administered GLP-1R agonist on drug reinforcement. Consistent
with our peripheral Ex-4 dose-response study, we also showed that Ex-4 reduced cocaine
seeking when infused directly into the VTA at a dose (0.05 µg) that does not affect ad
libitum chow intake or promote malaise-like effects in rats (Alhadeff et al., 2012; Dickson
et al., 2012; Mietlicki-Baase et al., 2013). Moreover, intra-VTA infusion of Ex-4 did not alter
sucrose seeking further supporting the selectivity of lower doses to reduce cocaine
seeking. There is some evidence that administration of 0.05 µg Ex-4 into the VTA reduces
operant responding for palatable food (Dickson et al., 2012). However, these effects are
transient and do not persist with more prolonged operant sessions (Dickson et al., 2012;
Schmidt et al., 2016). Thus, the present study showed that a GLP-1R agonist reduced
cocaine seeking at doses not associated with common adverse effects in rodents.
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Central GLP-1Rs and cocaine seeking
Mutant mice lacking GLP-1Rs have enhanced cocaine CPP compared to wild-type
controls (Harasta et al., 2015). These results suggest that activation of central GLP-1Rs
may function to reduce the rewarding effects of cocaine. Consistent with this hypothesis,
we recently showed that direct activation of GLP-1Rs in the VTA is sufficient to reduce
cocaine self-administration in rats (Schmidt et al., 2016). We expanded upon these studies
here and showed that the intake suppressive effects of peripheral Ex-4 on cocaine seeking
were due to activation of GLP-1Rs in the VTA and that direct activation of VTA GLP-1Rs
was sufficient to reduce cocaine seeking.

The current data clearly support a role for VTA GLP-1Rs in cocaine seeking, but it is
possible and in fact likely that GLP-1Rs expressed in other brain regions also play an
important role in cocaine seeking. GLP-1Rs are expressed ubiquitously throughout the
rodent brain (Merchenthaler et al., 1999) including nuclei known to regulate drug-seeking
behavior. Viral-mediated re-expression of GLP-1Rs in the lateral septum of constitutive
GLP-1R knockout mice attenuates cocaine CPP (Harasta et al., 2015) indicating that the
rewarding effects of cocaine are mediated, in part, by enhanced GLP-1 signaling in this
nucleus. GLP-1Rs are also expressed in the NAc, hippocampus, habenula and amygdala
(Merchenthaler et al., 1999; Tuesta et al., 2017) and future studies are required to define
the exact role of GLP-1 signaling in these nuclei in addiction-like behaviors.

The exact mechanism(s) by which GLP-1R activation in the VTA attenuates cocaine
seeking are unknown. Doses of peripheral Ex-4 that reduce cocaine CPP and selfadministration attenuate cocaine-mediated increases in extracellular dopamine in the
nucleus accumbens (NAc) (Egecioglu et al., 2013b; Sorensen et al., 2015). Since
increased dopamine signaling in the NAc promotes cocaine seeking (Schmidt et al., 2005;
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Schmidt et al., 2006; Schmidt and Pierce, 2006a), these results suggest that reduced
cocaine seeking following peripheral Ex-4 administration may involve decreased
extracellular dopamine levels in the NAc. The present findings also indicated that
peripheral Ex-4 bound putative GLP-1Rs expressed on neurons and astrocytes in the
VTA. However, it is not clear how exactly GLP-1R activation in the VTA may reduce
dopamine cell firing. GLP-1Rs are predominantly Gs-coupled receptors (although they can
activate Gq and Gi proteins as well) that are expressed on both pre- and post-synaptic
sites in the VTA (Holst, 2007; Hayes et al., 2011b). While the exact phenotypes of GLP1R-expressing cells in the VTA must be further characterized, there is some evidence that
GLP-1R activation increases glutamate release in the VTA of drug-naïve rats (MietlickiBaase et al., 2013). GLP-1R activation also enhances GABAA receptor-mediated currents
in the drug-naïve brain (Korol et al., 2015b; Korol et al., 2015a; Farkas et al., 2016),
suggesting a possible GABA-mediated mechanism in the VTA that may underlie the
suppressive effects of Ex-4 on cocaine seeking. Furthermore, a recent study showed that
GLP-1R agonists increase activation of astrocytes in the hindbrain (Reiner et al., 2016). It
is intriguing to think that increased activation of GLP-1Rs expressed on astrocytes in the
VTA may regulate glutamate homeostasis and drug-seeking behavior. The effects of GLP1R activation on dopamine cell firing in the VTA are likely to be complex and may differ
between drug-naïve and cocaine-experienced brains. Therefore, future studies are
required to determine the cellular and neurophysiological mechanisms through which
activation of GLP-1Rs in the VTA suppresses cocaine-seeking behavior.

Extinction following cocaine self-administration dynamically regulated endogenous PPG
mRNA expression in the NTS
To date no studies have examined the effects of cocaine self-administration and
subsequent extinction on endogenous central GLP-1 signaling. We have previously
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reported that cocaine activates GLP-1-expressing neurons in the NTS and that increased
VTA GLP-1 signaling in the brain may function as a homeostatic response to reduce
cocaine self-administration (Schmidt et al., 2016). To expand upon these data, we
examined the effects of one day and seven days of extinction following 21 days of cocaine
self-administration on GLP-1R mRNA expression in the VTA. We also quantified
expression of PPG mRNA in the NTS. PPG is the protein precursor to GLP-1 in NTS
neurons (Holst, 2007). Using quantitative real-time PCR, we found no effects of extinction
on VTA GLP-1R mRNA expression. In contrast, we found a non-significant trend (P=0.09)
toward increased PPG mRNA expression in the NTS during acute withdrawal from
cocaine self-administration. These results are consistent with our previous study showing
that cocaine increases activation of PPG-expressing neurons in the NTS (Schmidt et al.,
2016) and together suggest that increased endogenous PPG mRNA expression in the
NTS may represent a homeostatic compensatory response to cocaine self-administration
that serves to reduce further drug taking. Interestingly, we observed a significant decrease
in NTS PPG mRNA expression following seven days of extinction, a time point that
coincides with maximal drug-seeking behavior (Schmidt and Pierce, 2010; Schmidt et al.,
2015b). Since activation of central GLP-1Rs may serve as a ‘brake’ on cocaine selfadministration, this decrease in endogenous PPG mRNA expression in the caudal brain
may facilitate drug seeking during extinction. Support for this hypothesis comes from the
present study showing that direct activation of VTA GLP-1Rs was sufficient to reduce
cocaine priming-induced reinstatement of drug-seeking behavior. Our data are consistent
with previous literature demonstrating that reduced PPG mRNA expression in the NTS
increases the rewarding value of food. Viral-mediated knockdown of PPG mRNA
expression in the NTS produces hyperphagia and exacerbates high fat diet-induced
obesity (Barrera et al., 2011). Due to shared mechanisms mediating the rewarding
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properties of food and drugs of abuse (DiLeone et al., 2012; Volkow et al., 2013), our data
further support a role for central GLP-1 signaling in regulating motivated behaviors.

Conclusion
The present study identified a novel role for central GLP-1Rs in an animal model of
relapse. Moreover, we have identified doses of the GLP-1R agonist Ex-4 that selectively
reduced cocaine seeking and did not produce adverse effects in rats. Since GLP-1R
agonists are FDA-approved for treating diabetes type II and obesity, these findings
suggest that Ex-4 could be re-purposed as an anti-relapse medication. Additionally, we
provided evidence that extinction following cocaine self-administration decreased
endogenous PPG mRNA expression in the brain, which may facilitate drug-seeking
behavior.
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Figures

Figure 2.1 Systemic administration of fluoro-Ex-4 dose-dependently attenuated
cocaine priming-induced reinstatement of drug-seeking behavior. (A) Cocaine
seeking was significantly attenuated in rats pretreated with 3.0 µg/kg fluoro-Ex-4
compared to vehicle-treated controls (n=10/treatment). Since 3.0 µg/kg Ex-4 produces
malaise-like effects in rats (Hayes et al., 2011a; Kanoski et al., 2012), lower doses of
fluoro-Ex-4 were tested to identify doses that selectively reduce cocaine seeking. (B)
Doses of fluoro-Ex-4 (0.1 and 0.2 µg/kg) subthreshold for producing malaise-like effects
reduced cocaine seeking (n=16/treatment). (C) No effects of systemic fluoro-Ex-4 on 24 h
body weight were found in rats pretreated with 0.01, 0.1 and 0.2 µg/kg fluoro-Ex-4 prior to
a cocaine priming-induced reinstatement test session (n=16/treatment). (D) Cue-induced
reinstatement of cocaine-seeking behavior was significantly attenuated in rats pretreated
with 0.2 µg/kg fluoro-Ex-4 compared to vehicle-treated controls (n=5/treatment). *p<0.05,
Bonferroni
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Figure 2.2 Systemic administration of fluoro-Ex-4 did not affect ad libitum feeding
behavior in cocaine-experienced rats. There were no effects of 0.1 and 0.2 µg/kg
fluoro-Ex-4 pretreatment on 24 h body weight (A) in cocaine-experienced rats.
Moreover, fluoro-Ex-4 did not affect cumulative chow intake (B), meal frequency (C) or
meal size (D) at any time point following cocaine priming-induced reinstatement test
sessions (n=7/treatment).
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Figure 2.3 The suppressive effects of systemic fluoro-Ex-4 on cocaine seeking were
blocked by antagonism of VTA GLP-1Rs. Rats pretreated with fluoro-Ex-4 (3.0 µg/kg,
n=10) prior to a priming injection of cocaine in Figure 1A were perfused immediately after
the reinstatement test session (3 h post fluoro-Ex-4 infusion). Coronal sections at the level
of the midbrain (A) were used to determine if systemic fluoro-Ex-4 penetrates the brain
and localizes in the VTA. (B) 3.0 µg/kg fluoro-Ex-4 (green fluorescence) co-localized with
neurons labeled with NeuN (blue fluorescence) and astrocytes labeled with GFAP (red
fluorescence) in the VTA. (C) 3.0 µg/kg fluoro-Ex-4 co-localized with tyrosine hydroxylaselabeled dopamine neurons (red fluorescence) in the VTA. The VTA (D) of separate rats
treated with 0.2 µg/kg fluoro-Ex-4 were used to determine if lower doses of the GLP-1R
agonist that selectively attenuated cocaine seeking also penetrated the brain and localized
in the VTA (E & F). Images are compressed z-stacks with a 0.5 µm step size (scale bar:
20 µm). All images shown at 63x magnification. (G) Intra-VTA infusions of the GLP-1R
antagonist exendin-(9-39) (10 µg) prior to a systemic injection of 3.0 µg/kg fluoro-Ex-4
blocked fluoro-Ex-4-mediated reductions in total active lever responses during cocaine
reinstatement test sessions (n=13/treatment). (H) Representative coronal sections at the
level of the midbrain depict microinjection sites in the VTA. *p<0.05, Bonferroni
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Figure 2.4 Cocaine self-administration and subsequent extinction reduced
endogenous PPG mRNA expression in the NTS. (A) Expression of GLP-1R mRNA
transcripts in the VTA and PPG mRNA transcripts in the NTS was quantified following one
(Ext1) and seven (Ext7) days of extinction following cocaine self-administration. No
differences in GLP-1R mRNA expression in the VTA were found after one day of extinction
(n=8) (B) or seven days of extinction (n=7) (C) in cocaine-experienced rats compared to
yoked saline controls. (D) While not statistically significant (p<0.09), there was a trend
towards increased PPG mRNA expression in the NTS following one day of extinction (n=7)
in cocaine-experienced rats compared to control rats. (E) In contrast, statistically
significant decreases in NTS PPG mRNA expression were found following seven days of
extinction in cocaine-experienced rats compared to yoked saline controls. *p<0.01,
unpaired t-tests
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Figure 2.5 Administration of Ex-4 directly into the VTA dose-dependently attenuated
cocaine priming-induced reinstatement of drug-seeking behavior. (A) Infusions of
Ex-4 (0.05 µg) directly into the VTA prior to a cocaine priming injection reduced active
lever responses during subsequent reinstatement test sessions (n=8). The asterisk
indicates a significant difference in responding between rats pretreated with 0.05 µg Ex-4
and vehicle (*p<0.05, Bonferroni). Intra-VTA microinjection sites for the cocaine
reinstatement study are shown in B. (C) Ex-4 administration into the VTA had no effect on
sucrose seeking (n=7). Microinjection sites corresponding to intra-VTA infusions in
sucrose reinstatement test sessions are shown in D.
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Abstract

Recent evidence indicates that activation of glucagon-like peptide-1 (GLP-1) receptors
reduces cocaine-mediated behaviors and cocaine-evoked dopamine release in the
nucleus accumbens (NAc). However, no studies have examined the role of NAc GLP-1
receptors (GLP-1Rs) in the reinstatement of cocaine-seeking behavior, an animal model
of relapse. Here, we show that systemic infusion of a behaviorally relevant dose of the
GLP-1R agonist exendin-4 (Ex-4) penetrated the brain and localized with neurons and
astrocytes in the NAc. Administration of Ex-4 directly into the NAc core and shell
subregions significantly attenuated cocaine priming-induced reinstatement of drugseeking behavior. These effects were not due to deficits in operant responding or
suppression of locomotor activity as intra-NAc Ex-4 administration had no effect on
sucrose-seeking behavior. To determine the effects of GLP-1R activation on neuronal
excitability, Ex-4 was bath applied to ex vivo NAc slices from cocaine- and salineexperienced rats following extinction of cocaine-taking behavior. Ex-4 increased the
frequency of action potential firing of NAc core and shell medium spiny neurons (MSNs)
in cocaine-experienced rats while no effect was observed in saline controls. In contrast,
Ex-4 did not affect the frequency or amplitude of spontaneous excitatory post-synaptic
currents (sEPSCs) or alter the paired-pulse ratios (PPRs) of evoked EPSCs. These effects
were not associated with altered expression of GLP-1Rs in the NAc following cocaine selfadministration. Taken together, these findings indicate that increased activation of GLP1Rs in the NAc during cocaine abstinence increases intrinsic, but not synaptic, excitability
of MSNs and is sufficient to reduce cocaine-seeking behavior.
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Introduction
Almost one million people aged 12 years or older initiated cocaine use in 2015, which
represents a 61% increase compared to the total number of new users in 2013 (Hughes,
2016). Unfortunately, there are no FDA-approved medications to treat cocaine relapse,
which continues to be a major public health concern (O'Brien, 1997; Pierce et al., 2012).
Thus, novel molecular targets are needed to develop new medications for the treatment
of cocaine addiction.

An emerging body of evidence indicates that metabolic regulators of hunger and satiety
also modulate the rewarding and reinforcing properties of drugs of abuse (Kenny, 2011b;
Engel and Jerlhag, 2014). For example, glucagon-like peptide-1 (GLP-1) is a satiation
hormone and neuropeptide that has been shown to regulate cocaine-, alcohol-, nicotineand amphetamine-related behavioral responses in rodents (Egecioglu et al., 2013b;
Graham et al., 2013; Shirazi et al., 2013; Sorensen et al., 2015; Suchankova et al., 2015;
Vallof et al., 2016; Tuesta et al., 2017). Since GLP-1 analogs are currently FDA-approved
for treating type II diabetes and obesity (Lovshin and Drucker, 2009; Shukla et al., 2015),
these pre-clinical findings suggest that GLP-1 receptor (GLP-1R) agonists could be
repurposed for treating drug abuse in human addicts.

Studies have shown that systemic administration of GLP-1R agonists attenuates cocaineinduced locomotion, cocaine conditioned place preference (CPP) and cocaine selfadministration (Egecioglu et al., 2013b; Graham et al., 2013; Sorensen et al., 2015). While
systemic administration of GLP-1R agonists attenuates cocaine-mediated behaviors, the
role of central GLP-1Rs in addiction-like behaviors is largely understudied (Hayes and
Schmidt, 2016). GLP-1Rs are expressed throughout the brain including the mesolimbic
reward system (Merchenthaler et al., 1999). GLP-1R activation in the nucleus accumbens
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(NAc) and ventral tegmental area (VTA) has been shown to decrease food intake by
reducing the rewarding value of food (Alhadeff et al., 2012; Dickson et al., 2012; Dossat
et al., 2013; Mietlicki-Baase et al., 2013). Since there is significant overlap between the
neural mechanisms and circuits mediating the reinforcing effects of palatable food and
drugs of abuse (Narayanan et al., 2010; Kenny, 2011b; Volkow et al., 2013), it is likely that
activation of central GLP-1Rs also reduces voluntary cocaine taking- and seekingbehaviors. Indeed, we recently showed that activation of GLP-1Rs in the VTA reduces the
reinforcing efficacy of cocaine in rats self-administering cocaine (Schmidt et al., 2016).
While these results clearly indicate a novel role for GLP-1Rs in voluntary cocaine taking,
no studies to date have investigated central GLP-1Rs in the reinstatement of cocaineseeking behavior, an animal model of relapse.

It is well established that the NAc core and shell subregions play critical roles in the
reinstatement of cocaine-seeking behavior (Schmidt et al., 2005; Schmidt and Pierce,
2010). Here, we initially determined if systemic administration of the GLP-1R agonist
exendin-4 (Ex-4) entered the brain, localized in the NAc and attenuated cocaine-seeking
behavior. We then assessed the effects of direct activation of GLP-1Rs in the NAc core
and shell on cocaine-seeking behavior. Previous studies have shown that GLP-1R
agonists modulate neuronal activity in the brain by both pre-synaptic effects on
neurotransmitter release and regulation of post-synaptic membrane excitability (AcunaGoycolea and van den Pol, 2004; Mietlicki-Baase et al., 2014; Korol et al., 2015b).
Therefore, we aimed to identify a potential neurophysiological mechanism underlying the
effects of intra-NAc Ex-4 on cocaine seeking by examining ex vivo electrophysiological
measures of neuronal activity and GLP-1R expression in the NAc of cocaine-experienced
rats. Our results indicate that GLP-1R activation in the NAc following extinction of
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voluntary cocaine taking increases the frequency of action potential firing in medium spiny
neurons (MSNs) and attenuates the reinstatement of cocaine-seeking behavior.
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Materials and Methods
Animals and housing
Male Sprague-Dawley rats (Rattus norvegicus) weighing 225-250 g were obtained from
Taconic Laboratories. Rats were individually housed with food and water available ad
libitum in their home cages. A 12/12 hr light/dark cycle was used with the lights on at 7:00
a.m. All experimental procedures were performed during the light cycle. The experimental
protocols were consistent with the guidelines issued by the U.S. National Institutes of
Health and were approved by the University of Pennsylvania’s Institutional Animal Care
and Use Committee and the University of South Carolina School of Medicine’s Institutional
Animal Care and Use Committee.

Drugs
Cocaine was obtained from the National Institute on Drug Abuse (Rockville, MD) and
dissolved in bacteriostatic 0.9% saline. Ex-4 was purchased from the American Peptide
Company (Sunnyvale, CA) and dissolved in aCSF (Harvard Apparatus, Holliston, MA).
Fluoro-Ex-4 was purchased from AnaSpec (Fremont, CA) and dissolved in bacteriostatic
0.9% saline. The doses and time course of administration for each of the aforementioned
pharmacological compounds were based on the following systemic and intra-cranial
microinjection experiments in rats: Ex-4 (Alhadeff et al., 2012; Schmidt et al., 2016) and
fluoro-Ex-4 (Kanoski et al., 2012; Reiner et al., 2016).

Surgery
Rats were handled daily and allowed one week to acclimate to their home cages upon
arrival. Prior to surgery, rats were anesthetized with 80 mg/kg ketamine (Midwest
Veterinary Supply, Valley Forge, PA) and 12 mg/kg xylazine (Sigma-Aldrich/RBI, St. Louis,
MO). An indwelling catheter (SAI Infusion Technologies, Lake Villa, IL) was inserted into
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the right jugular vein and sutured in place as described in our previous publications
(Schmidt et al., 2015b; Schmidt et al., 2016). The catheter was routed to a mesh
backmount that was implanted subcutaneously above the shoulder blades. To prevent
infection and maintain patency, catheters were flushed daily with 0.2 ml of the antibiotic
Timentin (0.93 mg/ml; Fisher, Pittsburgh, PA) dissolved in heparinized 0.9% saline (Butler
Schein, Dublin, OH). When not in use, catheters were sealed with plastic obturators.

After catheter insertion, some rats were then immediately mounted in a stereotaxic
apparatus (Kopf Instruments, CA) and implanted with cannulae for intra-cranial
microinjections similar to our previous studies (Schmidt et al., 2013; Schmidt et al., 2015a).
Bilateral guide cannulae (26 gauge; 14mm; Plastics One, Roanoke, VA) were implanted
2mm dorsal to the NAc core and shell and cemented in place by affixing dental acrylic to
stainless steel screws secured in the skull. The coordinates for the ventral ends of the
guide cannulae, relative to bregma according to the atlas of Paxinos and Watson (1997),
were as follows: NAc shell: +1.0 mm A/P, ±1.0 mm M/L, and -5.0 mm D/V; NAc core: +1.0
mm A/P, ±2.5 mm M/L, and -5.0 mm D/V. An obturator (14 mm, 33 gauge; Plastics One)
was inserted into each guide cannula to prevent occlusion.

Cocaine self-administration, extinction and reinstatement of cocaine seeking
Rats were allowed 7 days to recover from surgery before behavioral testing commenced.
Initially, rats were placed in operant conditioning chambers and allowed to lever-press for
intravenous infusions of cocaine (0.25 mg cocaine/59 µl saline, infused over a 5 s period)
on a fixed-ratio 1 (FR1) schedule of reinforcement. Rats were allowed to self-administer a
maximum of 30 injections per 120 min operant session. Once a rat achieved at least 20
infusions of cocaine in a single daily operant session under the FR1 schedule, the subject
was switched to a fixed-ratio 5 (FR5) schedule of reinforcement. The maximum number
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of injections was again limited to 30 per daily self-administration session under the FR5
schedule. For both FR1 and FR5 schedules, a 20 s time-out period followed each cocaine
infusion, during which time active lever responses were tabulated but had no scheduled
consequences. Responses made on the inactive lever, which had no scheduled
consequences, were also recorded during both the FR1 and FR5 training sessions.
Following 21 days of daily cocaine self-administration sessions, drug-taking behavior was
extinguished by replacing the cocaine solution with 0.9% saline. Daily extinction sessions
continued until responding on the active lever was <15% of the total active lever responses
completed on the last day of cocaine self-administration. Typically, it took ~7 days for rats
to meet this criterion. Once cocaine taking was extinguished, rats entered the
reinstatement phase of the experiment. During reinstatement test sessions, satisfaction of
the response requirement (i.e., five presses on the active lever) resulted in an infusion of
saline rather than cocaine. Using a between-sessions reinstatement paradigm, each
reinstatement test session was followed by extinction sessions until responding was again
<15% of the total active lever responses completed on the last day of cocaine selfadministration. Generally, 1–2 days of extinction were necessary to reach extinction
criterion between reinstatement test sessions.

Cocaine reinstatement
To determine if systemic administration of a GLP-1R agonist reduces cocaine seeking and
penetrates the brain, initial studies utilized the GLP-1R agonist Ex-4 tagged with
fluorescein (fluoro-Ex-4). In addition to binding GLP-1Rs in vitro and in vivo, fluoro-Ex-4
produces behavioral responses identical to unlabeled Ex-4 (Rajan et al., 2015; Reiner et
al., 2016). Once cocaine-taking behavior was extinguished, rats were pretreated with
vehicle, 0.1 and 0.2 µg/kg fluoro-Ex-4 (i.p.) one hour prior to a 10 mg/kg priming injection
of cocaine and subsequent reinstatement test sessions. Using a within-subjects design,
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each rat served as its own control and fluoro-Ex-4 doses were counterbalanced to avoid
rank order effects of drug treatment. To determine if the suppressive effects of Ex-4 on
cocaine seeking are mediated, in part, by activation of central GLP-1Rs, rats were deeply
anesthetized and transcardially perfused with 0.1 M PBS, pH 7.4, followed with 4%
formalin in 0.1 M PBS immediately following their cocaine priming-induced reinstatement
test session (i.e., three hours post systemic fluoro-Ex-4 administration). Once brains were
removed and post-fixed overnight in 4% formalin in 0.1 M PBS and then cryoprotected in
20% sucrose in 0.1 M PBS at 4 oC for three days. Coronal sections (30 µm) were then
taken at the level of the striatum using a cryostat (Leica 3050S; Leica Corp., Deerfiled, IL).
Brain

sections were

stored

in

0.1

M

PBS at 4 oC until

processed

using

immunohistochemistry.

The effects of intra-NAc core and shell infusions of Ex-4 on cocaine priming-induced
reinstatement of drug-seeking behavior were studied in separate cohorts of rats.
Obturators were removed from the guide cannulae and 33 gauge stainless steel
microinjectors (16 mm; Plastics One) were inserted. Ex-4 (0.005 and 0.05 µg/500 nl) and
vehicle were microinjected into the core and shell 10 min prior to a priming injection of
cocaine (10 mg/kg, i.p.). Microinjectors were left in place for an additional one min
following infusions in order to allow for diffusion of the drug solution away from the tips of
the microinjectors. Using a within-subjects design, each rat served as its own control. To
control for potential rank order effects of drug and vehicle administrations, all treatments
were counterbalanced across reinstatement test sessions.

Sucrose self-administration, extinction and reinstatement of sucrose seeking
Potential nonspecific rate-suppressing effects of intra-NAc Ex-4 were evaluated by
assessing the influence of this compound on the reinstatement of sucrose-seeking
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behavior. Separate cohorts of rats were trained initially to self-administer 45 mg sucrose
pellets (Research Diets, New Brunswick, NJ) on a FR1 schedule of reinforcement. Once
rats achieved stable responding for sucrose (defined as <20% variation in responding over
3 consecutive days) on the FR1 schedule of reinforcement, the response requirement was
increased to an FR5 schedule of reinforcement. Rats were limited to 30 sucrose pellets
within each daily operant session and were restricted to ~25 g of lab chow (Harlan Teklad,
Wilmington, DE) daily in their home cages for the duration of the experiment. Water was
available ad libitum in the home cage.

After two weeks of sucrose-maintained responding on an FR5 schedule of reinforcement,
rats underwent an extinction phase where active lever pressing no longer resulted in
sucrose delivery. Once active lever responding decreased to <15% of the maximum
number of responses completed on the last day of sucrose self-administration, rats
proceeded to reinstatement testing. Ex-4 (0.005 and 0.05 μg/500 nl) and vehicle were
microinjected into the NAc core and shell 10 min prior to the beginning of the reinstatement
test sessions. Using a within-subjects design, each rat served as its own control and doses
were counterbalanced across test sessions. The experimenter remotely administered one
sucrose pellet every two min for the first 10 min of the reinstatement session. A betweensession paradigm was used so that each daily reinstatement test session was followed by
an extinction session the following day until responding was again <15% of the total active
lever responses maintained by sucrose.

Verification of cannula placements
After completion of all behavioral experiments, rats were given an overdose of
pentobarbital (100 mg/kg, i.p.). Brains were removed and drop fixed in 10% formalin.
Coronal sections (100 µm) were taken at the level of the striatum with a vibratome and
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mounted on gelatin-coated slides. An individual blinded to behavioral responses verified
microinjection sites using light microscopy. Rats with cannula placements outside of the
targeted NAc subregion and/or excessive mechanical damage were excluded from
subsequent data analyses.

Immunohistochemistry
Immunohistochemistry was performed on free-floating coronal sections containing the
NAc according to modified procedures from previously published studies (Reiner et al.,
2016; Schmidt et al., 2016). Briefly, sections were washed with 1% sodium borohydride
followed by 0.1 M PBS. Sections were then blocked in 0.1 M PBS containing 5% normal
donkey serum and 0.2% Triton-X for 1 hr at room temperature. Sections were incubated
in primary antibodies overnight, and then, following a PBS rinse, they were incubated in
secondary antibodies for 2 hrs. The primary antibodies used were rabbit anti-NeuN
(1:1000; ab177487, Abcam), and goat anti-GFAP (1:1000; ab53554, Abcam). Secondary
antibodies were donkey anti-goat Alexa Fluor 594 (1:500), and donkey anti-rabbit Alexa
Fluor 647 (1:500) from Jackson ImmunoResearch. Sections were then washed and
mounted onto glass slides and coverslipped using Vectashield with DAPI (Vector
Laboratories; Burlingame, CA). Sections were visualized with a Leica SP5 X confocal
microscope using the 20x and 63x oil-immersion objectives along with 405, 488, 594 and
633 nm laser lines. Image z-stacks with the 63x oil-immersion were collected with a step
size of 1 μm, while 2–3x optical zoom z-stack images using the same objective were
collected with a step size of 0.5 μm.

Cocaine self-administration and yoked saline controls for electrophysiology experiments
Rats underwent catheterization as described above and were allowed to recover for 7
days before cocaine self-administration commenced. Each rat trained to respond for
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contingent cocaine infusions was paired with a yoked subject that received infusions of
saline. Lever pressing for the saline-yoked rats had no scheduled consequences, but
these animals received the same number and temporal pattern of infusions as selfadministered by the paired cocaine-experimental rat. Cocaine-experimental rats were
allowed to self-administer cocaine for 21 days. On day 22, cocaine was replaced with
saline for the extinction phase, which lasted until total active lever responding decreased
to <15% of the maximum number of responses completed on the last day of cocaine selfadministration. Typically, it took ~7 days for rats to meet this criterion.

Electrophysiology
Rats were decapitated following isoflurane anesthesia 24 hrs after the last extinction
session. Brains were rapidly removed and coronal slices (300 μm) containing the NAc
were cut using a Vibratome (VT1000S; Leica Microsystems) in an ice-cold artificial
cerebrospinal fluid (aCSF) solution in which NaCl was replaced with an equiosmolar
concentration of sucrose. aCSF contained the following (in mM): 130 NaCl, 3 KCl, 1.25
NaH2PO4, 26 NaHCO3, 10 glucose, 1 MgCl2, and 2 CaCl2, pH 7.2–7.4, when saturated
with 95% O2 and 5% CO2. Slices were incubated in aCSF at 32–34°C for 45 min and kept
at 22–25°C thereafter, until transfer to the recording chamber. All solutions had osmolarity
between 305 and 315 mOsm. Slices were viewed under an upright microscope (Eclipse
FN1; Nikon Instruments) with infrared differential interference contrast optics and a 40×
water-immersion objective. For recordings, the chamber was continuously perfused at a
rate of 1–2 ml/min with oxygenated aCSF heated to 32 ± 1°C using an automated
temperature controller (Warner Instruments). Recording pipettes were pulled from
borosilicate glass capillaries (World Precision Instruments) to a resistance of 4–7 MΩ
when filled with the intracellular solution. The intracellular solution contained the following
(in mM): 145 potassium gluconate, 2 MgCl2, 2.5 KCl, 2.5 NaCl, 0.1 BAPTA, 10 HEPES, 2
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Mg-ATP, and 0.5 GTP-Tris, pH 7.2–7.3, with KOH, osmolarity 280–290 mOsm. NAc core
and shell MSNs were identified by their morphology and low resting membrane potential
(−70 to −85 mV) in current clamp. A current step protocol (from -500 to +500 pA; 20 pA
increments; 500 ms step duration) was run to determine action potential frequency versus
current (f-I) relationship. To evaluate spontaneous excitatory postsynaptic currents
(sEPSCs) and paired-pulse ratio (PPR) of evoked EPSCs (eEPSCs), the cells were
voltage-clamped at -70 mV. For PPR, evoked responses were triggered by 100 μs
constant-current pulses with an inter-stimulus interval of 100 ms generated by an A310
Accupulser (World Precision Instruments) and delivered at 0.2 Hz via a bipolar tungsten
stimulation electrode positioned within 100 μm of the recorded cell. Ex-4 (1 μM) was
applied via the Y-tube perfusion system modified for optimal solution exchange in brain
slices. Neurons from a total of four animals per group were analyzed. All Ex-4 data were
collected after a minimum of 4 min of Ex-4 exposure. Currents were low-pass filtered at 2
kHz and digitized at 20 kHz using a Digidata 1440A acquisition board (Molecular Devices)
and pClamp10 software (Molecular Devices). Access resistance (10–30 MΩ) was
monitored during recordings by injection of 10 mV hyperpolarizing pulses; data were
discarded if access resistance changed >25% over the course of data collection.

Cocaine self-administration and yoked saline controls for quantitative real-time PCR
A separate group of cocaine-experimental and yoked saline control rats was used to study
the effects of voluntary cocaine taking and subsequent abstinence on GLP-1R expression
in the NAc. Cocaine-experimental rats were allowed to lever press for intravenous cocaine
infusions as described above for a total of 21 days. Rats were then sacrificed either
immediately after the first extinction session (Ext1) or following 7 consecutive days of
extinction (Ext7), a time point associated with robust cocaine-seeking behavior. Brains
were collected and flash frozen in -20C isopentane and stored at -80C. Brains were
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subsequently mounted on a cryostat (Leica 3050S; Leica Corp., Deerfiled, IL) and coronal
sections at the level of the NAc were taken. Bilateral 1 mm 3 micropunches of the NAc core
and shell were collected for quantitative real-time PCR analyses of GLP-1R expression.
mRNA expression was quantified using Taqman gene expression kits (GLP-1R:
Rn00562406_m1; GAPDH: Rn01775763_g1; ThermoFisher Scientific, Waltham, MA).
qPCR was conducted using an Eppendorf Mastercycler ep realplex2 and the comparative
threshold cycle method was used to quantify relative mRNA expression. Relative foldexpression of NAc GLP-1R transcripts at Ext1 and Ext7 were normalized to yoked saline
controls and GAPDH levels.

Statistics
For all cocaine and sucrose reinstatement experiments, the total mean active lever
responses, inactive lever responses, and infusions were analyzed with two-way repeated
measures ANOVAs.

Pairwise analyses were made using Bonferroni post-hoc tests

(p<0.05). For electrophysiological studies, all analyses were completed using Clampfit 10
(Molecular Devices). Differences in action potential frequency were analyzed with twoway repeated measures ANOVAs with current injection step and drug treatment as
repeated measures and action potential frequency as a dependent variable. Bonferroni
post-hoc tests were used for pair-wise comparisons (p<0.05). Action potential amplitude
was measured from threshold to peak. Action potential duration was measured as duration
at 50% of peak amplitude (i.e. half-width). Mean sEPSC frequencies were analyzed from
20 s trace segments. Mean sEPSC amplitude and duration were quantified from an
average trace of at least 50 individual events in each cell. sEPSC duration was calculated
as the rate of a mono-exponential fitted to the decay phase of the mean sEPSC trace.
PPRs were calculated by averaging 5–10 responses and dividing the peak amplitude of
the second evoked EPSC by the peak amplitude of the first evoked EPSC. Statistical
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comparisons of PPR and sEPSC data were done using two-tailed paired Student's t tests.
Statistical significance thresholds were set at p<0.05.
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Results
Peripheral administration of fluoro-Ex-4 penetrates the brain, localizes in the NAc and
attenuates cocaine seeking in rats
Total active and inactive lever responses (mean ± SEM) in rats pretreated with systemic
fluoro-Ex-4 (vehicle, 0.1 and 0.2 µg/kg, i.p.) prior to a cocaine priming-induced
reinstatement test session are shown in Figure 1A. These data were analyzed with a twoway repeated measures ANOVA, which revealed significant main effects of treatment
[F(2,24)=7.681, p<0.01] and lever [F(1,12)=10.21, p<0.01] as well as a significant
interaction between lever and treatment [F(2,24)=5.509, p<0.05]. Subsequent pairwise
analyses indicated that active lever responses were significantly different between vehicle
and 0.1 and 0.2 µg/kg fluoro-Ex-4 (Bonferroni, p<0.05). No significant differences were
found on inactive lever responding between treatments.

Immediately following the reinstatement test session, rats pretreated with systemic fluoroEx-4 were sacrificed and their brains were collected to determine if fluoro-Ex-4 localized
in the NAc. Coronal sections of the striatum were processed using immunohistochemistry
to label neurons and astrocytes. Confocal microscopy revealed colocalization of fluoroEx-4 with both GFAP-positive astrocytes and NeuN-positive neurons in both the NAc core
(Figure 3.1B) and shell (Figure 3.1C). Overall, these data revealed that systemic
administration of fluoro-Ex-4 prior to a cocaine reinstatement test session penetrates the
brain and may activate GLP-1Rs in the NAc to reduce drug-seeking behavior.

Administration of Ex-4 directly into the NAc core and shell dose-dependently attenuates
cocaine seeking in rats.
To determine if activation of NAc GLP-1Rs alone is sufficient to attenuate cocaine
reinstatement, Ex-4 was infused directly into the core and shell subregions of the NAc 10
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minutes prior to a cocaine priming-induced reinstatement test session. Total active and
inactive lever responses (mean ± SEM) in rats pretreated with intra-NAc core Ex-4
(vehicle, 0.005 or 0.05 µg/500nl) are shown in Figure 3.2A. These data were analyzed
using a two-way repeated measures ANOVA, which revealed significant main effects of
treatment [F(2,32)=5.004, p<0.05] and lever [F(1,16)=46.04, p<0.0001] as well as a
significant treatment x lever interaction [F(2,32)=4.248, p<0.05]. Subsequent pairwise
analyses indicated that active lever responses were significantly different between vehicle
and 0.005 and 0.05 µg Ex-4 (Bonferroni, p<0.05). No significant differences were found
on inactive lever responding between treatments.

Total active and inactive lever responses (mean ± SEM) in rats pretreated with intra-NAc
shell Ex-4 (vehicle, 0.005 or 0.05 µg/500nl) are shown in Figure 3.2B. These data were
analyzed using a two-way repeated measures ANOVA, which revealed significant main
effects of treatment [F(2,28)=5.401, p<0.01] and lever [F(1,14)=100.3, p<0.0001] as well
as a significant treatment x lever interaction [F(2,28)=5.435, p<0.05]. Subsequent pairwise
analyses indicated that active lever responses were significantly different between vehicle
and 0.05 µg Ex-4 (Bonferroni, p<0.05). No significant differences were found on inactive
lever responding between treatments. Microinjections sites in the NAc core and shell are
illustrated in Figure 3.2C.

Administration of Ex-4 directly into the NAc core and shell had no effect on sucrose
seeking in rats.
While intra-NAc administration of Ex-4 had no significant effect on inactive lever
responding, one could argue that responses were too low to assess the potential ratesuppressing effects of intra-NAc Ex-4 treatment. Total active and inactive lever responses
(mean ± SEM) are shown in Figures 3.3A and 3.3B for rats pretreated with intra-NAc core
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and shell Ex-4, respectively, prior to a sucrose reinstatement test session. There were no
effects of intra-NAc core or shell Ex-4 on sucrose seeking. Taken together with the cocaine
reinstatement studies in Figure 3.2, these data indicate that activation of GLP-1Rs in the
core and shell reduces cocaine seeking and that these effects are not due to general motor
impairments.

Ex-4 increases action potential frequency in NAc MSNs of cocaine-experienced rats
Using whole-cell current clamp, we evaluated the effects of Ex-4 on action potential
frequency of MSNs in the NAc of cocaine-experienced rats (Figure 3.4). Application of 1
μM Ex-4 increased the frequency of action potential firing in the NAc core (Figures 3.4A
and 3.4B) and shell (Figures 3.4C and 3.4D) of cocaine-experienced rats. These data
were analyzed with two-way repeated measures ANOVAs, which indicated no significant
main effect of drug treatment [F(1,6)=1.185, p=0.32, partial 2=0.165], a significant main
effect of current injection [F(10,60)=38.94, p<0.01, partial 2=0.866], and a significant drug
by current interaction [F(10,60)=3.18, p<0.01, partial 2=0.346] in the NAc core.
Subsequent pairwise comparisons revealed significant differences between aCSF and Ex4 at 100, 120, 140, 160, 180, 200, and 220 pA current steps (Bonferroni, p<0.05). In the
NAc shell, two-way repeated measures ANOVAs revealed significant main effects of drug
treatment [F(1,5)=11.8, p<0.05, partial 2=0.702] and current injection [F(10,50)=80.87,
p<0.01, partial 2=0.942], and no drug by current interaction [F(10,50)=0.864, p=0.57,
partial 2=0.147]. Subsequent pairwise comparisons revealed significant differences
between aCSF and Ex-4 at 160, 180, and 200 pA current steps (Bonferroni, p<0.05).
When the core and shell data were combined, a two-way repeated measures ANOVA
indicated a significant main effect of drug treatment [F(1,12)=5.24, p<0.05, partial
2=0.304), a significant main effect of current [F(10,120)=105.7, p<0.0001, partial
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2=0.898), and a significant drug by current interaction [F(10,120)=2.372, p<0.05, partial
2=0.165). Subsequent pairwise comparisons indicated significant differences between
aCSF and Ex-4 at 120, 140, 160, 180, 200 and 220 pA current steps (Bonferroni, p<0.05).
Taken together, these results indicate that Ex-4 elicits broad changes in excitability of
MSNs in the NAc core and shell of cocaine-experienced rats. Notably, the significant drug
by current interaction in the core and combined core/shell datasets indicate that the effect
of Ex-4 on intrinsic excitability may be sensitive to the depolarization state of the neuronal
membrane (see Discussion).

Although we focused on electrophysiological correlates of behavioral effects in cocaineexperienced rats, we also collected data from MSNs in the NAc of yoked saline rats. We
did not discriminate between NAc subregions in these experiments and our analyses of
MSNs from these rats revealed no main effect of drug treatment [F(1,6)=0.004, p=0.95,
partial 2=0.001]; a significant main effect of current injection [F(10,60)=37.44, p<0.01,
partial 2=0.862] and no drug by current interaction [F(10,60)=1.253, p=0.27, partial
2=0.173) (Figures 3.4E, 3.4F, and 3.6). These results indicate that, in contrast to our
findings in the core/shell of cocaine-experienced rats, Ex-4 application has no effect on
MSNs in the NAc of yoked saline rats. No other measures of membrane excitability were
altered by Ex-4 application in cocaine-experienced or yoked saline control rats (Figure
3.6).

Previously, we reported presynaptic effects of GLP-1R activation in the VTA and NAc core
of drug-naïve rats (Mietlicki-Baase et al., 2013; Mietlicki-Baase et al., 2014). To explore
the role of presynaptic GLP-1R activation, we analyzed sEPSCs and PPR of eEPSCs of
NAc core and shell MSNs in cocaine-experienced rats and yoked saline controls. In
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contrast to our previous findings, Ex-4 application onto slices from cocaine-experienced
rats had no effect on sEPSC frequency or PPR of eEPSCs (Figure 3.5). Ex-4 also had no
effect on sEPSC amplitude or duration in MSNs from cocaine-experienced rats (Figure
3.7). Moreover, no effects of Ex-4 on PPR of eEPSCs or on sEPSC frequency, amplitude,
and duration in MSNs from cocaine-naïve rats were observed (data not shown).
Collectively, these findings indicate that stimulation of GLP-1Rs is associated with
increased intrinsic, but not synaptic, excitability of MSNs in the NAc core and shell.

Abstinence following cocaine self-administration has no effect on GLP-1R expression in
the NAc.
Using quantitative real-time PCR, we assessed the effects of cocaine self-administration
and subsequent extinction sessions on expression of GLP-1Rs in the NAc core and shell
to determine the potential effects of voluntary cocaine taking and subsequent abstinence
on endogenous NAc GLP-1 signaling (Figure 3.7A). There were no changes in GLP-1R
mRNA expression in the NAc core (Figure 3.7B) and shell (Figure 3.7C) of cocaineexperienced rats following one (Ext1) and seven (Ext7) days of extinction when compared
to yoked saline controls.
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Discussion
The present study represents the first investigation of the role of GLP-1Rs in the NAc core
and shell in the reinstatement cocaine-seeking behavior. Here, we demonstrate for the
first time that (1) systemically administered fluoro-Ex-4 localizes in the NAc and attenuates
cocaine seeking; (2) direct activation of GLP-1Rs in the NAc core and shell is sufficient to
reduce cocaine, but not sucrose, seeking; (3) activation of GLP-1Rs increases frequency
of MSN action potential firing in the NAc core and shell following extinction of voluntary
cocaine taking; and (4) abstinence following cocaine self-administration does not alter
endogenous GLP-1R expression in the NAc. Taken together, these results suggest that
increased excitability of NAc MSNs may contribute to the suppressive effects of a GLP1R agonist on cocaine priming-induced reinstatement of drug-seeking behavior.

Our findings contribute to and expand upon previous studies demonstrating a role for GLP1Rs in addiction-like behaviors. An emerging literature indicates that systemic
administration of GLP-1R agonists reduces the rewarding and reinforcing effects of
cocaine (Egecioglu et al., 2013b; Graham et al., 2013; Sorensen et al., 2015). However,
the mechanisms underlying these effects are not clear. GLP-1Rs are expressed
throughout the brain in nuclei known to mediate cocaine reinforcement and drug-seeking
behavior, including the VTA and NAc (Merchenthaler et al., 1999; Schmidt et al., 2005;
Schmidt and Pierce, 2010). We have shown previously that activation of GLP-1Rs in the
VTA attenuates the reinforcing efficacy of cocaine (Schmidt et al., 2016). Here, we show
that systemic fluoro-Ex-4 crosses the blood brain barrier, localizes in the NAc and
attenuates cocaine priming-induced reinstatement of drug-seeking behavior. Fluoro-Ex-4
was identified in proximity to both neurons and astrocytes in the NAc core and shell
suggesting that GLP-1R activation on these two cell populations mediates the effects of
peripheral fluoro-Ex-4 on cocaine seeking. However, future studies are required to
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investigate the exact role of GLP-1Rs on neurons and astrocytes in the NAc in cocaine
seeking.

Infusions of Ex-4 directly into the NAc core and shell were sufficient to attenuate cocaine
priming-induced reinstatement of drug-seeking behavior. These are the first data
supporting a novel role for GLP-1Rs in the NAc in drug-seeking behavior, generally, and
cocaine reinstatement, specifically. Interestingly, the effects of GLP-1R signaling on
cocaine seeking differed between NAc subregions. Cocaine-seeking behavior was
decreased in rats pretreated with 0.05 µg Ex-4 in both the NAc core and shell. In contrast,
0.005 µg Ex-4 significantly attenuated cocaine seeking when infused directly into the NAc
core, but not shell. GLP-1 signaling in the NAc has also been shown to affect food intake
(Dossat et al., 2013). The effects of GLP-1R activation on intake of palatable food are
more pronounced when Ex-4 is infused into the NAc core compared to the shell (Alhadeff
et al., 2012). The lowest effective dose of Ex-4 used in this study was 0.025 µg, which
produced a transient effect on food intake following activation of GLP-1Rs in the NAc core
and no effect on food intake when infused into the NAc shell (Alhadeff et al., 2012).
Collectively, these findings suggest that GLP-1 signaling in the NAc core may play a more
prominent role in regulating drug-seeking behavior and hedonic feeding. Moreover, results
from the present study also identify doses of a GLP-1R agonist that selectively reduce
cocaine seeking and do not affect ad libitum food intake (Alhadeff et al., 2012; Dickson et
al., 2012; Mietlicki-Baase et al., 2014) or produce aversive malaise-like effects (Hayes et
al., 2011a; Dickson et al., 2012; Kanoski et al., 2012).

Administration of Ex-4 directly into the NAc dose-dependently reduces sucrose selfadministration on a progressive ratio schedule of reinforcement (Dickson et al., 2012).
Doses of Ex-4 lower than 0.1 µg when infused into the NAc do not affect operant
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responding for sucrose or chow intake (Dickson et al., 2012). Consistent with these
effects, the behaviorally relevant dose of Ex-4 (0.05 µg) that attenuated cocaine seeking
when infused into the NAc core and shell did not affect the reinstatement of sucroseseeking behavior. Combined with our systemic administration study identifying doses of
Ex-4 that reduce cocaine seeking and do not produce adverse feeding effects (Hayes et
al., 2011a; Kanoski et al., 2012), these findings further strengthen evidence supporting the
selectivity of lower doses of GLP-1R agonists in attenuating cocaine seeking versus nondrug motivated behaviors.

The neural mechanisms underlying the effects of GLP-1R agonists on drug-mediated
behaviors are not clear. GLP-1R agonists have been shown to elicit increases in neuronal
activity in various brain regions by both pre- and post-synaptic mechanisms. In
hypocretin/orexin neurons of the lateral hypothalamus, Ex-4 increased action potential
firing by post-synaptic sodium channel-dependent mechanisms and also increased presynaptic glutamate release (Acuna-Goycolea and van den Pol, 2004). In our study, the
interaction between injected current level and Ex-4 suggests that Ex-4 may exert a
preferential effect at specific subtypes of voltage-gated sodium channels or unidentified
low voltage-gated conductances. Ex-4 has also been shown to enhance GABAA receptormediated synaptic and tonic currents in rat hippocampal pyramidal CA3 neurons (Korol et
al., 2015b). Finally, we have previously reported that Ex-4 increases miniature EPSC
frequency and decreases PPR of AMPA receptor-mediated currents in the VTA and NAc
core of drug-naïve rats, effects consistent with increased release of pre-synaptic
glutamate (Mietlicki-Baase et al., 2013; Mietlicki-Baase et al., 2014). Interestingly, while
cell-to-cell variability in the NAc of yoked saline animals (Figure 4F, inset) may indicate
discrete effects in the core and the shell, it also raises the possibility that regulation of
action potential firing may depend on relative efficacy of Ex-4 at excitatory vs. inhibitory
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inputs to NAc MSNs. Together, these observations paint a complex picture of the
mechanisms by which GLP-1R activation regulates neuronal output. Here, we show that
post-synaptic action potential frequency was increased by Ex-4 application in both the
NAc core and shell of cocaine-experienced rats. However, pre-synaptic glutamate release
mechanisms were not affected by GLP-1R activation in the NAc of cocaine-experienced
or yoked saline rats. Our findings suggest that cocaine and/or operant chamber
experience may facilitate a shift from a pre-synaptic to a post-synaptic site of Ex-4 action
in the NAc. Notably, our qPCR results indicate that this dynamic switch is unlikely to result
from an overall difference in GLP-1R mRNA expression in the NAc of cocaine-experienced
rats, although a change in the ratio of pre-synaptic versus post-synaptic GLP-1R protein
levels remains a possibility.

Our results show that GLP-1R activation in the NAc core and shell of cocaine-experienced
rats facilitates MSN firing rates and attenuates cocaine-seeking behavior. Cocaine
abstinence is associated with decreased NAc membrane excitability due to changes in
conductance of sodium, calcium and potassium (Zhang et al., 1998; Zhang et al., 2002;
Hu et al., 2004). Lower membrane excitability during cocaine abstinence may enhance
action potential sensitivity to GLP-1R activation that we report here. Cocaine exposure is
likely a critical component in this scenario, given the previous findings of minimal effects
of Ex-4 on NAc MSN firing in drug-naïve rats (Mietlicki-Baase et al., 2014). Indeed, a
recent study showed that Ex-4 reduces cocaine-evoked, but not electrically stimulated,
phasic release of dopamine in the NAc core (Fortin and Roitman, 2017). Moreover,
systemic Ex-4 pretreatment reduces cocaine-evoked dopamine release in the NAc
(Egecioglu et al., 2013b; Sorensen et al., 2015) and lateral septum (Reddy et al., 2016).
However, GLP-1 signaling has also been shown to regulate other neurotransmitter
systems including glutamatergic (Mietlicki-Baase et al., 2014) and GABAergic (Korol et
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al., 2015b) transmission in the brain. Understanding the mechanisms by which GLP-1R
activation in the NAc reduces cocaine seeking will benefit from a comprehensive analysis
of how Ex-4 regulates integration of synaptic and intrinsic MSN excitability in the context
of drug priming-induced reinstatement. Our results indicate that intrinsic GLP-1R-coupled
mechanisms may contribute to previous findings that a broad increase in NAc MSN action
potential output is associated with attenuation of rewarding consummatory behaviors
(Nicola et al., 2004; Wheeler and Carelli, 2009)

Previously, we showed that cocaine activates GLP-1-expressing neurons in the nucleus
tractus solitarius (NTS) of the caudal brainstem (Schmidt et al., 2016). Since the NTS
sends monosynaptic GLP-1-expressing efferent projections to the NAc (Alhadeff et al.,
2012), these findings suggest that increased endogenous GLP-1 signaling in the brain
may represent a homeostatic response to cocaine that functions to reduce on-going
cocaine consumption (Schmidt et al., 2016). However, no studies to date have
investigated the potential role of endogenous central GLP-1 signaling in cocaine seeking.
Here, we show that GLP-1R mRNA expression in the NAc core and shell was not altered
following one and seven days of extinction. Ex-4 binding has been shown to regulate
trafficking and surface expression of GLP-1Rs (Roed et al., 2014). It is possible that Ex-4
infusions into the NAc increase trafficking of GLP-1Rs to the post-synaptic membrane
resulting in enhanced firing of MSNs. Additionally, cocaine may affect endogenous GLP1 release from the NTS, which could also result in altered GLP-1R trafficking and surface
expression in the NAc. Future studies are required to further delineate the role of
endogenous central GLP-1 signaling in cocaine seeking, including whether cocaine
affects GLP-1R trafficking and/or the kinetics of ligand-mediated GLP-1R trafficking.
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A growing literature supports the efficacy of GLP-1R agonists in reducing cocainemediated behaviors. Our findings expand this literature and are the first to indicate that
exogenous activation of GLP-1Rs in the NAc core and shell is sufficient to reduce cocaineseeking behavior. Importantly, the doses of Ex-4 shown to attenuate cocaine seeking do
not produce adverse feeding and malaise-like effects. While future studies are needed to
further delineate the molecular and neurophysiological mechanisms by which GLP-1R
activation in the NAc reduces cocaine seeking, our data show that the suppressive effects
of intra-NAc Ex-4 on cocaine seeking are associated with increased action potential firing
of MSNs. These findings provide strong rationale for pilot translational studies screening
the efficacy of GLP-1R agonists in human cocaine addicts.
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Figures
Figure 1
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Figure 3.1 Systemic administration of the GLP-1R agonist Ex-4 attenuates cocaine
seeking and localizes in the NAc. Rats were pretreated with intraperitoneal infusions of
vehicle, 0.1 and 0.2 µg/kg fluoro-Ex-4 prior to a cocaine priming-induced reinstatement
test session (n=7 per treatment). (A) Total numbers of active lever responses (mean ±
SEM) were significantly different between rats pretreated with vehicle and 0.1 and 0.2
µg/kg fluoro-Ex-4. (*p<0.05, Bonferroni). Immediately following the reinstatement test
session, rats pretreated with systemic fluoro-Ex-4 were sacrificed and brains removed.
Immunohistochemical analyses identified fluoro-Ex-4 (green fluorescence = fluoro-Ex-4)
in the NAc core (B) and shell (C) where it localized with neurons (blue fluorescence =
NeuN) and astrocytes (red fluorescence = GFAP).
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Figure 2
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Figure 3.2 Administration of Ex-4 directly into the NAc dose-dependently attenuates
cocaine-seeking behavior in rats. Cocaine seeking was attenuated in rats pretreated
with Ex-4 in the NAc core and shell prior to a cocaine priming-induced reinstatement test
session. (A) Total numbers of active lever responses (mean ± SEM) were significantly
different between rats pretreated with vehicle and 0.005 and 0.05 µg Ex-4 in the NAc core
(n=9 per treatment). (B) Total numbers of active lever responses were also significantly
different between rats pretreated with vehicle and 0.05 µg Ex-4 in the NAc shell (n=8 per
treatment). (C) Microinjection sites corresponding with infusions into the core (open
circles) and shell (closed circles). (*p<0.05, Bonferroni)
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Figure 3
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Figure 3.3 Intra-NAc administration of Ex-4 does not affect sucrose seeking in rats.
Ex-4 (0.005 and 0.05 µg) administered directly into the NAc core (A) and shell (B) did not
alter sucrose-seeking behavior in rats. Microinjection sites corresponding with infusions
into the core (open circles) and shell (closed circles) are shown in C. (n=6 per treatment
in the core; n=8 per treatment in the shell)
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Figure 4

aCSF
60mV
100ms

Ex-4

C. NAc shell

Spike Frequency

B.

A. NAc core

40

aCSF
Ex-4

30

*

20
10
0

0

100
200
300
Current Injected (pA)

60mV
100ms

Ex-4

40

aCSF
Ex-4

30

**

aCSF

Spike Frequency

D.

20
10
0

0

100
200
300
Current Injected (pA)

Figure 3.4 Ex-4 increases action potential frequency in NAc core and shell MSNs in
cocaine-experienced rats. Representative membrane potential traces recorded before
(aCSF) and after (Ex-4) application of Ex-4 (1µM) in response to a hyperpolarizing (-100
mV) and a depolarizing (+200 mV) current step in MSNs from cocaine-experienced and
yoked saline rats (A, C, E). Corresponding plots of mean action potential frequency (+/SEM) across a range of injected current steps are shown in B, D and F. Insets illustrate
cell-to-cell variability of spike frequency at the +180 pA step for all recorded neurons
before and after Ex-4 application. Note that cells with identical aCSF or Ex-4 values are
not distinguishable. Thick black lines in the insets represent spike frequency means. (*
p<0.05, for drug treatment by current interaction in Cocaine: NAc core and * p<0.05, for
drug treatment in Cocaine: NAc shell, two-way repeated measures ANOVAs). Cocaine:
NAc core, n=7 cells, N=4 rats; Cocaine NAc shell, n=6 cells, N=4 rats; Yoked Saline: NAc
core/shell, n=7 cells, N=3 rats.
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Figure 5
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Figure 3.5 Ex-4 effects on action potential firing in NAc MSNs are not modulated by
presynaptic mechanisms.
Representative traces of sEPSCs from before (aCSF) and after (Ex-4) application of Ex4 (1µM) in the NAc core and shell are shown in A. Ex-4 had no effect on sEPSC frequency
in either subregion of the NAc (B). Representative traces showing paired pulse ratios
(PPRs) before and after Ex-4 application are shown in C. Ex-4 had no effect on PPR in
the core and shell (D). (n=8 cells, N=4 rats for Cocaine: NAc core; n=8 cells, N=4 rats for
Cocaine: NAc shell).

77

Table 1: Effects of exendin-4 on neuronal activity in the nucleus accumbens
Cocaine: NAc Core

Cocaine: NAc Shell

Yoked Saline: NAc Core/Shell

aCSF

exendin-4

aCSF

exendin-4

aCSF

exendin-4

76.0 ± 1.3 mV

71.0 ± 1.9 mV

73.5 ± 1.4 mV

72.0 ± 2.1 mV

78.0 ± 2.4 mV

77.0 ± 2.3 mV

Rheobase

160 ± 24 pA

132 ± 37 pA

151 ± 16 pA

140 ± 16 pA

190 ± 27 pA

176 ± 25 pA

Action potential amplitude

88 ± 1.9 mV

87 ± 2.6 mV

83 ± 1.5 mV

83 ± 3.2 mV

86 ± 2.8 mV

85 ± 3.3 mV

1.1 ± 0.04 ms

1.2 ± 0.07 ms

1.1 ± 0.03 ms

1.1 ± 0.07 ms

1.02 ± 0.04 ms

1.05 ± 0.05 ms

sEPSC amplitude

24.58 ± 1.93 pA

24.09 ± 2.02 pA

25.88 ± 2.39 pA

24.45 ± 1.27 pA

24.79 ± 4.0 pA

23.93 ± 2.43 pA

sEPSC duration

4.52 ± 0.42 ms

4.86 ± 0.19 ms

4.21 ± 0.23 ms

4.05 ± 0.42 ms

4.75 ± 0.42 ms

4.86 ± 0.19 ms

Resting membrane potential

Action potential duration

Figure 3.6 Effects of Ex-4 on neuronal activity in the NAc
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Figure 6
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Figure 3.7 Cocaine self-administration and subsequent abstinence are not
associated with altered expression of GLP-1Rs in the NAc. (A) Experimental design
depicting the drug taking and extinction phases. Tissue was collected immediately after
extinction sessions. GLP-1R mRNA expression in the NAc core (B) and shell (C) was not
altered following one (Ext1; n=7) and seven (Ext7; n=9) days of abstinence compared to
yoked saline controls. (p>0.05; un-paired t-tests)
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Abstract
Current preclinical literature demonstrates the promise of GLP-1 receptor (GLP-1R)
agonists as therapeutics for cocaine use disorder. Our recently published studies showed
that activation of central GLP-1Rs in the ventral tegmental area (VTA) attenuated the
reinstatement of cocaine-seeking behavior, an animal model of relapse. The goal of this
study was to expand our understanding of the central GLP-1R-expressing circuits and cell
types that regulate cocaine seeking. The lateral dorsal tegmental nucleus (LDTg) is a brain
region that expresses GLP-1Rs, receives direct projections from GLP-1-producing
neurons in nucleus tractus solitarius (NTS), and plays a critical role in cocaine seeking.
Here, we showed that administration of the GLP-1R agonist exendin-4 (Ex-4) into the
LDTg significantly reduced cocaine seeking at a dose that does not affect food intake or
body weight. We also demonstrated that GLP-1Rs are expressed primarily on GABAergic
neurons in the LDTg and that Ex-4 decreased cocaine seeking, in part, through activation
of LDTg GABA neurons that project to the VTA. Additionally, we investigated the role of
endogenous hindbrain GLP-1-producing circuits in cocaine seeking by chemogenetically
activating NTS afferents to the LDTg. We found that NTS-to-LDTg circuit activation
decreased cocaine seeking via a GLP-1-dependent mechanism. Overall, these findings
identified a central mechanism by which Ex-4 attenuates cocaine seeking and
demonstrated that GLP-1R signaling in the LDTg is an important regulator of cocainecraving induced relapse.
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Introduction
Cocaine continues to be one of the highest used illicit drugs used in the United States and
a major public health concern (NSDUH, 2018). Although there is still a lack of available
FDA-approved pharmacotherapies to treat this disease, recent preclinical studies have
highlighted the glucagon-like peptide-1 (GLP-1) system as an attractive potential target
for treating cocaine use disorder [for review see: (Hernandez and Schmidt, 2019)].

GLP-1 is a satiation hormone and neuropeptide known to regulate the rewarding value of
food as well as drugs of abuse through activation of central GLP-1 receptors (GLP-1Rs)
in the mesolimbic reward system (Skibicka, 2013; Hayes and Schmidt, 2016). Our recently
published findings show that central GLP-1Rs are a potential target for treating cocaine
craving-induced relapse as administration of the GLP-1R agonist exendin-4 (Ex-4) into the
ventral tegmental area (VTA) or nucleus accumbens (NAc) decreases the reinstatement
of cocaine-seeking behavior, an animal model of relapse (Hernandez et al., 2018;
Hernandez et al., 2019). Since GLP-1 analogs are currently FDA-approved for treating
type II diabetes and obesity (Lovshin and Drucker, 2009; Shukla et al., 2015), these preclinical findings suggest that GLP-1R agonists could be repurposed for treating cocaine
use disorder. However, the exact mechanisms by which Ex-4 attenuates cocaine seeking
are unclear. Thus, in order further support the use of GLP-1R agonists in treating cocaine
relapse, it is imperative to investigate the central mechanisms that underly the effects of
Ex-4 on cocaine seeking and expand our knowledge of the GLP-1-expressing circuits and
cell types that regulate cocaine-mediated behaviors.

The laterodorsal tegmental nucleus (LDTg), a region of the mesopontine tegmentum,
receives input from limbic sites and sends direct projections to the VTA (Cornwall et al.,
1990; Oakman et al., 1995; Omelchenko and Sesack, 2005). Thus, the LDTg is
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anatomically positioned to influence the mesolimbic reward system and drug-mediated
behaviors. Indeed, the LDTg is known to be critical for burst firing of dopamine neurons
and dopamine release in the NAc through its connections to the VTA (Blaha et al., 1996;
Forster and Blaha, 2000; Omelchenko and Sesack, 2005; Lodge and Grace, 2006; Dautan
et al., 2016). In addition, activation of excitatory LDTg-to-VTA projections elicits
conditioned place preference (CPP) and reinforces operant responding in rodents
(Lammel et al., 2012; Steidl and Veverka, 2015; Xiao et al., 2016; Steidl et al., 2017). With
regard to cocaine-mediated behaviors, ablation or pharmacological inactivation of
cholinergic neurons and inhibition of glutamate signaling in the LDTg increases the latency
to self-administer cocaine, inhibits acquisition of cocaine CPP, and attenuates the
reinstatement of cocaine-seeking behavior (Schmidt et al., 2009; Shinohara et al., 2014;
Steidl et al., 2015). While these findings clearly indicate that excitatory LDTg signaling
drives in reward and cocaine-mediated behaviors, the role of inhibitory signaling in the
LDTg remains largely unexplored.

The LDTg expresses GLP-1Rs and LDTg GLP-1R activation via Ex-4 decreases feeding
behaviors in drug-naïve rats (Goke et al., 1995; Merchenthaler et al., 1999; Reiner et al.,
2018). In addition to expressing GLP-1Rs, the LDTg also receives direct projections from
GLP-1-producing neurons in the nucleus tractus solitarius (NTS) of the brainstem
(Cornwall et al., 1990; Rinaman, 2010; Grill and Hayes, 2012; Reiner et al., 2018). Studies
show that cocaine increases neuronal activity in the NTS, including GLP-1-producing
neurons (Zahm et al., 2010; Buffalari and Rinaman, 2014; Schmidt et al., 2016).
Additionally, our previous studies show that cocaine taking and subsequent abstinence
dynamically regulate expression of preproglucagon (PPG), the gene that encodes GLP-1,
in the NTS (Hernandez et al., 2018). While these studies indicate that cocaine influences
the NTS GLP-1 system, no studies to date have examined the endogenous relevance of
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GLP-1 circuits in cocaine seeking. Taken together, we hypothesized that both exogenous
activation of LDTg GLP-1Rs and endogenous GLP-1 signaling in the LDTg attenuates
cocaine seeking, possibly through inhibitory mechanisms.

Overall, the present study aimed to: 1) determine if GLP-1R activation in the LDTg
decreases cocaine seeking; 2) investigate the mechanisms by which Ex-4 acts in the
LDTg to attenuate cocaine seeking; 3) examine the role of endogenous GLP-1 circuits
that project to the LDTg in regulating cocaine-seeking behavior. Using behavioral
pharmacology, fluorescent in-situ hybridization, transgenic rat models, viral-mediated
knockdown of GLP-1Rs and chemogenetic manipulations of hindbrain circuits, our data
establish that LDTg GLP-1Rs play a critical role in cocaine seeking. We show that GLP1Rs are expressed primarily on GABA neurons in the LDTg and that Ex-4 activates
GABAergic LDTg-to-VTA projections to reduce cocaine-seeking behavior. We also
demonstrate that NTS-to-LDTg circuit activation is sufficient to decrease cocaine seeking
through a GLP-1-dependent mechanism. Thus, these results highlight a novel role for
hindbrain circuits and GLP-1R signaling in the regulation of cocaine-seeking behavior.
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Materials and Methods
Animals and housing
Male Sprague-Dawley rats weighing 220-250g were obtained from Taconic Laboratories
(Rensselaer, NY). Transgenic rats expressing Cre recombinase under the GAD1 promoter
(LE-Tg(Gad1-iCre)3Ottc), were purchased from the Rat Resource and Research Center
(RRRC P40OD011062; University of Missouri, Columbia, MO). Rats were housed
individually on a 12/12 hr light/dark cycle and maintained on ad libitum food and water.
The experimental protocols were consistent with the guidelines issued by the U.S.
National Institutes of Health and were approved by the University of Pennsylvania’s
Institutional Animal Care and Use Committee.

Drugs
Cocaine was obtained from the National Institute on Drug Abuse (Rockville, MD) and
dissolved in bacteriostatic 0.9% saline. Ex-4 and exendin-(9-39) were purchased from
Bachem (Torrance, CA) and were dissolved in artificial cerebrospinal fluid (aCSF; Harvard
Apparatus, Holliston, MA). Fluoro-Ex-4 was purchased from AnaSpec (Fremont, CA) and
dissolved in bacteriostatic 0.9% saline. Clozapine N-Oxide (CNO) was obtained from
Toronto Research Chemicals (North York, ON) and dissolved in 1% DMSO in
bacteriostatic 0.9% saline. The doses and time course of administration for each of the
aforementioned pharmacological compounds were based on the following systemic and
intra-cranial microinjection experiments in rats: Ex-4 (Alhadeff et al., 2012; Schmidt et al.,
2016; Hernandez et al., 2018), exendin-(9-39) (Alhadeff et al., 2012; Schmidt et al., 2016;
Hernandez et al., 2018), fluoro-Ex-4 (Kanoski et al., 2012; Reiner et al., 2016; Hernandez
et al., 2018; Hernandez et al., 2019) and CNO (Boender et al., 2014; Scofield et al., 2015;
Alhadeff et al., 2017a; McGlinchey and Aston-Jones, 2018).
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Surgery
Rats were handled daily and allowed one week to acclimate to their home cages upon
arrival. Prior to surgery, rats were anesthetized with 80 mg/kg ketamine (Midwest
Veterinary Supply, Valley Forge, PA) and 12 mg/kg xylazine (Sigma-Aldrich/RBI, St. Louis,
MO). An indwelling catheter (SAI Infusion Technologies, Lake Villa, IL) was inserted into
the right jugular vein and sutured in place. The catheter was routed to a mesh backmount
that was implanted subcutaneously above the shoulder blades. To prevent infection and
maintain patency, catheters were flushed daily with 0.2 ml of the antibiotic Timentin (0.93
mg/ml; Fisher, Pittsburgh, PA) dissolved in heparinized 0.9% saline (Butler Schein, Dublin,
OH). When not in use, catheters were sealed with plastic obturators.

After catheter insertion, some rats were then immediately mounted in a stereotaxic
apparatus (Kopf Instruments, CA) and implanted with cannulae for intra-cranial
microinjections. Bilateral guide cannulae (26 gauge; 16 mm; Plastics One, Roanoke, VA)
were implanted 2.5mm dorsal to the LDTg (for LDTg injections) and 2 mm dorsal to the
VTA (for VTA injections) and cemented in place by affixing dental acrylic to stainless steel
screws secured in the skull. The coordinates for the ventral ends of the guide cannulae,
relative to bregma according to the atlas of Paxinos and Watson (1997), were as follows:
LDTg (-9.1 mm A/P, ±0.5 mm M/L, and -4.1 mm D/V), VTA (-6.0 mm A/P, ±0.5 mm M/L,
and -6.6 mm D/V). An obturator (33 gauge; Plastics One) was inserted into each guide
cannula to prevent occlusion.

Cocaine self-administration, extinction and reinstatement of cocaine seeking
Rats were allowed 7 days to recover from surgery before behavioral testing commenced.
Initially, rats were placed in operant conditioning chambers and allowed to lever-press for
intravenous infusions of cocaine (0.25 mg/kg/infusion, infused over a 5 s period) on a
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fixed-ratio 1 (FR1) schedule of reinforcement. Rats were allowed to self-administer a
maximum of 30 injections per 120 min operant session. Once a rat achieved at least 20
infusions of cocaine in a single daily operant session under the FR1 schedule, the subject
was switched to a fixed-ratio 5 (FR5) schedule of reinforcement. The maximum number
of injections was again limited to 30 per daily self-administration session under the FR5
schedule. For both FR1 and FR5 schedules, a 20 s time-out period followed each cocaine
infusion, during which time active lever responses were tabulated but had no scheduled
consequences. Responses made on the inactive lever, which had no scheduled
consequences, were also recorded during both the FR1 and FR5 training sessions.
Following 21 days of daily cocaine self-administration sessions, drug-taking behavior was
extinguished by replacing the cocaine solution with 0.9% saline. Daily extinction sessions
continued until responding on the active lever was <15% of the total active lever responses
completed on the last day of cocaine self-administration. Typically, it took ~7 days for rats
to meet this criterion. Once cocaine self-administration was extinguished, rats entered the
reinstatement phase of the experiment. During reinstatement test sessions, satisfaction of
the response requirement (i.e., five presses on the active lever) resulted in an infusion of
saline rather than cocaine. Using a between-sessions reinstatement procedure, each
reinstatement test session was followed by extinction sessions until responding was again
<15% of the total active lever responses completed on the last day of cocaine selfadministration. Generally, 1–2 days of extinction were necessary to reach extinction
criterion between reinstatement test sessions.

The effects of intra-LDTg Ex-4 administration on cocaine reinstatement
Once cocaine-taking behavior was extinguished, obturators were removed from the guide
cannulae and 33 gauge stainless steel microinjectors (18mm; 2.5mm projection, Plastics
One) were inserted. Using a within-subjects counterbalanced design, rats were infused
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bilaterally with 0, 0.005 or 0.025 µg/100 nl Ex-4 directly into the LDTg. Microinjectors were
left in place for an additional one minute following infusions in order to allow for diffusion
of the drug solution away from the tips of the microinjectors. Rats were then placed back
in their home cages. Ten minutes later rats received a priming injection of cocaine
(10mg/kg, i.p.) and then placed immediately into the operant conditioning chambers and
a two-hour reinstatement test session commenced. Twenty-four hours after each
treatment, rats were weighed to assess if Ex-4 affects body weight.

The effects of LDTg GABA neuron-specific GLP-1R knockdown on progressive ratio and
cocaine reinstatement
We

have

previously

used

the

short

hairpin

RNA

(shRNA)

sequence

5′-

GATCGGGTTGCTGGTGGAAGGCGTGTATCTGTACTCAAGAGGTACAGATACACGC
CTTCCACCAGCAACCTTTTTT-3′ to target GLP-1R transcripts (Schmidt et al., 2016;
Alhadeff et al., 2017b). Our in vitro studies demonstrated ~ 88% knockdown of GLP-1R
expression in a rat neuronal cell line transfected with this shRNA and ~50% knockdown
in vivo (Schmidt et al., 2016; Alhadeff et al., 2017b). The shRNA sequence was cloned
and packaged into an adeno-associated virus (AAV; serotype 1) downstream of the CB7
promotor and co-expressed with GFP. For Cre recombinase-dependent expression a
FLEX switch was added to produce the following virus: AAV1.CB7.CI.FLEX.miR-GLP-1REGFP.WPRE.bGH, hereby referred to as AAV-FLEX-shRNA-GLP-1R. A GFP-expressing
AAV1 (AAV1.CAG.FLEX.EGFP.WRPE.bGH) was used as a control and hereby referred
to as AAV-FLEX-GFP. Viruses were obtained through the Viral Core at the University of
Pennsylvania.

For cell type-specific knockdown of GLP-1R expression in GABA neurons, GAD1-Cre rats
underwent catheter surgery and LDTg-directed guide cannulae insertion as described
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above. Immediately after catheter and cannula implantation, rats received bilateral
infusions of AAV-FLEX-shRNA-GLP-1R or AAV-FLEX-GFP (2e12 gc/ml, 500nl over 90
sec) directly into the LDTg. Microinjectors were left in place for an additional 90 sec after
infusion to allow for diffusion away from the injection site. After a one week recovery, rats
underwent 14 days cocaine self-administration as described above. The effects of GLP1R knockdown in LDTg GABA neurons on the motivation to self-administer cocaine was
then assessed for 3 consecutive days on a progressive-ratio (PR) schedule of
reinforcement as described previously (Schmidt et al., 2016). Briefly, under a PR
schedule, the response requirement for each subsequent infusion increased exponentially
until the rat failed to meet a requirement in 30 min. The response requirement for the i th
reinforcement was given by R(i)=[5e 0.2i -5]. The breakpoint was operationally defined as
the last response requirement completed before the termination of the PR test session.
Responding on the PR schedule were averaged across the three days of PR test sessions.
After PR testing, rats underwent five days of FR5 responding to stabilize cocaine selfadministration before extinction took place. Once cocaine-taking behavior was
extinguished, the effect of GLP-1R knockdown in LDTg GABA neurons on the ability of
intra-LDTg Ex-4 or systemic Ex-4 to reduce cocaine reinstatement was assessed. Rats
were pretreated with vehicle or 0.005 µg Ex-4 in the LDTg 10 min prior to a priming
injection of cocaine. Additional rats received vehicle or 0.2 µg/kg i.p. Ex-4 one hour prior
to a priming injection of cocaine and cocaine reinstatement was assessed. These doses
of intra-LDTg and systemic Ex-4 were used because of data showing that they are
selective for decreasing cocaine seeking without having adverse side effects on feeding
or body weight [Figure 4.1; (Hernandez et al., 2018)]. All treatments were given in a withinsubjects counterbalanced design.
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Following behavioral testing, brains were dissected and flash frozen in -20C isopentane
and stored at -80C. 1 mm3 bilateral micropunches of the LDTg were collected to assess
GLP-1R expression using quantitative real-time PCR (qPCR). GLP-1R levels were
quantified

using

Taqman

gene

expression

kits

(GLP-1R:

Rn00562406_m1;

GAPDH:Rn01775763_g1; Life Technologies) and PCR reagents (Applied Biosystems).
qPCR was conducted using an Eppendorf Mastercycler ep realplex2 and the comparative
threshold cycle method was used to quantify relative mRNA expression as described
above. An LDTg-containing coronal section (30 μm) was collected from each brain to verify
correct placement of AAV injections by visualizing GFP fluorescence. Only rats with
correct placement and viral expression were included in data analysis.

The effects of chemogenetic inhibition of GABAergic LDTg-to-VTA projections on cocaine
reinstatement
GAD1-Cre rats underwent catheter surgery and received bilateral infusions of an AAV
expressing the Cre recombinase-dependent inhibitory DREADD (Designer Receptors
Exclusively Activated by Designer Drugs) (AAV2-hSyn-DIO-hM4D(Gi)-mCherry) or control
virus (AAV2-hSyn-DIO-mCherry) provided by Addgene (Watertown, MA) at the level of
the LDTg (virus titer: 1e 12 gc/ml, 500nl over 90 sec). Microinjectors were left in place for
an additional 90 sec after infusion to allow for diffusion away from the injection site. After
viral infusion, VTA-directed guide cannulae were implanted and cemented in place. After
a one week recovery, rats underwent cocaine self-administration and extinction as
described above. In order to determine if inhibiting LDTg GABA terminals in the VTA
prevents the ability of Ex-4 to decrease cocaine seeking, prior to reinstatement test
sessions, rats received bilateral microinjections of CNO (0, 1 mM; 100nl) in the VTA. After
10 min, rats received systemic injections of Ex-4 (0, 0.2 µg/kg, i.p) one hour prior to their
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priming-injection of cocaine and reinstatement test sessions immediately commenced. All
treatments were administered in a within-subjects counterbalanced design. After
behavioral experiments, rats were perfused and brains collected. VTA- and LDTgcontaining coronal sections (30 μm) were collected from each brain to verify correct
placement of cannula and viral expression by visualizing mCherry fluorescence. Only rats
with correct placement and viral expression were included in data analysis.

The effects of chemogenetic activation of NTS-to-LDTg projections on cocaine
reinstatement
Sprague Dawley rats underwent catheter surgery and received bilateral infusions of the
retrogradely infecting canine adeno virus-2 expressing Cre recombinase (CAV2-Cre;
IGMM, Montpellier, FR) directly into the LDTg. In the same surgical session, an AAV
(Addgene, Watertown, MA) expressing the activating DREADD (AAV2-hSyn-DIOhM3D(Gq)-mCherry) or control virus (AAV2-hSyn-DIO-mCherry) was bilaterally infused
directly into the caudal NTS (-1.0 mm to occipital A/P, ±0.5 mm M/L, -6.0 mm D/V) via
microinjectors through guide cannula (2 mm projection). All viruses were infused at a titer
of 1e12 gc/ml at a volume of 500 nl over 90 secs. Microinjectors were left in place for an
additional 90 sec after infusion to allow for diffusion away from the injection site. This dual
viral approach allowed for DREADD manipulation of NTS neurons that specifically project
to the LDTg and was adapted from previously published studies (Boender et al., 2014;
Alhadeff et al., 2017a). After a one week recovery, rats underwent cocaine selfadministration, extinction and reinstatement as previously described above. In order to
activate NTS to LDTg projections, using a within-subjects counterbalanced design,
systemic injections of CNO (0, 0.1 or 1.0 mg/kg, i.p.) were given 30 min prior to a priming
injection of cocaine and the ability of CNO to decrease cocaine reinstatement was
assessed.
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During surgery, a subset of rats had LDTg guide cannula cemented in place after viral
infusion in order to administer the GLP-1R antagonist exendin-(9-39) (Ex-9) prior to
cocaine reinstatement. The purpose of this experiment was to determine if the effects of
activating NTS-to-LDTg projections on cocaine seeking are due to increased GLP-1R
activation in the LDTg. Using a within-subjects counterbalanced design, prior to
reinstatement test sessions, rats were pretreated with bilateral infusions of Ex-9 directly
into the LDTg (10 µg/100nl) 10 min before a systemic injection of CNO (1.0 mg/kg, i.p.). A
priming injection of cocaine was given 30 min later and the ability of intra-LDTg Ex-9 to
block the effects of CNO on cocaine seeking was assessed.

After behavioral testing, brains were collected and immunohistochemistry was performed
on coronal sections of the NTS to visualize viral expression, the ability of CNO to induce
cFos in DREADD-expressing neurons, and co-localization of GLP-1 with AAV-DIOhM3Dq-mCherry. mCherry and cFos co-localization following CNO treatment was
quantified using 3 representative coronal sections of the NTS at the level of the obex for
each brain (n=6/treatment). Any missed cannula placement or viral injection/expression
resulted in animals being excluded from data analysis.

Sucrose self-administration, extinction and reinstatement of sucrose seeking
Separate cohorts of rats were trained initially to self-administer 45 mg sucrose pellets
(Research Diets, New Brunswick, NJ) on a FR1 schedule of reinforcement during daily
one-hour operant sessions. Once rats achieved stable responding for sucrose (defined as
<20% variation in responding over 3 consecutive days) on the FR1 schedule of
reinforcement, the response requirement was increased to an FR5 schedule of
reinforcement. Rats were limited to 30 sucrose pellets within each daily operant session
and were restricted to ~20-25 g of chow (Harlan Teklad, Wilmington, DE) daily in their
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home cages for the duration of the experiment. Water was available ad libitum in the home
cage.

After two weeks of sucrose-maintained responding on an FR5 schedule of reinforcement,
rats underwent an extinction phase where active lever pressing no longer resulted in
sucrose delivery. Once active lever responding decreased to <15% of the maximum
number of responses completed on the last day of sucrose self-administration, rats
proceeded to reinstatement testing. Ex-4 (0, 0.005 and 0.025µg/100 nl) was microinjected
into the LDTg 10 min prior to reinstatement test sessions. A within-subjects
counterbalanced design was used for treatments. The experimenter remotely
administered one sucrose pellet every two min for the first 10 min of the reinstatement
session. A between-session procedure was used so that each daily reinstatement test
session was followed by an extinction session the following day until responding was again
<15% of the total active lever responses maintained by sucrose.

Ad libitum food intake
We assessed if our manipulations affected ad libitum food intake after reinstatement test
sessions in three different experiments: effects intra-LDTg 0.005 µg Ex-4 on cocaine
seeking, effects of NTS-to-LDTg circuit activation on cocaine seeking or CNO itself on
cocaine seeking. A subset of rats for each experiment were housed in hanging wire cages
with ad libitum access to food and water as we have described previously (Reiner et al.,
2016; Alhadeff et al., 2017b; Hernandez et al., 2018) during the extinction and
reinstatement phases of the experiment. Rats were pretreated with vehicle, 0.005 µg Ex4 or 1 mg/kg CNO prior to a cocaine priming-induced reinstatement test session. Rats
were returned to the hanging wire cages immediately following the reinstatement session
and given ad libitum access to normal chow. Food weights were measured every 1, 3, 6,
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and 24 h post session (3, 5, 8, and 26 h post infusion) accounting for spillage. Body weight
was measured 24 h post session (26 h post infusion).

Immunohistochemistry
Rats were deeply anesthetized and transcardially perfused with 0.1 M PBS, pH 7.4,
followed with 4% formalin in 0.1 M PBS. Rats treated with Ex-4 or fluoro-Ex-4 (0.2 µg/kg,
i.p.) were injected 90 min prior to perfusion. Once brains were removed, they were
postfixed overnight in 4% formalin in 0.1 M PBS and then cryoprotected in 20% sucrose
in 0.1 M PBS at 4oC for three days. Coronal brain sections (30 µm) were taken using a
cryostat (Leica 3050S; Leica Corp., Deerfield, IL). Brain sections were stored in 0.1 M
PBS at 4oC until processed. Immunohistochemistry was performed on free-floating
coronal sections containing the LDTg, VTA or NTS according to modified procedures from
previously published studies (Reiner et al., 2016; Schmidt et al., 2016; Hernandez et al.,
2019). Briefly, sections were washed with 1% sodium borohydride followed by 0.1 M PBS.
Sections were then blocked in 0.1 M PBS containing 5% normal donkey serum and 0.2%
Triton-X for 1 h at room temperature. Sections were incubated in primary antibodies
overnight, and then, following a PBS rinse, they were incubated in secondary antibodies
for 2 h. The primary antibodies used were rabbit anti-NeuN (1:1000; ab177487, Abcam,
Cambridge, UK), goat anti-GFAP (1:1000; ab53554, Abcam, Cambridge, UK), mouse anticFos (1:500, sc-271243, Santa Cruz Biotechnology, Inc., Dallas, TX), rabbit anti-GLP-1
(1:1000 T-4363, Peninsula Laboratories International, Inc., San Carlos, CA), rabbit anti‐
dsRed (1:1000; 632496, Takara, Kyoto, Japan), mouse anti-mCherry (1:1000 632543,
Takara, Kyoto, Japan), and rabbit anti-tyrosine hydroxylase (1:1000; 2792; Cell Signaling,
Danvers, MA). Secondary antibodies were donkey anti-rabbit Alexa Fluor 594 (1:500),
donkey anti-goat Alexa Fluor 647 (1:500), donkey anti-mouse Alexa Fluor 488 (1:500),
donkey anti-rabbit Alexa Fluor 488 (1:500), donkey anti-mouse Alexa Fluor 594 (1:500),
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from Jackson ImmunoResearch (West Grove, PA). GABA neurons were labeled by
infusing GAD1-Cre rats with AAV-hSyn-DIO-mCherry into the LDTg 2 weeks prior to
perfusion. Sections were then washed and mounted onto glass slides and coverslipped
using Vectashield (Vector Laboratories; Burlingame, CA). Sections were visualized with a
Leica SP5 X confocal microscope using the 20x 63x oil-immersion objectives along with
488, 594 and 633 nm laser lines. Image z-stacks were captured at the 20x and 63x oilimmersion objective with a step size of 2 and 1 μm, respectively.

Fluorescent in situ hybridization (FISH)
Brains were collected and flash frozen in -20C isopentane and stored at -80C. Brains
were subsequently mounted on a cryostat (Leica 3050S; Leica Corp., Deerfield, IL) and
18 µm coronal sections at the levels of the LDTg were taken and immediately mounted
onto Superfrost Plus slides (Fisher Scientific). mRNA expression of GLP-1Rs, GAD1,
vGlut2 and ChAT via FISH was carried out using RNAscope Multiplex Fluorescent
Reagent Kit V2 (Cat. 320850; Advanced Cell Diagnostics (ACD), Hayward, CA) per
manufacturer’s protocol. In brief, slide mounted sections were rinsed in 4%
paraformaldehyde for 15 min at room temperature (RT). Following two quick rinses in
0.1 M phosphate-buffered saline (PBS), the sections were dehydrated in ascending
ethanol solutions (5 min washes in 50, 70, 100, 100% ethanol) followed by an overnight
incubation in 100% ethanol at − 20 °C. Next, slides were air-dried and a hydrophobic
barrier was made around all of the sections on the slide using a hydrophobic pen (Vector
Labs). The sections were rinsed with PBS and treated with Protease IV for 30 min at RT
(followed by 2×1 min rinses in PBS).

Pre-treated tissue sections were processed immediately using probes designed by ACD
to detect GLP-1R mRNA (Rn-Glp1r; 315221), GAD1 mRNA (Rn-Gad1-C2; 316401-C2),
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vGlut2 mRNA (Rn-Slc17a6-C3; 317011-C3), and ChAT mRNA (Rn-Chat-C2; 430111-C2).
Sections were incubated in a cocktail containing probes (concentrations indicated by
manufacturer) for 2 h at 40 °C in a HybEZTM oven (ACD). Slides were rinsed twice in
RNAscope wash buffer followed by a series of amplification steps via Fluorescent
Multiplex Detection Reagents (Cat. 320851, ACD) at 40 °C separated by two brief washes
in RNAScope wash buffer (Cat. 310091, ACD): 30 min AMP 1-FL, 15 min AMP 2-FL,
30 min AMP 3-FL, and then 15 min AMP 4 Alt B-FL (C1, Atto 550 nm; C2 Alexa 488 nm;
C3 Atto 647 nm). After the final wash buffer, slides were coverslipped using Fluorogel
mounting medium with DAPI (Fisher Scientific). Sections were visualized with a Leica SP5
X confocal microscope using the 40x oil-immersion objectives and the 405, 488, 555, and
647 laser lines. Image z-stacks were collected with the 40x oil-immersion objective with a
step size of 2 µm.

Quantitative real-time PCR, cocaine self-administration and yoked saline controls
Separate rats underwent jugular catheterization as described above. Following a recovery
period, the rats were randomly assigned to one of two groups: cocaine-experimental or
yoked saline controls. Each rat allowed to respond for contingent cocaine infusions was
paired with a yoked rat that received infusions of saline. While lever pressing for the salineyoked rats had no scheduled consequences, these rats received the same number and
temporal pattern of infusions as self-administered by their paired cocaine-experimental
rat. Cocaine-experimental rats were allowed to lever press for intravenous cocaine
infusions on a FR1 schedule as described above for a total of 21 days.

To assess the effects of cocaine self-administration and extinction on expression of LDTg
GLP-1Rs, rats were sacrificed either immediately after the first extinction session (Ext1)
or following 7 consecutive days of extinction (Ext7). Brains were collected and flash frozen
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in -20C isopentane and stored at -80C. Brains were subsequently mounted on a cryostat
(Leica 3050S; Leica Corp., Deerfield, IL) and coronal sections at the levels of the LDTg
were taken. Bilateral 1mm3 micropunches of the LDTg were collected for quantitative realtime PCR. mRNA expression was quantified using Taqman gene expression kits (GLP1R: Rn00562406_m1; GAPDH: Rn01775763_g1; ThermoFisher Scientific, Waltham,
MA). qPCR was conducted using an Eppendorf Mastercycler ep realplex2 and the
comparative threshold cycle method was used to quantify relative mRNA expression.
Relative fold-expression of LDTg GLP-1Rs at Ext1 and Ext7 were normalized to yoked
saline controls and GAPDH levels.

Electrophysiology experiments validating CNO-mediated DREADD activation
Rats expressing AAV2-hSyn-DIO-hM4D(Gi)-mCherry in the LDTg or AAV2-hSyn-DIOhM3D(Gq)-mCherry in the NTS were deeply anesthetized with isoflurane then quickly
transcardially perfused with ice-cold cutting solution containing (in mM): 92 N-methyl-dglucamine (NMDG), 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 20 HEPES, 25 glucose, 5 sodium
ascorbate, 2 thiourea, 3 sodium pyruvate, 10 MgSO 4, and 0.5 CaCl2, saturated with
carbogen (95% O2/5% CO2), pH 7.4 with HCl, osmolarity 305-315 mOsm (Ting et al.,
2014). Following decapitation, brains were removed for dissection, and horizontal slices
(250 μM thick) of target brain regions (either the NTS or LDTg) were obtained using a
VT1000S vibratome (Leica, Weltzar, Germany). Slices were made at 4°C then transferred
to a holding chamber of the same cutting solution, and incubated at 37°C for 10-12 min.
Slices were then moved to a beaker of room temperature holding ACSF containing (in
mM): 86 NaCl, 2.5 KCl, 1.2 NaH2PO4, 35 NaHCO3, 20 HEPES, 25 glucose, 5 sodium
ascorbate, 2 thiourea, 3 sodium pyruvate, 1 MgCl2, and 2 CaCl2, saturated with carbogen,
pH 7.3-7.4, osmolarity 305-315 mOsm. Slices were allowed to recover for at least 45 min
before performing recordings.
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Slices were transferred to a Nikon Eclipse FN1 upright microscope equipped for
Differential Interference Contrast (DIC) infrared optics. The recording chamber was
continuously perfused with oxygenated recording ACSF containing (in mM): NaCl 119,
KCl 2.5, NaHCO3 26, NaH2PO4 1.2, glucose 12.5, HEPES 5, MgSO4 1, CaCl2 2, pH 7.37.4, osmolarity 305-315 mOsm. Solution was heated to 32 ± 1°C using an automatic
temperature controller (Warner Instruments). Target brain regions were identified using a
4X objective and individual neurons were magnified with a 40X water immersion lens.
DREADD-positive neurons were further identified by fluorescence with a DS-Red filter.
Recording pipettes were pulled from borosilicate glass capillaries (World Precision
Instruments) to a resistance of 3.5-5.5 MΩ when filled with intracellular solution. The
intracellular solution contained the following (in mM) potassium gluconate 145, KCl 2.5,
NaCl 2.5, BAPTA 0.1, HEPES 10, L-glutathione 1.0, sodium phosphocreatine 7.5, MgATP 2.0, and Tris-GTP 0.25, pH 7.2-7.3 with KOH, osmolarity 285-295 mOsm. All
recordings were performed in whole-cell current-clamp mode using a MultiClamp 700B
amplifier. Baseline spontaneous firing was recorded for ≥ 5 min prior to the activation or
inhibition of DREADD-positive neurons by CNO (30 μM) dissolved in the recording ACSF.
After ≥ 5 min CNO was washed out with regular recording ACSF. All recordings were lowpass filtered at 3kHz, amplified 5 times, and then digitized at 20kHz using a Digidata
1440A acquisition board and pClamp10 software (both from Molecular Devices). For all
experiments, access resistance was 15–25 MΩ, uncompensated, and monitored
continuously during recording. Cells with a change in access resistance >20% over the
course of data acquisition were not accepted for data analysis.

Verification of cannula placements
After completion of all microinjection experiments, rats were given an overdose of
pentobarbital (100 mg/kg, i.p.). Brains were removed and drop fixed in 10% formalin.
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Coronal sections (100 µm) were taken at the level of the LDTg or VTA with a vibratome
and mounted on gelatin-coated slides. An individual blinded to behavioral responses
verified microinjection sites using light microscopy. Rats with cannula placements outside
of the LDTg or VTA and/or excessive mechanical damage were excluded from subsequent
data analyses.

Statistics
For all cocaine and sucrose reinstatement experiments, the total mean active lever
responses, inactive lever responses, and food intake measurements were analyzed with
two-way repeated measures mixed-factors ANOVAs. Pairwise analyses were made using
Bonferroni post-hoc tests (p<0.05). LDTg GABA neuron GLP-1R knockdown virus versus
control virus on PR responding and cocaine reinstatement, fold change in GLP-1R mRNA
expression, and cFos quantification were analyzed using unpaired t-tests.
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Results
Administration of Ex-4 directly into the LDTg significantly decreased cocaine priminginduced reinstatement of drug-seeking behavior at a dose that did not affect sucrose
seeking, chow intake or body weight.
Our previously published studies identified systemic doses of the GLP-1R agonist fluoroEx-4 (0.2 µg/kg) that selectively decreased cocaine seeking without producing adverse
feeding or malaise-like effects (Hernandez et al., 2018). Additionally we showed that
peripheral fluoro-Ex-4 bound putative GLP-1Rs localized on neurons and astrocytes in the
VTA and NAc (Hernandez et al., 2018; Hernandez et al., 2019). To determine if the effects
of systemic fluoro-Ex-4 on cocaine seeking are also due, in part, to activation of GLP-1Rs
in the LDTg, rats were pretreated with a systemic injection of 0.2 µg/kg fluoro-Ex-4.
Sections of the LDTg were then immunohistochemically processed to label neurons and
astrocytes, which revealed fluoro-Ex-4 binding to GLP-1Rs on both GFAP-positive
astrocytes and NeuN-positive neurons in the LDTg (Figure 4.1A).

To directly test if activation of GLP-1Rs in the LDTg decreased cocaine seeking, rats were
pretreated with the GLP-1R agonist Ex-4 directly into the LDTg 10 min prior to a cocaine
priming-induced reinstatement test session. Total active and inactive lever responses in
rats pretreated with Ex-4 (0, 0.005 or 0.025 µg/100nl, n=15) are shown in Figure 4.1B.
These data were analyzed using a two-way repeated measures ANOVA, which revealed
significant main effects of treatment [F(2,28)=15.05, p<0.001] and lever [F(1,14)=76.23,
p<0.001] as well as a significant treatment x lever interaction [F(2,28)=15.89, p<0.001].
Subsequent pairwise analyses indicated that active lever responses were significantly
different between vehicle treatment versus 0.005µg and 0.025 µg Ex-4 (Bonferroni,
p<0.01). No significant differences were found on inactive lever responding between
treatments. Microinjection sites corresponding to this experiment shown in Figure 4.1D&G.
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Due to a previous study showing that intra-LDTg Ex-4 at 0.025 and 0.05 µg decreased
food intake and body weight in drug-naïve rats (Reiner et al., 2018), we wanted to
determine if the doses of intra-LDTg Ex-4 used in Figure 4.1B (0.005 and 0.025 µg)
produced adverse feeding effects. Additionally, we wanted to control for any motor
suppressing effects or deficits in operant responding following Ex-4 treatment in cocaineexposed rats. Therefore, parallel studies of sucrose-seeking behavior were performed in
a separate group of rats (Figure 4.1C). These data were analyzed using a two-way
repeated measures ANOVA, which revealed significant main effects of treatment
[F(2,56)=6.735, p<0.01] and lever [F(1,56)=75.37, p<0.001] as well as a significant
treatment x lever interaction [F(2,56)=6.828, p<0.01]. Subsequent pairwise analyses
indicated that active lever responses were significantly different between vehicle and
0.025 µg Ex-4 (Bonferroni, p<0.05). However, no significant effects between vehicle and
0.005 µg Ex-4 on active or inactive lever responding vehicle were observed. Microinjection
sites corresponding to this experiment are shown in Figure 4.1H. Additionally, 24 hr body
weight was assessed in rats that underwent cocaine reinstatement test sessions (Figure
4.1B). Mean 24 hr body weight change following intra-LDTg 0, 0,005 or 0.025 µg treatment
and cocaine reinstatement are shown in Figure 4.1E (n=15). These data were analyzed
using a one-way ANOVA which revealed significant main effects of treatment
[F(2,28)=6.10, p<0.01]. Subsequent pairwise analyses indicated that 24 hr body weight
change was significantly different between vehicle and 0.025 µg Ex-4 (Bonferroni,
p<0.05). No differences were observed between vehicle and 0.005 Ex-4. Taken together,
these data showed that although the 0.025 µg dose of Ex-4 decreased body weight and
sucrose seeking, the 0.005 µg dose of Ex-4 selectively decreased cocaine seeking without
causing any effects on 24 hr body weight or sucrose seeking. To further validate that 0.005
µg Ex-4 had no adverse effects on feeding, 24 hr cumulative chow intake was measured
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in a subset of rats that underwent cocaine reinstatement test sessions (n=7). There were
no significant effects of 0.005 µg Ex-4 treatment observed at any time point (Figure 4.1F).
Microinjection sites corresponding to these experiments are shown in Figure 4.1D, G, &
H. Taken together, these data demonstrate that intra-LDTg Ex-4 attenuates cocaine
seeking at a dose (0.005 µg) subthreshold for effects on ad libitum chow intake, body
weight and sucrose-seeking behavior.

Cocaine self-administration and subsequent abstinence do not affect GLP-1R expression
in the LDTg.
To determine if cocaine exposure alters endogenous GLP-1 signaling in the LDTg, we
assessed the effects of cocaine self-administration and subsequent extinction sessions
on LDTg GLP-1R mRNA expression levels using quantitative real-time PCR (Figure 4.2A).
There were no changes in GLP-1R mRNA expression in the LDTg of cocaine-experienced
rats following one (Ext1) and seven (Ext7) days of extinction when compared to yoked
saline controls (Figure 4.2B). These data indicated that the effects of GLP-1R activation
on cocaine seeking are not due to altered GLP-1R mRNA expression in the LDTg.

GABA neurons are the primary cell-type in the LDTg that express GLP-1Rs and are
activated by systemic Ex-4.
In order to investigate the mechanisms by which Ex-4 in the LDTg decreases cocaine
seeking, we first characterized the neuronal cell types that express GLP-1Rs. Fluorescent
in situ hybridization was conducted on LDTg coronal sections to determine the neuronal
cell types that express GLP-1R mRNA. Colocalization of GLP-1R transcripts with GAD1,
vGLUT2 or ChAT mRNA are shown in Figure 4.3A-C. Zoomed in representative images
are shown in Figure 4.3D. LDTg GLP-1R-expressing neurons were found to co-express
GAD1 and vGLUT2. However, there was no co-expression observed between GLP-1R
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and ChAT. Quantification revealed that 70% of GLP-1R-expressing neurons are
GABAergic, and 25% are glutamatergic, with 0% being cholinergic (Figure 4.3E). The 5%
remaining GLP-1R-expressing cell types in the LDTg are most likely glial cells as GLP1Rs are expressed on astrocytes and involved in energy balance control (Reiner et al.,
2016).

Due to the majority of GLP-1Rs being expressed on GABAergic neurons in the LDTg, we
hypothesized that activating GLP-1Rs on this cell population mediates Ex-4’s suppressive
effects on cocaine seeking. To further test this hypothesis, we determined if systemic
fluoro-Ex-4 localized with GABAergic neurons in the LDTg. Indeed, we found that fluoroEx-4 colocalized with LDTg GABA neurons (Figure 4.3F). We then assessed if Ex-4
treatment increased activation of LDTg GABA neurons in cocaine-experienced rats. Ex-4
induced cFos expression in the LDTg as measured by immunohistochemistry to label cFos
in rats treated with Ex-4 (0.2 µg/kg) when compared with saline treated controls (Figure
4.3G). Percentages of total LDTg GABAergic cells co-expressing cFos showed ~18%
percent co-localization in Ex-4 treated rats compared to ~3% in saline treated controls
[t(6)=12.49, p<0.001; n=4/treatment] (Figure 4.3H). Percentages of total cFos-positive
cells co-expressing GABA showed ~62% co-localization in Ex-4 treated rats compared to
~31% in saline treated controls [t(6)=4.57, p<0.01; n=4/treatment] (Figure 4.3H). Taken
together, these data support the hypothesis that Ex-4 activates GABA neurons in the LDTg
to decrease cocaine-seeking behavior.

GLP-1Rs on LDTg GABA neurons are endogenously relevant for regulating cocaine taking
and mediate the effects of systemic Ex-4 on cocaine seeking.
To directly test the functional relevance of LDTg GABA GLP-1Rs in cocaine taking and
seeking, AAV-FLEX-shRNA-GLP-1R or AAV-FLEX-GFP were administered directly into
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the LDTg of GAD1-Cre rats to knockdown (KD) GLP-1R expression exclusively in LDTg
GABA neurons (Figure 4.4A&B). After viral infusion, rats were allowed to self-administer
cocaine. There was no effect of LDTg GABA GLP-1R KD on FR5 responding for cocaine
(data not shown), however when tested on a PR schedule of reinforcement, rats with
reduced LDTg GABA GLP-1R expression had significantly greater total active lever
responses [t(20)=2.72, p<0.05], infusions [t(20)=3.30, p<0.01], and breakpoints
[t(20)=3.11, p<0.01] when compared to control rats (Figure 4.4C-E). These data indicate
that endogenous GLP-1 signaling on LDTg GABA GLP-1Rs is functionally relevant for
controlling cocaine self-administration.

After cocaine self-administration, rats underwent extinction and cocaine reinstatement
tests to determine if endogenous LDTg GABA GLP-1Rs mediate the effects of intra-LDTg
Ex-4 on cocaine seeking. Control rats and GLP-1R KD rats were treated with vehicle or
0.005 µg Ex-4 directly into the LDTg 10 min before cocaine priming-induced reinstatement
test sessions. Total active lever responses for both groups and treatments are shown in
Figure 4.4F with corresponding microinjection placements in Figure4.4H&I. These data
were analyzed using a two-way repeated measures ANOVA, which revealed a significant
treatment x group interaction [F(1,6)=11.46, p<0.05]. Subsequent pairwise analyses
indicated that vehicle and Ex-4 treatment were significantly different in the control group
(Bonferroni, p<0.05) but not for the GLP-1R KD group. These data show that LDTg GLP1Rs on GABA neurons are necessary for the suppressive effects of intra-LDTg Ex-4 on
cocaine seeking. We also wanted to determine the mechanisms of systemic Ex-4 to
decrease cocaine seeking and hypothesized that these effects are mediated, in part, by
activation of LDTg GABA GLP-1Rs. Therefore, control and GLP-1R KD rats were treated
with vehicle or 0.2 µg/kg Ex-4 i.p. prior to a cocaine priming-induced reinstatement test
session. Total active lever responses for both groups and treatments are shown in Figure
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4.4G. These data were analyzed using a two-way repeated measures ANOVA, which
revealed a significant treatment x group interaction [F(1,17)=8.51, p<0.01]. Subsequent
pairwise analyses indicated that vehicle and Ex-4 treatment were significantly different in
the control group (Bonferroni, p<0.05) but not for the GLP-1R KD group. Taken together,
LDTg GABA GLP-1Rs play a role in the suppressive effects of Ex-4 on cocaine seeking.

Systemic Ex-4 decreases cocaine seeking by activating LDTg GABA neurons that project
to the VTA.
To further investigate the circuits that are activated by systemic Ex-4 to attenuate cocaine
seeking, we determined if the effects of Ex-4 are mediated through LDTg GABA neurons
that project to the VTA. The role of the LDTg in motivated behaviors is largely attributed
to its projections to the VTA and regulation of dopamine burst firing. (Omelchenko and
Sesack, 2005; Lodge and Grace, 2006; Lammel et al., 2012; Steidl et al., 2017). Thus, we
hypothesized that Ex-4 reduces cocaine seeking by acting on LDTg GABA neurons that
project to the VTA. We tested this hypothesis by using DREADD-mediated inhibition of
GABAergic LDTg-to-VTA projections. A virus expressing the inhibitory DREADD (AAVDIO-hM4D(Gi)-mCherry) was infused into the LDTg of GAD1-Cre rats and guide cannula
were implanted at the level of the VTA (Figure 4.5A). Expression of hM4D(Gi) in the LDTg
is shown in Figure 4.5B. GABAergic terminals expressing hM4D(Gi) were visualized in the
VTA and localized with VTA dopaminergic neurons (Figure 4.5C). Representative
electrophysiological traces validating the ability of the DREADD agonist clozapine-n-oxide
(CNO) to inhibit activity of hM4D(Gi)-expressing neurons are shown in Figure 4.5E.

Prior to cocaine priming-induced reinstatement test sessions, CNO (1mM, 100 nl) was
infused into the VTA to inhibit LDTg GABA terminals before an injection of Ex-4 (0.2 µg/kg,
i.p.). Using a within-subjects design, there were 4 treatment conditions (intra-VTA
105

vehicle/i.p. vehicle, intra-VTA CNO/i.p. vehicle, intra-VTA vehicle/i.p. Ex-4, intra-VTA
CNO/i.p. Ex-4; n=10/treatment). Total active lever responses are shown in Figure 4.5D.
These data were analyzed with a two-way repeated measures ANOVA which revealed
significant main effects of systemic treatment [F(1,9)=11.62, p<0.01] and intra-VTA
treatment [F(1,9)=7.22, p<0.05] as well as a significant systemic treatment x intra-VTA
treatment interaction [F(1,9)=6.87, p<0.05]. Subsequent pairwise analyses indicated a
significant difference in total active lever responding between intra-VTA vehicle/i.p.
vehicle, intra-VTA CNO/i.p. vehicle, and intra-VTA CNO/i.p. Ex-4 versus intra-VTA
vehicle/i.p. Ex-4 treated rats (Bonferroni, p<0.05). There was no effect of treatment on
total inactive lever responding (data not shown). Corresponding microinjection sites in the
VTA are shown in Figure 4.5G. These data demonstrate that Ex-4 decreases cocaine
seeking, in part, by activating LDTg GABAergic projections to the VTA.

Although CNO is often used as the inert ligand for DREADDs, recent studies show
minimal, yet significant, reverse metabolism to clozapine, which may cause off-target
effects on behavior (Manvich et al., 2018). Therefore, we validated the effects we
observed from intra-VTA CNO treatment on cocaine seeking were due to inhibiting
hM4D(Gi)-expressing LDTg terminals and not due to any off-target effects of CNO. Thus,
a separate group of rats was infused with control virus AAV-DIO-mCherry in the LDTg and
the same experimental procedures were performed as described above. Total active lever
responses are shown in Figure 4.5F (n=10/treatment). These data were analyzed with a
two-way repeated measures ANOVA which revealed significant main effects of systemic
treatment [F(1,9)=43.50, p<0.01] with no effects on intra-VTA treatment [F(1,9)=0.74,
p=0.41] or treatment x intra-VTA treatment interaction [F(1,9)=0.89, p=.37]. Subsequent
pairwise analyses indicated a significant difference in total active lever responding
between intra-VTA vehicle/i.p. vehicle and intra-VTA CNO/i.p. vehicle versus intra-VTA
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vehicle/i.p. Ex-4 and intra-VTA CNO/i.p. Ex-4 treated rats (Bonferroni, p<0.05). There was
no effect of treatment on total inactive lever responding (data not shown). Corresponding
microinjection sites in the VTA are shown in Figure 4.5H.

Activation of the endogenous NTS-to-LDTg pathway attenuates cocaine seeking
Thus far, our data identified important mechanisms that underly the role of exogenous
LDTg GLP-1R activation on cocaine-seeking behavior. However, the role of endogenous
GLP-1 signaling from the NTS to the LDTg in regulating cocaine seeking needs to be
explored. The LDTg receives direct projections from the NTS (Cornwall et al., 1990;
Rinaman, 2010; Reiner et al., 2018), however, the role of the NTS-to-LDTg pathway in
addiction-like behaviors is not clear. Therefore, we determined if activation of NTS
projections to the LDTg regulates cocaine seeking. In order to selectively activate the
NTS-to-LDTg pathway, a retrogradely infecting virus CAV2 expressing Cre recombinase
(CAV2-Cre) was infused in the LDTg and a Cre-dependent virus expressing the neural
activating DREADD (AAV-DIO-hM4D(Gi)-mCherry) was infused into the NTS (Figure
4.6A). A representative image of hM3D(Gq)-expressing NTS-to-LDTg neurons is shown
in Figure 4.6B. To validate that CNO activates hM3D(Gq)-expressing NTS neurons,
immunohistochemistry was performed on NTS sections to label cFos after CNO injection
in both hM3D(Gq)- and mCherry control-expressing rats (Figure 4.6C). Quantification
revealed that CNO treatment significantly induced cFos in NTS hM3D(Gq)-expressing
neurons (n=5) compared to mCherry-expressing neurons (n=6) [t(9)=3.50, p<0.01] (Figure
4.6C). Additionally, representative electrophysiological traces validating the ability of CNO
to increase neuronal activity of NTS hM3D(Gq)-expressing neurons are shown in Figure
4.6D.
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To asses if the NTS-to-LDTg pathway regulates cocaine seeking, CNO (0, 0.1, 1 mg/kg,
i.p) was administered 30 min prior to a cocaine priming-induced reinstatement test
session. Total active and inactive lever responses are shown in Figure 4.6E (n=8). These
data were analyzed using a two-way repeated measures ANOVA, which revealed
significant main effects of treatment [F(2,14)=11.93, p<0.01] and lever [F(1,7)=21.21,
p<0.01] as well as a significant treatment x lever interaction [F(2,14)=11.87, p<0.01].
Subsequent pairwise analyses indicated that active lever responses were significantly
different between vehicle and 1 mg/kg CNO (Bonferroni, p<0.05). These results indicate
that activation of the NTS-to-LDTg circuit is sufficient to reduce cocaine-seeking behavior.

To validate that the effects of systemic CNO treatment on cocaine seeking were due to
activating NTS hM3D(Gq)-expressing neurons and not due any off-target effects, a
separate group of rats was infused with the control virus AAV-DIO-mCherry in the NTS
and the same experimental procedures were performed as described above. Total active
and inactive lever responses are shown in Figure 4.5F (n=7). These data were analyzed
using a two-way repeated measures ANOVA, which revealed significant main effects of
lever [F(1,6)=17.70, p<0.01] and no effect of treatment [F(1,6)=0.24, p=0.64] or treatment
x lever interaction [F(1,6)=0.44, p=0.53]. Subsequent pairwise analyses indicated that
there were no differences between vehicle and 1 mg/kg CNO on total active lever
responses.

Activation of the NTS-to-LDTg circuit decreases cocaine seeking through a GLP-1dependent manner.
The NTS is a heterogeneous population of neurons (Rinaman, 2010; Buffalari and
Rinaman, 2014; Zheng et al., 2015), thus, it is unclear if GLP-1-producing neurons
mediate the effects of NTS-to-LDTg activation on cocaine seeking. Through
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immunohistochemical analysis, hM3D(Gq)-expressing NTS neurons that project to LDTg
were found to colocalize with GLP-1 (Figure 4.6G). To test if reduced cocaine-seeking
behavior following NTS-to-LDTg activation was GLP-1-mediated, rats were infused with
CAV2-Cre in the LDTg, AAV-DIO-hM4D(Gi)-mCherry in the NTS, and implanted with
guide cannula at the level of the LDTg. Prior to reinstatement test sessions, the GLP-1R
antagonist Ex-9 (10 µg/100nl) was infused directly into the LDTg before administration of
CNO (1 mg/kg, i.p.) to determine if pharmacological inhibition of LDTg GLP-1Rs blocked
the ability of NTS-to-LDTg activation to decrease cocaine seeking. Using a within-subjects
design, there were 4 treatment conditions (intra-LDTg vehicle/i.p. vehicle, intra-LDTg Ex9/i.p. vehicle, intra-LDTg vehicle/i.p. CNO, intra-LDTg Ex-9/i.p. CNO; n=9/treatment).
Total active lever responses are shown in Figure 4.6H. These data were analyzed with a
two-way repeated measures ANOVA which revealed a significant systemic treatment x
intra-LDTg treatment interaction [F(1,8)=7.69, p<0.05]. Subsequent pairwise analyses
indicated a significant difference in total active lever responding between intra-LDTg
vehicle/i.p. vehicle, intra-LDTg Ex-9/i.p. vehicle, and intra-LDTg Ex-9/i.p. CNO versus
intra-LDTg vehicle/i.p. CNO treated rats (Bonferroni, p<0.05). There was no effect of
treatment on total inactive lever responding (data not shown). Corresponding
microinjection sites in the LDTg are shown in Figure 4.6I. Taken together, these data
demonstrate that NTS GLP-1-producing neurons that project to the LDTg regulate
cocaine-seeking behavior.

NTS-to-LDTg activation has no effect on food intake or body weight in cocaineexperienced rats.
Previous studies have shown that endogenous GLP-1R signaling in the LDTg and
DREADD manipulation of NTS GLP-1-producing neurons alters feeding behavior in rats
and mice (Gaykema et al., 2017; Liu et al., 2017; Shi et al., 2017; Reiner et al., 2018; Holt
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et al., 2019). Therefore, we assessed if activation of NTS to LDTg projections caused any
adverse effects on feeding and body weight in rats that underwent cocaine reinstatement.
Cumulative chow intake and body weight were measured in rats that received vehicle or
1 mg/kg CNO treatment during cocaine reinstatement test sessions (Figure 4.7A&B; n=9).
No effects from CNO treatment were observed at any time point. We also determined if
CNO itself had any off-target effects on feeding by assessing 24 hr cumulative chow intake
and body weight in rats that expressed control virus AAV-DIO-mCherry and underwent
cocaine reinstatement. No effects from CNO treatment were observed (Figure 4.7C&D;
n=7).
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Discussion
The present study identified the GLP-1 system as a critical mechanism by which the LDTg
acts to reduce cocaine seeking behavior. Specifically, we found that activation of LDTg
GLP-1Rs via Ex-4 decreased cocaine seeking at a dose that had no effect on food intake
or body weight in cocaine-experienced animals or sucrose seeking behavior in drug-naïve
rats. Next, we found that GLP-1Rs are primarily expressed on GABA neurons in the LDTg.
In addition, Ex-4 treatment significantly activated LDTg GABA neurons. Using GAD1-Cre
rats, we selectively manipulated GLP-1Rs on LDTg GABAergic neurons to specifically test
the role of this receptor population in cocaine self-administration and reinstatement.
Knockdown of GLP-1R expression on LDTg GABA neurons augmented cocaine selfadministration and prevented the ability of Ex-4 to decrease cocaine seeking. To
investigate the GABAergic LDTg circuits that mediate Ex-4’s effects on cocaine seeking,
we chemogenetically inhibited LDTg-to-VTA GABAergic neurons which blocked the ability
of Ex-4 to decrease cocaine seeking. These results highlight, for the first time, the role of
the LDTg GABAergic system in regulating cocaine-seeking behavior. To continue to
investigate the mechanisms by which GLP-1 signaling in the LDTg decreases cocaine
seeking, we investigated the endogenous GLP-1 circuits that project to the LDTg. Using
a dual virus approach, we selectively activated NTS afferents that project to the LDTg and
assessed this circuit in controlling cocaine-seeking behavior. Our results showed that
activation of the NTS-to-LDTg pathway attenuated cocaine seeking, was mediated by
increased GLP-1R activation in the LDTg, and did not cause adverse feeding effects.
Overall, these findings contribute to and expand upon previous studies demonstrating a
role for central GLP-1Rs in addiction-like behaviors and highlight a novel role for hindbrain
circuits in the regulation of cocaine-seeking behavior.
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GLP-1R activation in the LDTg decreases cocaine seeking behavior
Within the mesolimbic reward system, the LDTg receives glutamatergic projections from
the prefrontal cortex and sends direct projections to the VTA which are essential for the
burst firing of dopamine neurons (Satoh and Fibiger, 1986; Sesack et al., 1989; Cornwall
et al., 1990; Omelchenko and Sesack, 2005; Lodge and Grace, 2006; Schmidt et al., 2009;
Dautan et al., 2016). Thus, the LDTg is a key nucleus to study in the context of cocaine
seeking. Indeed, studies have shown that cocaine exposure increases presynaptic
glutamate release onto LDTg cholinergic neurons and facilitates LDTg stimulation-induced
dopamine release to the NAc (Lester et al., 2010; Kurosawa et al., 2013). In addition,
pharmacological blockade of excitatory signaling LDTg attenuates cocaine-mediated
behaviors including cocaine seeking (Schmidt et al., 2009; Shabani et al., 2010; Shinohara
et al., 2014). Therefore, studies examining mechanisms that can regulate the effects of
excitatory transmission in the LDTg to promote cocaine-mediated behaviors may be
critical in order to find potential targets for treating cocaine use disorder.

Here, we showed that activation of LDTg GLP-1Rs via intra-LDTg administration of Ex-4
(0.005 µg and 0.025 µg) significantly attenuated cocaine seeking. Due to the known
effects of Ex-4 to cause reductions in food intake and nausea/malaise (Hayes et al.,
2011a; Kanoski et al., 2012), it is important to control for any adverse effects in order to
support the therapeutic efficacy of GLP-1R agonists in humans with cocaine use disorder.
Previous studies have shown that intra-LDTg 0.025 µg Ex-4 decreases food intake and
body weight in drug-naïve rats without causing any effects on nausea/malaise (Reiner et
al., 2018). However, the effects of lower doses of Ex-4 on food intake and body weight
have not been assessed. Consistent with previous findings, we observed that 0.025 µg
Ex-4 in the LDTg decreased body weight in rats that underwent cocaine reinstatement.
Additionally, we showed for the first time, that GLP-1R signaling in the LDTg reduces
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responding for palatable foods as intra-LDTg Ex-4 (0.025 µg) attenuated sucrose seeking
in drug-naïve rats. Conversely, we found that the 0.005 µg dose of intra-LDTg Ex-4
significantly decreased cocaine seeking without affecting body weight or sucrose seeking.
Additional food intake experiments were conducted and revealed that 0.005 µg Ex-4 had
no effects on cumulative chow intake in cocaine-experienced rats. Therefore, these
findings identified a dose of intra-LDTg Ex-4 (0.005 µg) that selectively attenuated cocaine
seeking without causing adverse feeding effects. These data are consistent with our
previous studies showing that lower doses of systemically administered Ex-4 (0.1 and 0.2
µg/kg) are sufficient to decrease cocaine seeking and do not affect ad libitum food intake
(cumulative chow intake, meal size or meal frequency) or body weight in cocaineexperienced rats (Hernandez et al., 2018). Similarly, our previous studies examining the
effects of GLP-1R activation in the NAc and VTA show that intra-VTA and intra-NAc Ex-4
(0.005 µg and 0.05 µg) reduce cocaine seeking at doses that do not affect ad libitum chow
intake or promote malaise-like effects in rats (Alhadeff et al., 2012; Dickson et al., 2012;
Mietlicki-Baase et al., 2013; Hernandez et al., 2018; Hernandez et al., 2019). Moreover,
intra-VTA or intra-NAc infusions of Ex-4 (0.05 µg) do not alter the reinstatement of sucrose
seeking, which further support the selectivity of lower doses to reduce cocaine seeking
(Hernandez et al., 2018; Hernandez et al., 2019). The translational implications of these
findings are profound in that they support potential therapeutic approaches toward the
specific use of GLP-1R agonists for the treatment of cocaine craving and relapse. These
findings are also provocative in that they suggest that drug and non-drug motivated
behaviors can be differentially modulated by GLP-1R activation in a cocaine-experienced
animal.
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Cocaine seeking is reduced by activation of GLP-1Rs on LDTg GABA neurons
The LDTg contains distinct populations of cholinergic, glutamatergic and GABAergic
neurons (Wang and Morales, 2009; Luquin et al., 2018). However, the role of the LDTg in
addiction has been largely attributed to the excitatory cholinergic projections and their
ability to promote reward-related behaviors (Oakman et al., 1995; Omelchenko and
Sesack, 2005; Lodge and Grace, 2006; Mena-Segovia et al., 2008; Holmstrand and
Sesack, 2011; Dautan et al., 2016; Xiao et al., 2016; Kaneda, 2018). The role of the other
cell types in the LDTg to regulate addiction-like behaviors is largely unexplored. Therefore,
we investigated the exact cell types that express GLP-1Rs in the LDTg in order to
determine the mechanisms by which LDTg GLP-1R activation decreases cocaine seeking.
Using FISH, we characterized the GLP-1R-expressing neuronal cell types in the LDTg
and found that 70% were GABAergic neurons, 25% were glutamatergic neurons and 0%
were cholinergic neurons. The 5% remaining GLP-1R-expressing cell types in the LDTg
are most likely glial as there are no other neuronal cell-types in the LDTg and GLP-1Rs
are known to be expressed on astrocytes and involved in energy balance control (Reiner
et al., 2016). These findings, to our knowledge, are the first to characterize GLP-1Rexpressing neurons in the LDTg and provide important insights on the mechanisms that
underly the effects of GLP-1R activation on cocaine seeking. The GLP-1R is a G-protein
coupled receptor known to interact predominately through the Gs subunit (Fletcher et al.,
2016). Studies have shown that activation of GLP-1Rs increases intracellular calcium and
cAMP, PKA and MAPK activation (Perfetti and Merkel, 2000; Gomez et al., 2002; Hayes
et al., 2011b). Indeed, previous electrophysiological studies show that GLP-1R agonists
enhances neuronal activity in the brain by both pre-synaptic effects on neurotransmitter
release and of post-synaptic membrane excitability (Acuna-Goycolea and van den Pol,
2004; Mietlicki-Baase et al., 2013; Mietlicki-Baase et al., 2014; Korol et al., 2015b;
Hernandez et al., 2019). Therefore, the effects of LDTg GLP-1R activation to attenuate
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cocaine seeking are unlikely due to glutamatergic or cholinergic neurons as activation of
these excitatory neurons in the LDTg to the VTA are rewarding and promote cocainemediated behaviors (Schmidt et al., 2009; Shabani et al., 2010; Lammel et al., 2012;
Shinohara et al., 2014; Xiao et al., 2016; Steidl et al., 2017). Furthermore, although we
saw a 25% colocalization of GLP-1Rs on LDTg glutamate neurons, glutamate release in
the mesolimbic reward system is well established to promote cocaine-seeking behavior
(Schmidt and Pierce, 2010), and since administration of Ex-4 in the LDTg reduced cocaine
seeking, it is unlikely that these effects are due to glutamatergic neurons.

Due to this knowledge and the fact that we found the majority of GLP-1Rs expressed on
LDTg GABAergic neurons, we hypothesized that the suppressive effects of LDTg GLP1R activation on cocaine seeking are mediated by this cell type. Indeed, we showed that
Ex-4 activated LDTg GABA neurons and that selectively knocking down GLP-1Rs in this
neuronal population blocked the ability of both intra-LDTg Ex-4 and systemic Ex-4 to
decrease cocaine seeking. These data show that GLP-1Rs on LDTg GABA neurons are
necessary for Ex-4’s effects on cocaine seeking. Additionally, we found that LDTg GABA
GLP-1R knockdown augmented cocaine-self administration, indicating the endogenous
relevance of GLP-1 signaling to LDTg GABA neurons in controlling cocaine-taking
behavior. However, GLP-1R knockdown had no effect on cocaine-seeking behavior in
vehicle-treated rats compared to controls. These findings may be due to a potential ceiling
effect from the 10 mg/kg priming-dose of cocaine. Thus, lower priming-doses of cocaine
may be needed to visualize differences in cocaine seeking compared to controls. Overall,
our results show for the first time that LDTg GABA neurons play critical role in animal
models of cocaine addiction and that both exogenous and endogenous GABAergic GLP1R activation in the LDTg regulates cocaine-mediated behaviors.
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The efficacy of Ex-4 in reducing cocaine seeking depends upon activation of GABAergic
projections from the LDTg to the VTA.
In addition to establishing a role for GABAergic GLP-1Rs in the LDTg, we also investigated
the cell type-specific circuits in the LDTg that that mediate the suppressive effects of Ex4 on cocaine seeking. We chemogenetically inhibited LDTg GABA projections to the VTA
upon administration of Ex-4 and found that the suppressive effects of Ex-4 on cocaine
seeking were reversed when this pathway was inhibited. These data reveal an important
mechanism of action of Ex-4 to decrease cocaine seeking but also highlight the relevance
of LDTg-to-VTA GABA projections. Although 40-45% of neurons in the LDTg are
GABAergic (Wang and Morales, 2009; Luquin et al., 2018), very little is known about the
role of LDTg GABAergic circuits in motivated behaviors as the majority of studies focus
solely on LDTg cholinergic neurons. To date, the existing literature consists of a study that
identified presumed GABAergic LDTg synapses on VTA neurons (Omelchenko and
Sesack, 2005) and a study who found that non-cell type-specific stimulation of LDTg
neurons in rats resulted in a ~30% inhibition of VTA neuronal activity which included
putative dopaminergic and GABAergic VTA neurons (Coimbra et al., 2017). Here, we
showed that LDTg GABAergic fibers are localized in the VTA and associated with
dopamine neurons. Our findings suggest that Ex-4 decreases cocaine seeking by inducing
LDTg GABA-mediated inhibition of dopamine neurons. Support for this hypothesis comes
from previous studies showing that systemic and ICV infusions of Ex-4 decreases cocaineevoked dopamine release in the NAc (Egecioglu et al., 2013b; Sorensen et al., 2015;
Fortin and Roitman, 2017). However, future studies are needed to directly assess if LDTg
GABAergic neurons make synaptic contacts on to VTA dopamine neurons. Additionally,
studies must continue to investigate the neural circuits activated by Ex-4 as other brain
regions are also known to be involved in Ex-4’s effects on cocaine seeking (Hernandez et
al., 2018; Hernandez et al., 2019). Overall, we highlighted that the LDTg GABA system is
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an important mechanism of action by which Ex-4 decreases cocaine seeking and the first
to establish the relevance of LDTg-to-VTA GABAergic projections in regulating cocaineseeking behavior.

Endogenous GLP-1-expressing NTS-to-LDTg circuits regulate cocaine-seeking behavior
While the current study revealed no effects of cocaine self-administration and abstinence
on LDTg GLP-1R expression, our previously published findings have shown that cocaine
taking and subsequent abstinence dynamically regulate expression of preproglucagon
(PPG), the gene that encodes GLP-1, in the NTS. Specifically, cocaine self-administration
increased endogenous PPG expression in the NTS (Hernandez et al., 2018). These data
are consistent with findings that support the hypothesis that increased central GLP-1
signaling may serve as a ‘brake’ to reduce further cocaine consumption (Schmidt et al.,
2016). In contrast, PPG expression in the NTS was significantly decreased following
seven days of abstinence (Hernandez et al., 2018), a time point that coincides with robust
drug-seeking behavior (Anderson et al., 2008; Schmidt et al., 2015b; Hernandez et al.,
2019). These results suggest that decreased endogenous PPG expression in the NTS
and reduced GLP-1 signaling in target nuclei during abstinence may facilitate cocaine
craving and relapse. Therefore, we tested if chemogenetically activating NTS-to-LDTg
circuits would attenuate cocaine-seeking behavior. Indeed, NTS-to-LDTg activation
significantly decreased cocaine seeking and these effects were dependent on GLP-1R
activation in the LDTg. Therefore, our data indicates that endogenous NTS GLP-1R
signaling to the LDTg regulates cocaine-seeking behavior. It is important to note that NTS
GLP-1-producing neurons are also known to co-release glutamate (Zheng et al., 2015).
However, the observed suppressive effects on cocaine seeking following NTS-to-LDTg
activation are unlikely due to increased glutamate release as blocking glutamate
transmission in the LDTg attenuates cocaine-seeking behavior (Schmidt et al., 2009). Our
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data also found that not all hM3D(Gq)-expressing NTS-to-LDTg neurons were GLP-1
positive. Thus, future studies should investigate if other NTS cell types, such as
noradrenergic neurons, also play a role in regulating cocaine-seeking behavior as cocaine
exposure has been shown to activate noradrenergic neurons in the NTS (Buffalari and
Rinaman, 2014).

In addition to assessing NTS-to-LDTg activation on cocaine seeking, our data showed that
activating NTS-to-LDTg circuits in cocaine-experienced rats had no effect on cumulative
chow intake or body weight when measured after cocaine reinstatement test sessions.
These data are consistent with previous studies that chemogenetically activated GLP-1producing neurons in the NTS using glucagon (Gcg) promoter-driven Cre mice. These
studies show that both global chemogenetic activation of NTS GLP-1-producing neurons
and selective activation of NTS to the paraventricular hypothalamus circuit reduces chow
intake in only the first 2-4 hrs with no effects on body weight or food intake at longer time
points (Gaykema et al., 2017; Liu et al., 2017; Shi et al., 2017; Holt et al., 2019). Taken
together, these findings show that the chow intake-suppressive effects of NTS circuit
activation are transient and do not cause no long-term effects on feeding or body weight.
Overall, to our knowledge, this study is the first to demonstrate that NTS GLP-1 circuits
not only play a role in energy balance control but also function to regulate cocainemediated behaviors.

Conclusion
We report that the LDTg is a critical nucleus in regulating cocaine seeking through
activation of the GLP-1 system. Our results show, for the first time, that GLP-1Rs on LDTg
GABA neurons and LDTg-to-VTA GABAergic projections mediate the effects of Ex-4 on
cocaine seeking. Additionally, we demonstrate that endogenous GLP-1 circuits from the
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NTS are important regulators of cocaine craving-induced relapse. Thus, our findings
support the ever growing literature that central GLP-1 system may be an essential target
for treating cocaine abuse disorder.
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Figures

Figure 4.1 Intra-LDTg Ex-4 attenuates cocaine seeking at a dose that does not affect
sucrose seeking, food intake or body weight. (A) 0.2 µg/kg fluoro-Ex-4 (green)
colocalized with neurons (blue) and astrocytes (red) in the LDTg (63x). (B) Bilateral
infusions of intra-LDTg Ex-4 (0.005 and 0.025 µg) significantly attenuated cocaine seeking
(n=15). (C) Bilateral infusions of intra-LDTg Ex-4 at 0.025 µg significantly decreased
sucrose seeking in drug naïve rats while 0.005 µg had no effect on sucrose seeking
(n=11). (D) Representative histological section showing verification of LDTg cannula
placement. (E) Intra-LDTg Ex-4 (0.005 µg) had no effect on body weight while 0.025 µg
Ex-4 significantly reduced body weight in rats that underwent cocaine reinstatement
(n=15). (F) 0.005 µg intra-LDTg Ex-4 had no effect on chow intake in rats that underwent
cocaine reinstatement (n=7). (G) Microinjection sites corresponding to the cocaine
reinstatement group in B. (H) Microinjection sites corresponding to the sucrose
reinstatement group in C. Data are mean ± SEM. *p<0.05
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Figure 4.2 Intra-LDTg Ex-4 attenuates cocaine seeking at a dose that does not affect
sucrose seeking, food intake or body weight
(A) Expression of GLP-1R mRNA transcripts in the LDTg were quantified following one
(Ext1) and seven (Ext7) days of extinction following cocaine self-administration. (B) There
were no differences in LDTg GLP-1R mRNA expression after one (n=7) or 7 days (n=9)
of extinction compared to controls. Data are mean ± SEM
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Figure 4.3 GLP-1Rs are primarily expressed on GABA neurons in the LDTg.
Representative 40x images of FISH in the LDTg with GLP1R in red and DAPI in blue with
GAD1 (A), vGLUT2 (B), and ChAT (C). White arrows indicate colocalization with GLP-1R.
White boxes indicate zoomed-in images shown in (D). (E) Quantification of GLP-1R
colocalization with different cell types. (F) 63x image of 0.2 µg/kg fluoro-Ex-4 (green)
colocalized with GABA neurons (red). (G) 0.2 µg/kg Ex-4 induces cFos (green) in LDTg
GABA neurons (red), taken at 20x and quantified in (H) (n=4/treatment). Data are mean ±
SEM. *p<0.05

122

Figure 4.4 Knockdown of GABA GLP-1 receptors in the LDTg augments cocaine
self-administration and prevents the ability of Ex-4 to reduce cocaine seeking. (A)
Bilateral infusions of a Cre-dependent AAV1 expressing shRNA against the GLP-1R or
control virus was administered in the LDTg of GAD1-Cre rats. (B) Visualization of virus
expression in the LDTg at 10x. Knockdown (KD) of LDTg GABA GLP-1Rs significantly
increased total active lever responses (C), total infusions (D), and breakpoint (E) (n=10)
for cocaine a progressive ratio (PR) schedule of reinforcement compared to rats infused
with control virus (n=12). Knockdown of GABA GLP-1Rs blocked the ability of intra-LDTg
0.005 µg Ex-4 (n=4/group) (F) and 0.2 µg/kg i.p. Ex-4 (control: n=8; GLP-1R KD: n=11)
(G) to reduce cocaine seeking. Microinjection sights corresponding to Control (H) and
GLP-1R KD (I) groups shown in F. Data are mean ± SEM. *p<0.05
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Figure 4.5 LDTg GABA neurons projecting to the VTA mediate the ability of Ex-4 to
reduce cocaine seeking. (A) GAD1-Cre rats received bilateral infusions of a Credependent AAV2 expressing the inhibitory DREADD hM4D(Gi) or control virus in the
LDTg. Guide cannula were inserted at the level of the VTA for CNO administration. (B)
Visualization of hM4D(Gi) expression in LDTg GABA neurons at 10x. (C) LDTg GABA
hM4D(Gi)-expressing terminals (red) localized in the VTA with dopamine neurons (green).
(D) Inhibition of LDTg GABA terminals in the VTA via intra-VTA CNO infusions prevented
the ability of Ex-4 (0.2 µg/kg, i.p.) to reduce cocaine seeking (n=10). (E)
Electrophysiological recordings validating the ability of CNO to decrease neuronal activity
in LDTg hM4D(Gi)-expressing neurons. (F) There was no effect of intra-VTA CNO on the
attenuation of cocaine seeking from Ex-4 treatment in rats that were infused with control
virus (n=10). (G) Microinjection sites corresponding to rats in D. (H) Microinjection sites
corresponding to the rats in F. Data are mean ± SEM. *p<0.05
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Figure 4.6 NTS to LDTg circuit activation attenuates cocaine seeking. (A) Bilateral
infusions of CAV2-Cre and Cre-dependent AAV2 expressing the activating DREADD
hM3D(Gq) were administered in the LDTg and NTS, respectively (B) Visualization of
hM3D(Gq) expression in NTS neurons that project to the LDTg taken at 20x. (C)
Representative images and quantification of CNO inducing cFos in NTS hM3D(Gq)expressing neurons compared to rats expressing control virus (hM3D(Gq): n=5; control:
n=6). (D) Electrophysiological recordings validating the ability of CNO to increase neuronal
firing in NTS hM3D(Gq)-expressing neurons. (E) 1 mg/kg, i.p. CNO administration in rats
to activate NTS to LDTg circuits significantly attenuated cocaine seeking (n=8). (F) CNO
treatment had no effect on cocaine seeking in rats infused with control virus (n=7). (G)
Representative image of NTS hM3D(Gq)-expressing neurons co-expressing GLP-1. (H)
Pharmacologically inhibiting LDTg GLP-1Rs via Ex-9 blocked the effect of NTS to LDTg
circuit activation on cocaine seeking (n=9). (I) Microinjection sights in the LDTg
corresponding to H. Data are mean ± SEM. *p<0.05

125

A

4

Body Weight Change
(g/24 hr)

Cumulative Chow Intake (g)

B
hM3D(Gq)

30

20

10

0
1

3

6

Body Weight Change
(g/24 hr)

Cumulative Chow Intake (g)

1.0 mg/kg CNO

2

20

10

0
1

3

6

0

D

Control

30

2

-2

24
0 mg/kg CNO

C

hM3D(Gq)

Control

0

-2

-4

24

Figure 4.7 NTS to LDTg circuit activation has no effect on chow intake or body
weight in cocaine-experienced rats. There was no effect of CNO treatment on
cumulative chow intake (A) or 24 hr body weight (B) in rats expressing hM3D(Gq) (n=9)
or control virus (C&D) (n=6) that underwent cocaine reinstatement test sessions. Data are
mean ± SEM.

126

CHAPTER 5: General Discussion and Conclusion

There is a critical need for preclinical research to identify key neurobiological systems that
can be targeted by novel pharmacotherapies for treating cocaine use disorder. A
promising target is the central GLP-1 system and identifying the mechanisms and sites of
action of GLP-1 and its clinically relevant receptor agonists is paramount in approving
GLP-1 analogs for treating cocaine use disorder. The data presented in this dissertation
provides evidence that GLP-1Rs expressed in nuclei of the mesolimbic reward system,
VTA, NAc and LDTg, are important for regulating cocaine-seeking behavior. Additionally,
this dissertation shows that endogenous GLP-1 circuits from the NTS of the brainstem
function to reduce cocaine seeking. As a whole these data broaden our view of the central
GLP-1 system as well as the neural circuits that regulate addiction-like behaviors. In this
chapter, I summarize and discuss key findings and propose future avenues of research.

The Role of Systemic Ex-4 on Cocaine Seeking
Previous studies have shown that systemic administration of Ex-4 (2.4 – 100.0 µg/kg)
reduces cocaine CPP and self-administration in mice (Egecioglu et al., 2013b; Graham et
al., 2013; Sorensen et al., 2015). However, a notable caveat to these studies is the
exceedingly high doses of Ex-4 used, which have been shown to produce nausea and
malaise-like symptoms in addition to suppressing locomotion. Doses of Ex-4 as low as 0.3
µg/kg suppress locomotor activity in both mice and rats (Talsania et al., 2005; Mack et al.,
2006; Sorensen et al., 2015) and doses of Ex-4 as low as 0.25 µg/kg produce
nausea/malaise in rodents (Kanoski et al., 2012). These findings clearly indicate that
doses of Ex-4 greater than 0.25 µg/kg produce malaise-like adverse effects. Additionally,
nausea is associated with high doses of GLP-1R agonists in humans (Buse et al., 2009).
Since the high doses of Ex-4 (2.4 – 100.0 µg/kg) are likely producing malaise-like effects
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in rodents, it is impossible to draw firm conclusions about the exact role of GLP-1Rs in
addiction-like behaviors from the previous studies

The data in Chapter 2 found that systemic administration of Ex-4 (0.1 and 0.2 µg/kg, i.p.)
significantly attenuated the reinstatement of drug-seeking behavior elicited by both a
priming injection of cocaine and re-exposure to conditioned cues previously paired with
cocaine taking. Importantly, these doses of Ex-4 did not affect ad libitum food intake
(cumulative chow intake, meal size or meal frequency) or body weight in cocaineexperienced rats. Moreover, these behaviorally-relevant doses of Ex-4 do not produce
nausea/malaise-like adverse effects in rodents (Kanoski et al., 2012) further highlighting
the selectivity of this behavioral response at these doses. This is the first study to our
knowledge identifying systemic doses of a GLP-1R agonist that selectively attenuate
cocaine-mediated behaviors and do not produce adverse effects commonly associated
with higher doses in rodents. The translational implications of these findings are profound
in that they support potential therapeutic approaches toward the specific use of GLP-1R
agonists for the treatment of cocaine craving and relapse. However, future studies are
also needed to assess the efficacy of repeated administration of GLP-1R agonists on
voluntary cocaine taking and seeking as studies to date have only assessed the acute
effects of Ex-4 on these behaviors. It will be important to know if tolerance and/or adverse
effects develop to repeated administration of GLP-1R agonists. Furthermore, no studies
to date have examined potential sex differences in the efficacy of GLP-1R agonists to
reduce cocaine-mediated behaviors. Recent evidence indicates that females are more
sensitive to the effects of a GLP-1R agonist infused directly into the brain on food intake
(Richard et al., 2016). It is provocative to think that the potency of GLP-1R agonists may
differ between sexes in preclinical models of addiction. In addition to Ex-4, preclinical
studies should also test the efficacy of other GLP-1 system-targeted drugs with different
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pharmacokinetic profiles (e.g., liraglutide) and pharmacological mechanisms of action
(e.g., sitagliptin) in reducing cocaine-taking and -seeking behaviors. Overall, more
research is still needed to prove the therapeutic efficacy of GLP-1R agonists to treat
cocaine use disorder.

The Role of VTA and NAc GLP-1Rs in Cocaine Seeking
The data in Chapter 2 showed that VTA GLP-1Rs play an important role in the
reinstatement of cocaine-seeking behavior. Systemic doses of Ex-4 that selectively
attenuated cocaine reinstatement crossed the blood brain barrier and bound putative GLP1Rs located on neurons and astrocytes throughout the brain including the VTA, which
suggested that the suppressive effects of peripheral Ex-4 on cocaine seeking are due, in
part, to activation of VTA GLP-1Rs. Pharmacological inhibition of GLP-1Rs in the VTA
was sufficient to attenuate the efficacy of systemic Ex-4 to reduce cocaine reinstatement
providing further support for this hypothesis. More direct evidence supporting a critical role
of central GLP-1Rs in cocaine seeking was provided in Chapter 2 by showing that
infusions of Ex-4 (0.05 µg) directly into the VTA significantly decreased cocaine seeking.
Overall, these findings clearly indicate that activation of VTA GLP-1Rs is sufficient to
reduce cocaine-seeking behavior. Moreover, intra-VTA infusion of Ex-4 (0.05 µg) did not
alter the reinstatement of sucrose seeking supporting the selectivity of this dose to reduce
cocaine seeking. The dose of intra-VTA Ex-4 (0.05 µg) used in this study reduced cocaine
seeking and has been shown to have no effects on ad libitum chow intake or promote
malaise-like effects in rats (Alhadeff et al., 2012; Dickson et al., 2012; Mietlicki-Baase et
al., 2013). There is some evidence that administration of 0.05 µg Ex-4 into the VTA
reduced operant responding for palatable food (Dickson et al., 2012). However, these
effects were transient and did not persist with more prolonged operant sessions (Dickson
et al., 2012; Schmidt et al., 2016). Overall, Chapter 2 identified an intra-VTA dose of Ex-4
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that selectively reduce seeking-behaviors in rats and not produce adverse feeding or
malaise-like effects.

While

activation

of

GLP-1Rs

in

the

VTA attenuates

cocaine

seeking,

the

neurophysiological mechanisms underlying these behavioral responses are not clear.
Previous studies have shown that GLP-1R agonists modulate neuronal activity in the brain
by both pre-synaptic effects on neurotransmitter release and regulation of post-synaptic
membrane excitability (Acuna-Goycolea and van den Pol, 2004; Mietlicki-Baase et al.,
2014; Korol et al., 2015b). In drug-naïve mice, Ex-4 reduces AMPA receptor-mediated
EPSCs in VTA dopamine neurons that project to the NAc shell (Wang et al., 2015).
AMPA/NMDA EPSC ratio in the VTA is also decreased following Ex-4 application
suggesting a postsynaptic modification that functions to reduce excitatory synaptic
strength via removal of AMPA receptors from the postsynaptic membrane (Wang et al.,
2015). Interestingly, Ex-4 also increases amplitude of spontaneous inhibitory postsynaptic
currents (sIPSCs) in VTA dopamine neurons (Wang et al., 2015). These results indicate
that GLP-1R activation modulates both excitatory and inhibitory transmission in VTA
dopamine neurons that project to the NAc. It is interesting to think that similar mechanisms
(i.e., decreased excitatory synaptic strength and/or facilitation of inhibitory synaptic inputs
in VTA dopamine neurons) may mediate the effects of GLP-1R activation in the VTA on
cocaine taking and seeking. Indeed, data in Chapter 4 demonstrated the relevance of
VTA-projecting GABAergic terminals from the LDTg in mediating the effects of Ex-4 on
cocaine seeking. Thus, future electrophysiological studies in the VTA are needed to
investigate the pre- and post-synaptic mechanisms induced by Ex-4 in cocaineexperienced animals. Additional studies investigating the cell types in the VTA that
express GLP-1Rs are also necessary to determine the mechanisms that underly VTA
GLP-1R activation on cocaine-mediated behaviors. As data in Chapter 4 showed the
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importance of GABAergic neurons in mediating the effects of LDTg GLP-1R activation on
cocaine seeking, future experiments should investigate if VTA GABAergic interneurons
express GLP-1Rs. A potential hypothesis is that Ex-4 decreases cocaine-mediated
behaviors through activation GLP-1Rs on VTA GABAergic interneurons to reduce
dopamine cell firing and subsequent dopamine release to forebrain areas.

Previous studies have begun to investigate the effects of Ex-4 on dopamine release,
particularly in the NAc. Initial studies show that systemic infusions of Ex-4 reduces
cocaine-evoked dopamine release in the NAc (Egecioglu et al., 2013b; Sorensen et al.,
2015). However, the relative contributions of peripheral and central GLP-1Rs to these
neurochemical changes is not clear. A recent study investigated the role of central GLP1Rs in attenuating cocaine-evoked dopamine release in the NAc core and shell
subregions using in vivo fast-scan cyclic voltammetry. Intracerebroventricular (ICV)
infusion of Ex-4 attenuated phasic dopamine release in the NAc core, but not the shell, of
rats receiving non-contingent infusions of cocaine (Fortin and Roitman, 2017). To
investigate the mechanisms by which Ex-4 reduces cocaine-evoked dopamine release in
the NAc core, electrical stimulation of the VTA was performed in rats receiving noncontingent infusions of cocaine. Ex-4 did not affect the ability of cocaine to attenuate
dopamine uptake, which suggests that GLP-1R activation exerts its suppressive effects
on cocaine-induced dopamine release in the NAc core by reducing the excitability of
midbrain dopamine neurons (Fortin and Roitman, 2017). While these findings are the first
to highlight a role for central GLP-1Rs in suppression of cocaine-evoked dopamine release
in the NAc (Fortin and Roitman, 2017), one limitation of this study is that ICV delivery of
Ex-4 causes broad GLP-1R activation throughout the brain. Therefore, it is difficult to
delineate the exact brain regions mediating the neurochemical and neurophysiological
effects of Ex-4. Also, while Ex-4 attenuates cocaine self-administration (Sorensen et al.,
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2015; Schmidt et al., 2016), it is not clear whether Ex-4 suppresses conditioned phasic
dopamine release aligned with cocaine-predictive cues and operant responding observed
during voluntary cocaine taking (Phillips et al., 2003; Stuber et al., 2005). Additionally, very
little is known about how activation of central GLP-1Rs affects phasic versus tonic
dopamine cell firing. Thus, our understanding of how central GLP-1R activation influences
the mesolimbic dopamine system to reduce addiction-like behaviors would benefit from
future electrophysiological studies delineating these effects.

Chapter 3 directly tests the role of GLP-1Rs in the NAc to regulate cocaine-seeking
behavior. The data in Chapter 3 show that, in addition to binding putative GLP-1Rs in the
VTA, doses of systemic Ex-4 that attenuate cocaine seeking also distribute to the core
and shell subregions of the NAc. These functionally distinct subregions are known to play
differential roles in motivated behaviors including drug addiction (Di Chiara, 2002). The
NAc shell, which is classified as part of the limbic system, is implicated in the primary
rewarding effects of drugs of abuse as well as regulating instrumental responding in the
presence of motivationally relevant stimuli (Schmidt and Pierce, 2010). Alternatively, the
NAc core, which is considered part of the basal ganglia, mediates the incentive value of
reward-conditioned stimuli and contributes to drug-associated, cue-induced cocaine
seeking (Schmidt and Pierce, 2010). In Chapter 3, infusions of Ex-4 directly into the NAc
core and shell were sufficient to attenuate cocaine seeking. Interestingly, the potency of
Ex-4 differed between subregions. Cocaine-seeking behavior was decreased in rats
pretreated with 0.05 µg Ex-4 in both the NAc core and shell. In contrast, 0.005 µg Ex-4
significantly attenuated cocaine seeking when infused directly into the NAc core, but not
shell. Previous studies have also demonstrated differential effects of GLP-1R agonist
doses in the shell and core subregions in decreasing food intake (Dossat et al., 2011;
Alhadeff et al., 2012). Lower doses of Ex-4 reduced intake of palatable food when infused
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into the NAc core compared to the NAc shell (Alhadeff et al., 2012). The lowest effective
dose of Ex-4 used in this study was 0.025 µg, which produced a transient effect on food
intake following activation of GLP-1Rs in the NAc core and no effect on food intake when
infused into the NAc shell (Alhadeff et al., 2012). Collectively, these findings suggest that
GLP-1 signaling in the NAc core may play a more prominent role in regulating drugseeking behavior and hedonic feeding. A potential explanation may be that there is
differential expression of GLP-1Rs in the shell vs core, with a possibility of more GLP-1Rs
in the NAc core. Thus, quantification of GLP-1R-expressing cells in these two sub-regions
should be conducted.

In contrast to the effects intra-NAc Ex-4 on cocaine seeking, 0.05 µg Ex-4 in the NAc core
and shell had no effects on sucrose seeking. Although administration of Ex-4 directly into
the NAc shell reduced sucrose self-administration on a progressive ratio schedule of
reinforcement (Dickson et al., 2012), doses of Ex-4 lower than 0.1 µg when infused into
the NAc shell or core do not affect operant responding for sucrose, ad libitum chow intake,
or produce adverse malaise-like effects (Alhadeff et al., 2012; Dickson et al., 2012;
Mietlicki-Baase et al., 2014). Therefore, Ex-4 infusions into the NAc core (0.05 and 0.005
µg) and shell (0.05 µg) of cocaine-experienced rats selectively reduced cocaine seeking
and did not affect food intake.

In order to investigate the neurophysiological mechanisms by which GLP-1R activation in
the NAc attenuates cocaine-mediated behaviors, Chapter 3 employed ex vivo
electrophysiological studies to elucidate the effects of GLP-1R activation on neuronal
activity in a cocaine-exposed brain. Specifically, we assessed the effects of Ex-4 on
activity of medium spiny neurons (MSNs) in the NAc of cocaine-experienced rats.
Following extinction of cocaine self-administration, application of 1 μM exendin‐4
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increased the frequency of MSN action potential firing in the NAc core and shell. No other
measures of membrane excitability (e.g., resting membrane potential, rheobase, action
potential amplitude and action potential duration) were altered by GLP-1R activation in ex
vivo striatal slices from cocaine‐experienced rats. In contrast to previous studies showing
presynaptic effects of GLP-1R activation in the VTA and NAc core of drug-naïve rats
(Mietlicki-Baase et al., 2013; Mietlicki-Baase et al., 2014), Ex-4 had no effects on
spontaneous excitatory post-synaptic currents (sEPSCs) frequency and paired pulse ratio
(PPR) of evoked EPSCs in NAc core and shell MSNs from cocaine‐experienced rats.
Taken together, the results in Chapter 3 indicate that increased activation of GLP-1Rs in
the NAc during cocaine abstinence increases intrinsic, but not synaptic, excitability of
MSNs and is sufficient to reduce the reinstatement of cocaine-seeking behavior. It should
be noted that these results are limited to activity exclusively within the NAc, as these
studies were conducted in NAc slices without input from VTA cell bodies. The effects of
GLP-1R activation on NAc MSN activity should be further explored in an in vivo model, as
it has been shown that input from the VTA to the NAc impacts dopamine signaling
dynamics. Specifically, phasic dopamine release in the NAc is dependent on burst firing
of VTA dopamine neurons (Sombers et al., 2009). Moreover, studies utilizing
amphetamine have highlighted the importance of VTA input on NAc dopamine release
patterns. While dopamine efflux is preserved in ex vivo slices treated with amphetamine
(Jones et al., 1998), phasic dopamine release is only observed in in vivo studies with
preserved VTA inputs to the NAc (Covey et al., 2016). Thus, active VTA input into the NAc
may be required for a more accurate picture of how GLP-1R activation modulates NAc
MSN activity in cocaine-experienced animals.

An interesting alternative hypothesis is that VTA input may not be necessary to stimulate
dopamine release in the NAc. Recent studies have revealed that cholinergic interneurons
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in the NAc are capable of stimulating dopamine release and that these effects are
regulated, in part, by the endocannabinoid system and prefrontal cortical afferents to the
NAc (Cachope et al., 2012; Cachope and Cheer, 2014; Mateo et al., 2017). Since GLP1R activation has been shown to modulate both endocannabinoid signaling and
presynaptic glutamate release (Mietlicki-Baase et al., 2014; Reddy et al., 2016), it is
possible that Ex-4 may influence cholinergic interneuron signaling in the NAc via these
systems or by direct action on interneurons themselves. Further support for cholinergic
interneurons playing a role in modulating the effects of metabolic factors on striatal
dopamine levels and reward comes from a recent study showing that insulin increases
striatal dopamine release by activating cholinergic interneurons in the NAc (Stouffer et al.,
2015). Thus, future studies are needed to determine if GLP-1Rs are expressed on NAc
interneurons and if the effects of Ex-4 on MSN activity are due to activation of cholinergic
interneurons alone or require VTA input as discussed above.

GLP-1R activation increases MSN intrinsic excitability in cocaine-experienced rats
Cocaine abstinence is associated with decreased NAc MSN membrane excitability due to
changes in conductance of sodium, calcium and potassium (Zhang et al., 1998; Zhang et
al., 2002; Hu et al., 2004). Lower membrane excitability during cocaine abstinence may
enhance action potential sensitivity to GLP-1R activation in the NAc. Cocaine exposure is
likely a critical component in this scenario, given the previous findings of minimal effects
of Ex-4 on NAc MSN firing in drug-naïve rats (Mietlicki-Baase et al., 2014) combined with
data in Chapter 3 showing that increased frequency of MSN action potential firing in the
NAc core and shell in cocaine-experienced rats. In line with this hypothesis, a recent study
showed that Ex-4 suppressed cocaine-evoked phasic release of dopamine in the NAc
core, effects not due to changes in dopamine reuptake (Fortin and Roitman, 2017). These
neurophysiological changes, however, may not be specific to the NAc as Ex-4
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administration was also associated with reduced cocaine-evoked dopamine release in the
lateral septum (Harasta et al., 2015; Reddy et al., 2016). Understanding the mechanisms
by which GLP-1R activation in the NAc reduces cocaine seeking will benefit from a
comprehensive analysis of how Ex-4 regulates integration of synaptic and intrinsic MSN
excitability in the context of drug priming-induced reinstatement. Thus, intrinsic GLP-1Rcoupled mechanisms may contribute to previous findings that a broad increase in NAc
MSN action potential output is associated with attenuation of rewarding consummatory
behaviors (Nicola et al., 2004; Wheeler and Carelli, 2009). Additionally, studies show that
decreased NAc MSN membrane excitability from cocaine withdrawal induces synaptic
accumulation of calcium-permeable AMPA receptors and upregulation of excitatory
synaptic strength which promotes cocaine seeking after abstinence (Wang et al., 2018).
Indeed, disruption of this synaptic dysregulation after cocaine exposure prevents
incubation of cocaine craving (Wang et al., 2018). Thus, increased membrane excitability
in NAc MSNs following Ex-4 treatment may attenuate cocaine seeking by blocking
enhanced excitatory synaptic drive onto NAc MSNs following a priming injection of
cocaine.

The Role of LDTg GLP-1Rs in Cocaine Seeking
The data in Chapter 4 showed that the LDTg is an important nucleus in which GLP-1R
activation regulates cocaine-seeking behavior. Systemic Ex-4 bound to putative GLP-1Rs
located on neurons and astrocytes in the LDTg, which suggested that the suppressive
effects of peripheral Ex-4 on cocaine seeking are due, in part, to activation of LDTg GLP1Rs. Indeed, infusions of Ex-4 (0.005 and 0.025 µg) directly into the LDTg significantly
decreased cocaine seeking. Overall, these findings indicate that activation of LDTg GLP1Rs is sufficient to reduce cocaine-seeking behavior. Moreover, intra-LDTg infusion of Ex4 (0.005 µg) did not alter ad libitum feeding or body weight in rats that underwent cocaine
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reinstatement nor altered the reinstatement of sucrose seeking supporting the selectivity
of this dose to reduce cocaine seeking. Taken together with data in Chapter 2 and 3 that
identified behaviorally-selective systemic, intra-VTA and intra-NAc doses of Ex-4 that
reduced cocaine seeking, these findings further strengthen evidence supporting the
efficacy of lower doses of GLP-1R agonists to selectively attenuate cocaine seeking
versus non-drug motivated behaviors.

The experiments in Chapter 4 set out to determine the mechanisms by which LDTg GLP1R activation decreased cocaine-seeking behavior, first, by characterizing the exact cell
types that express GLP-1Rs in the LDTg. The GLP-1R-expressing neuronal cell types in
the LDTg were found to be 70% GABAergic, 25% glutamatergic and 0% cholinergic. The
5% remaining GLP-1R-expressing cell types in the LDTg are most likely glial cells as there
are no other neuronal cell-types in the LDTg and GLP-1Rs are known to be expressed on
astrocytes and involved in energy balance control (Reiner et al., 2016). It is unlikely that
the cocaine seeking suppressive effects of intra-LDTg Ex-4 were due to activation of GLP1Rs on LDTg glutamate neurons, as glutamate release in the mesolimbic reward system
such as the VTA is well established to promote cocaine-seeking behavior (Sun et al., 2005;
Schmidt et al., 2009; Schmidt and Pierce, 2010). Similarly, for GLP-1R-expressing
astrocytes in the LDTg, GLP-1R activation increases PKA (Hayes et al., 2011b; Rupprecht
et al., 2013), and PKA is known to contribute to the decrease of glutamate transporters on
astrocytes after morphine exposure (Lim et al., 2005). Thus, a GLP-1R-mediated
decrease in glutamate transporter expression would result in an increase in synaptic
glutamate and promote cocaine seeking. Support for this hypothesis comes from studies
showing that cocaine exposure alters glutamate reuptake in astrocytes to increase
synaptic glutamate levels that act to promote cocaine-mediated behaviors (Kalivas, 2009).
Additionally, delivery of a glutamate receptor antagonist into the LDTg attenuates cocaine
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seeking in rats (Schmidt et al., 2009). Therefore, it makes sense that LDTg GLP-1R
activation on inhibitory GABAergic neurons would mediate the suppressive effects of Ex4 on cocaine seeking. Indeed, data in Chapter 4 show that LDTg GLP-1Rs on GABA
neurons mediate the effects of both intra-LDTg Ex-4 and systemic Ex-4 to decrease
cocaine seeking.

There is an extreme lack of literature examining the role of GABA neurons in the LDTg to
control motivated behaviors. The existing literature on the role of the LDTg in reward and
addiction focus almost exclusively on LDTg cholinergic neurons and their ability to drive
cocaine-mediated behaviors (Kaneda, 2018). The current knowledge thus far on LDTg
GABA neurons influencing the mesolimbic reward system are that a subset of LDTg
projections to the VTA are presumed to be GABAergic (Omelchenko and Sesack, 2005)
and that stimulation of LDTg neurons results in a ~30% inhibition of putative dopaminergic
and GABAergic neurons in the VTA (Coimbra et al., 2017). However, one study has
assessed the role of LDTg GABA neurons in mediating the effects of the metabolic factor
amylin on decreasing food intake. Similar to GLP-1Rs, amylin receptors were not
expressed on cholinergic neurons but were expressed on GABAergic neurons in the
LDTg. Moreover, pharmacologically inhibiting GABA receptor transmission in the LDTg
blocked the effects amylin to decrease food intake and body weight (Reiner et al., 2017).
Overall, this study showed a role for LDTg GABA neurons in regulating feeding behaviors
and combined with the data in Chapter 4, suggests that GABA-mediated decreases in
motivated behavior may be a conserved mechanism across different metabolic hormones.
Additionally, it is possible that combination therapy of GLP-1 and amylin receptor agonists
may be more effective at attenuating cocaine-mediated behaviors and could serve as
better therapeutics for cocaine use disorder. Thus, future studies are needed to explore
this possibility. Overall, more studies are needed to characterize the cell types that
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express different metabolic factor receptors in nuclei that are known to regulate motivated
behaviors.

Future studies are needed to further delineate the types of GABAergic neurons in the
LDTg that mediate the effects of GLP-1R activation on cocaine seeking. In Chapter 4,
inhibition of LDTg GABAergic terminals that project to the VTA blocked the effects of Ex4 on cocaine seeking, showing for the first time the relevance of VTA-projecting LDTg
GABA neurons in cocaine-mediated behaviors. Additionally, LDTg GABAergic fibers were
visualized in the VTA and associated with dopamine neurons. Our hypothesis is that Ex4 decreases cocaine seeking by inducing LDTg GABA-mediated inhibition of dopamine
neurons. However, future studies are needed to directly assess if LDTg GABAergic
neurons make synaptic contacts onto VTA dopamine neurons and if these neurons
express GLP-1Rs. Furthermore, chemogenetic or optogenetic studies directly activating
GABAergic LDTg-to-VTA projections are needed to further show the significance of this
circuit in reducing reward-mediated behaviors independent of Ex-4. It is also possible that
GLP-1Rs are expressed on LDTg GABAergic interneurons that may decrease cocaine
seeking through local inhibition of cholinergic neurons. One study showed that chronic
cocaine exposure induced a noradrenergic-mediated reduction of inhibitory synaptic
transmission to LDTg cholinergic neurons which is thought to contribute to the
development of addiction-like behavior (Taoka et al., 2016). However, these findings did
not determine if the decrease in inhibitory transmission was from presynaptic GABAergic
terminals or local GABAergic interneurons. A previous study has examined the role of
LDTg GABAergic interneurons in the context of innate fear and showed differential roles
of parvalbumin vs somatostatin interneurons in promoting or decreasing olfactory cue–
induced innate fear responses (Yang et al., 2016). It would be an interesting hypothesis if
only a subset of LDTg interneurons mediate the effects of Ex-4 on cocaine seeking. Thus,
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further characterization of the types of LDTg GABAergic neurons that express GLP-1Rs
(i.e. projection neurons vs interneurons; parvalbumin vs somatostatin) are needed to
directly test each of these populations in reducing cocaine seeking behavior. Overall, the
role of the LDTg GABAergic system in motivated behaviors is largely unexplored and
future studies are needed to further delve into this exciting new avenue of research.

The Role of the Endogenous GLP-1 System in Cocaine Seeking
In Chapters 2, 3, and 4, the effects of cocaine self-administration and subsequent
abstinence on GLP-1R mRNA expression in the VTA, NAc and LDTg were examined.
Collectively, cocaine self-administration and extinction had no effect on endogenous VTA,
NAc or LDTg GLP-1R expression. However, Ex-4 binding has been shown to regulate
trafficking and surface expression of GLP-1Rs (Roed et al., 2014). Therefore, it is possible
that cocaine taking and subsequent abstinence may alter GLP-1R trafficking and/or
surface expression in nuclei known to regulate drug-taking and -seeking behaviors. Future
studies are required to further delineate the role of endogenous central GLP-1 signaling
in cocaine-mediated behaviors, including if cocaine affects GLP-1R trafficking and/or the
kinetics of ligand-mediated GLP-1R trafficking. Additionally, the intra-cellular signaling
pathways that are activated by GLP1 receptors to reduce cocaine taking and seeking are
not known. The GLP-1R is known to exhibit signal bias (Koole et al., 2013), and thus
chronic cocaine exposure may change the known downstream signaling cascades of the
GLP-1R such as PKA, PKC, MAPK and AKT (Holst, 2007; Hayes et al., 2011b; Rupprecht
et al., 2013). Thus, the exact signal transduction pathways activated following GLP-1R
activation after repeated cocaine exposure should be examined.

In Chapter 2, cocaine taking and subsequent abstinence were shown to dynamically
regulate mRNA expression of PPG (gene that encodes GLP-1) in the NTS. Specifically,
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cocaine self-administration increased endogenous PPG expression in the NTS. These
data are consistent with findings that support the hypothesis that increased central GLP1 signaling may serve as a ‘brake’ to reduce further cocaine consumption (Schmidt et al.,
2016). In contrast, PPG expression in the NTS was significantly decreased following
seven days of abstinence, a time point that coincides with robust drug-seeking behavior
(Anderson et al., 2008; Schmidt et al., 2015b). These results suggest that decreased
endogenous NTS PPG expression and presumed GLP-1 tone in the brain during
abstinence may facilitate cocaine craving and relapse. It is possible that that decreased
NTS PPG expression may result in a ‘hunger-like’ state that promotes cocaine seeking,
as hunger is a potent driver of reward seeking and motivated behaviors (Hsu et al., 2018;
Maniscalco and Rinaman, 2018). For example, previous studies have shown that chronic
food restriction results in enhanced burst firing of substantia nigra dopamine neurons,
augmentation of cocaine-induced burst firing, and persistence of increased burst firing
after animals are refed (Branch et al., 2013). Consistent with these neurophysiological
effects, food-restriction enhances cocaine-induced conditioned place preference
indicating an important modulatory role for energy balance in drug reward (Zheng et al.,
2012). Further evidence supporting the hypothesis that decreased NTS PPG expression
produces a hunger-like behavioral state that promotes/facilitates drug seeking comes from
a previous study showing that decreased PPG expression in the NTS produces
hyperphagia and exacerbates high fat diet-induced obesity (Barrera et al., 2011).

In Chapter 4, the effects of increased endogenous GLP-1 signaling to the LDTg on
cocaine-seeking behavior were examined. Chemogenetic activation of NTS-to-LDTg
circuits significantly attenuated cocaine seeking. These effects were shown to be
dependent on GLP-1 as pharmacologically inhibiting GLP-1Rs in the LDTg prevented the
ability of NTS-to-LDTg activation to decrease cocaine seeking. Although the data in
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Chapter 4 show the importance of NTS-to-LDTg projections in cocaine seeking, NTS GLP1-producing neurons project to many midbrain and forebrain areas relevant in addictionlike behaviors such as the VTA and NAc (Alhadeff et al., 2012). Thus, a circuit-wide
assessment of NTS GLP-1 projections and the functional relevance of each circuit to
regulate cocaine seeking should be examined. However, Chapter 4 demonstrated, for the
first time, that NTS GLP-1 circuits function to regulate cocaine-seeking behavior and
supported our hypothesis that the endogenous central GLP-1 system is a homeostatic
regulator of drug reward. Further support for this hypothesis comes from previous studies
that have selectively manipulated NTS GLP-1-producing neurons in mice and found that
these neurons have no significant effect on daily chow intake, body weight or glucose
tolerance (Holt et al., 2019). Only after bigger challenges to homeostasis were GLP-1producing neurons necessary for food intake control such as large meals and stressedinduced hypophagia (Holt et al., 2019). Cocaine exposure is well known to alter
homeostasis in both stress and reward responses, which along with our previous studies
and data in this dissertation, provides strong evidence that NTS GLP-1-producing neurons
play a critical role in regulating homeostatic responses to cocaine.

The NTS is comprised of heterogeneous cell populations (Rinaman, 2010; Buffalari and
Rinaman, 2014; Zheng et al., 2015), and in addition to GLP-1, investigating the exact role
of each of the different neuronal populations in cocaine-mediated behaviors should be
investigated. For example, the noradrenergic system is involved in cocaine-seeking
behaviors and noradrenergic neurons in the NTS are known to be the primary source of
noradrenaline in the NAc shell (Delfs et al., 1998; Zhang and Kosten, 2005; Brown et al.,
2011; Schroeder et al., 2013). Additionally, cocaine exposure has been shown to activate
noradrenergic neurons in the NTS (Buffalari and Rinaman, 2014). Thus, it would be
interesting to determine if NTS noradrenergic neurons function to promote or reduce
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cocaine-seeking behaviors and would highlight the brainstem as a whole as a critical
nucleus in the regulation of addiction-like behaviors.

An important characteristic of the endogenous GLP-1 system to consider is that NTS GLP1-producing neurons also co-express glutamate (Zheng et al., 2015). Thus, there are two
important future directions: 1) examine the relationship between GLP-1 and glutamate
release and 2) how GLP-1 may influence glutamatergic signaling in the mesolimbic reward
system. Electrophysiological studies should assess the time course of release of
glutamate vs. GLP-1 in GLP-1/glutamate-releasing neurons in the NTS and determine the
overall effects of this co-release on the neuronal activity of postsynaptic targets.
Additionally, previous studies in drug-naïve rats have shown that GLP-1R activation can
increase presynaptic glutamate signaling in the VTA and NAc (Mietlicki-Baase et al., 2013;
Mietlicki-Baase et al., 2014). However, the data in Chapter 2 showed that in cocaineexperienced rats GLP-1R activation had no effect on presynaptic mechanisms in the NAc
but increased postsynaptic intrinsic excitability in MSNs. These data provide strong
evidence that cocaine exposure changes how GLP-1R activation influences presynaptic
vs postsynaptic mechanisms. Future electrophysiological studies should assess how
GLP-1R activation effects presynaptic and postsynaptic glutamatergic signaling in the VTA
and LDTg in cocaine experienced rats. The glutamate system is well known to be altered
by chronic cocaine exposure and critical in promoting drug-seeking behaviors (Schmidt
and Pierce, 2010), thus characterizing the mechanisms by which GLP-1 influences this
system is an important future direction to investigate how the GLP-1R signaling reduces
cocaine-seeking behavior.

143

Circuitry mediating the effects of GLP-1R activation on cocaine seeking
The data in Chapter 2, 3, and 4 show the VTA, NAc and LDTg as important sites of action
for Ex-4 to attenuate cocaine seeking. Additionally, data in Chapter 4 show the importance
of NTS-to-LDTg GLP-1 projections and LDTg-to-VTA GABAergic projections in regulating
cocaine-seeking behavior. Furthermore, the data in Chapters 2 and 4 showed that
pharmacological inhibition of GLP-1Rs in the VTA or blocking LDTg GABAergic signaling
in the VTA completely reversed the effects of systemic Ex-4 on cocaine seeking. These
findings highlight the VTA as a critical nucleus in mediating the effects of GLP-1R
activation on cocaine-seeking behavior. Overall the data in this dissertation suggests that
GLP-1 release from the NTS activates GLP-1Rs on LDTg GABAergic neurons that project
to the VTA which may result in a decreased dopamine release in the NAc to reduce
cocaine seeking (Figure 5.1).

Much remains to be discovered about the central GLP-1 circuits activated by Ex-4 that
function to reduce cocaine-mediated behaviors. GLP-1Rs are expressed in many other
brain regions involved in motivated behaviors such as the lateral hypothalamus, lateral
septum, hippocampus, and amygdala (Goke et al., 1995; Merchenthaler et al., 1999;
Hayes and Schmidt, 2016). Therefore, research must be dedicated to assessing the
potential mechanisms of Ex-4 to act in these brain regions and others to control for
cocaine-mediated behaviors. For example, previous studies have shown that GLP-1Rs in
the ventral hippocampus play a role in food intake control and spatial learning (During et
al., 2003; Hsu et al., 2015). Thus, it is possible that hippocampal GLP-1Rs regulate
cocaine-associated contexts/memories that contribute to addiction-like behaviors. In
addition, due to the importance of the amygdala in regulating drug seeking elicited by
cocaine-associated cues (Berglind et al., 2006; Arguello et al., 2017), the role of GLP-1Rs
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in this nucleus should be investigated as Chapter 2 showed that systemic Ex-4
significantly decreased cue-induced cocaine seeking.

Clinical Potential of GLP-1R Agonists to Treat Cocaine Use Disorder
Although strong preclinical evidence indicates that various metabolic hormones regulate
addiction-like phenotypes in animal models (Engel and Jerlhag, 2014; Jerlhag, 2018;
Hernandez and Schmidt, 2019), the relationship between endogenous levels of metabolic
factors and substance abuse disorders in humans is not clear. A recent study investigated
the effects of cocaine on plasma levels of metabolic factors [ghrelin (total and acly-ghrelin),
amylin, GLP-1, insulin, leptin and peptide YY (PYY)] in human cocaine addicts (Bouhlal et
al., 2017). Acute cocaine (25 mg) significantly decreased serum GLP-1 and PYY
concentrations in cocaine users with trends towards decreased insulin and amylin
concentrations (Bouhlal et al., 2017). However, these effects were seen in a relatively
small sample size (n=8). Thus, future studies with larger sample sizes and healthy controls
are needed to further validate and determine the specificity of these effects in human
cocaine addicts. Additionally, future studies would benefit from correlating metabolic
hormone serum concentrations with drug craving to further support the hypothesis that
GLP-1, and possibly PYY, may serve as potential targets to treat cocaine craving and
relapse. Consistent with these effects, other clinical studies have shown that crack cocaine
use is associated with lower serum levels of leptin (Escobar et al., 2018). Preclinical
studies have also assessed the correlation between circulating levels of metabolic
hormones and cocaine taking and seeking in rats. Serum ghrelin levels have been shown
to be positively correlated with increased reinstatement of cocaine-seeking behavior
(Tessari et al., 2007). Interestingly, a recent study has shown that 14 days of cocaine selfadministration in rats was associated with increased ghrelin and GLP-1 plasma levels
while leptin and insulin levels were decreased (You et al., 2018). While these preclinical
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findings appear to contrast findings from human GLP-1 studies, they are consistent with
the working hypothesis that cocaine-induced increases in central GLP-1 signaling may
represent a homeostatic response to reduce further cocaine consumption (Schmidt et al.,
2016). Thus, larger clinical trials are needed to determine the exact effects of cocaine
taking and withdrawal on plasma GLP-1 levels and validate findings from preclinical
models quantifying drug-induced changes in circulating metabolic factors.

The mechanisms by which cocaine decreases GLP-1 serum concentrations in human
cocaine addicts and the functional significance of decreased circulating GLP-1 remains to
be determined. However, taken together with preclinical studies showing that increased
GLP-1R activation decreases cocaine taking- and seeking-behaviors, these results
suggest that decreased GLP-1 may promote cocaine use. This hypothesis is consistent
with data presented in Chapter 2 demonstrating that cocaine taking and subsequent
abstinence decreased PPG mRNA expression in the NTS, effects likely associated with
reduced GLP-1 signaling in the mesolimbic reward system, which may promote cocaine
seeking. It is also interesting to speculate that decreased serum GLP-1 levels observed in
human addicts may serve as a biomarker for cocaine use disorder and/or treatment
response (Bough et al., 2014). Moreover, there are several known single nucleotide
polymorphisms (SNPs) in the human GLP-1R (Beinborn et al., 2005). One SNP in
particular, the T149M variant, displayed reduced GLP-1 binding and cAMP signaling as
well as differences in the extent of reduced functional responses to various GLP-1R
ligands (Beinborn et al., 2005; Koole et al., 2011). It is possible that expression of the
T149M variant and/or decreased baseline circulating GLP-1 levels in human cocaine
addicts may serve as predictors of treatment response and/or relapse, as these
phenotypes are associated with decreased endogenous GLP-1 signaling in the body. If
increased endogenous GLP-1 signaling functions as a ‘brake’ to reduce cocaine
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consumption (Schmidt et al., 2016), cocaine users with the T149M variant and/or reduced
blood GLP-1 levels may be more susceptible to cocaine craving and relapse. This
hypothesis is supported by clinical studies showing that another GLP-1R SNP variant
(168Ser) is associated with alcohol use disorder and increased alcohol consumption in
humans with alcohol use disorder (Suchankova et al., 2015). Thus, it is provocative to
think that GLP-1R variants may be predictors of relapse and/or treatment response in
humans with cocaine use disorders.

From a translational perspective, previous studies and data shown in Chapters 2, 3, and
4 have identified systemic and intra-cranial doses of Ex-4 that attenuate cocaine taking
and seeking (Schmidt et al., 2016) and do not produce notable metabolic or adverse
effects associated with GLP-1R agonists in humans and rodents (Buse et al., 2009; Hayes
et al., 2011a; Kanoski et al., 2012). Since GLP-1 analogs are currently FDA-approved for
treating type II diabetes and obesity (Lovshin and Drucker, 2009; Shukla et al., 2015),
these preclinical findings suggest that GLP-1R agonists could be re-purposed at low doses
to treat cocaine use disorder. However, clinical studies are needed to validate the efficacy
of GLP-1R agonists in reducing cocaine craving-induced relapse and to determine if
circulating GLP-1 could be used as a biomarker for craving and/or treatment response.

There are currently many variations of GLP-1R agonists available on the market to treat
type II diabetes (Gentilella et al., 2019). The elimination half-lives of GLP-1R agonists
differ depending upon their chemical structures, that include, but are not limited to, specific
amino acid sequences that are resistant to DPP-IV degradation, as well as conjugations
(i.e., pegylation, acetylations, etc.) to the peptide sequence (Hayes et al., 2014). These
important pharmacokinetic properties are likely to influence brain penetrance, distribution
to nuclei known to regulate drug reinforcement, and the therapeutic utility of GLP-1R
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agonists for treating cocaine use disorder. Thus, it is important for future studies to directly
compare the efficacy of different GLP-1R agonists in attenuating drug-mediated
behaviors. It will also be important for future clinical trials to determine the efficacy of
recently developed oral formulations of GLP-1 analogs in treating cocaine use disorder as
the safety and pharmacokinetics of these medications may differ from GLP-1R agonists
administered subcutaneously (Granhall et al., 2018).

In addition to causing nausea and malaise in humans, GLP-1 analogs have also been
shown to reduce blood glucose concentrations and food intake in healthy subjects
(Edwards et al., 2001; Thazhath et al., 2016). However, GLP-1R agonists cause fewer
hypoglycemic events compared to insulin in patients with type II diabetes and no reports
of hypoglycemia or severe weight loss have been observed in healthy subjects (Edwards
et al., 2001; Diamant et al., 2010; Giorgino et al., 2015; Thazhath et al., 2016). Therefore,
it is unlikely that GLP-1R agonist treatment will result in glycemic dysregulation in
otherwise healthy patients (Holst, 2007; Drucker, 2018). Moreover, there is no scientific
evidence supporting development of pancreatic toxicity as initially suggested in patients
treated with GLP-1R agonists (Drucker, 2018). Thus, the benefit/risk profile of GLP-1R
agonists supports their clinical use and the translational relevance of preclinical drug
addiction studies.

Potential Efficacy of GLP-1R Agonists in Treating Other Substance Use Disorders
In addition to reducing cocaine-mediated behaviors, the efficacy of GLP-1R agonists in
regulating behaviors associated with other drugs of abuse has been investigated.
Specifically, GLP-1R agonists have been shown to reduce ethanol-, amphetamine-, and
nicotine-mediated behaviors in rodents (Egecioglu et al., 2013b, a; Egecioglu et al., 2013c;
Shirazi et al., 2013; Vallof et al., 2016; Tuesta et al., 2017). Systemic administration of Ex148

4 (2.4 µg/kg) decreased ethanol-induced CPP, the locomotor-activating effects of ethanol,
and ethanol self-administration (Egecioglu et al., 2013c). These behavioral responses
were associated with reduced ethanol-induced dopamine release in the striatum
(Egecioglu et al., 2013c). Other studies have replicated these findings and shown that
higher doses of Ex-4 (20 µg/kg) decreased ethanol-induced CPP in mice while 0.3 and
1.0 µg/kg Ex-4 decreased voluntary ethanol intake in rats (Shirazi et al., 2013). These
effects are mediated, in part, by central GLP-1Rs as infusions of Ex-4 directly into the VTA
were sufficient to reduce ethanol self-administration in rats (Shirazi et al., 2013).
Analogous findings have been shown in studies investigating the efficacy of GLP-1R
agonists in reducing amphetamine-mediated behaviors. Specifically, administration of Ex4 (2.4 µg/kg) attenuated amphetamine-induced locomotor activity, CPP and accumbal
dopamine release (Egecioglu et al., 2013b). With regard to nicotine use disorder, Ex-4
(2.4 µg/kg) pretreatment reduced nicotine-induced locomotion, sensitization, CPP and
accumbal dopamine release (Egecioglu et al., 2013a). Another study has expanded these
findings and shown that nicotine activates endogenous GLP-1-producing neurons in the
NTS (Tuesta et al., 2017). Moreover, systemic administration of Ex-4 (10 µg/kg) and the
DPP-IV inhibitor sitagliptin (10 mg/kg) decreased nicotine consumption in mice (Tuesta et
al., 2017). Consistent with these effects, GLP-1R knockout mice self-administer more
nicotine than wild-type controls (Tuesta et al., 2017). To investigate the endogenous
circuits mediating these behavioral responses, optogenetic studies revealed that GLP-1
excites medial habenula projections to the interpeduncular nucleus and that activation of
GLP-1Rs in this circuit is sufficient to attenuate nicotine consumption (Tuesta et al., 2017).
The authors conclude that GLP-1 acts as a ‘satiety sensor’ to limit nicotine intake by
stimulating the medial habenula to interpeduncular nucleus circuit to promote nicotine
avoidance before its aversive effects are encountered (Tuesta et al., 2017). One study
examined the ability of Ex-4 to regulate animal models of opioid use disorder and found
149

that systemic treatment of Ex-4 had no effects on self-administration of remifentanil in
mice (Bornebusch et al., 2019). However, more studies are needed to validate these
findings. Collectively, these studies indicate that systemic administration of a GLP-1R
agonist decreases the reinforcing and rewarding efficacy of multiple drugs of abuse and
that these effects are associated with decreased drug-evoked dopamine release in the
NAc. It is important to note, however, that relatively high doses of systemic GLP-1R
agonists were used in these studies and that these doses have been shown previously to
produce nausea/malaise and decrease food intake and body weight in rats (Hayes et al.,
2011a; Kanoski et al., 2012). Achieving behavioral selectivity through proper dosing of
GLP-1R agonists is critical for drawing firm conclusions about the efficacy of GLP-1R
agonists to reduce addiction-like phenotypes in preclinical models. These foundational
studies do, however, provide preliminary data supporting the potential efficacy of GLP-1R
agonists in treating alcohol, nicotine, and amphetamine use disorders.

Conclusion
Collectively, the data presented in this dissertation expands our understanding of the
central GLP-1 circuits that regulate cocaine-seeking behavior, as well as the cellular,
molecular and neurophysiological mechanisms by which GLP-1R agonists attenuate
cocaine seeking. This dissertation takes the critical first steps toward characterizing
central GLP-1 circuits and phenotyping GLP-1R-expressing cells in brain nuclei know to
regulate drug-taking and -seeking behaviors as well as their downstream targets.
Additionally, this dissertation shows that the endogenous central GLP-1 system,
particularly GLP-1-producing neurons in the NTS, are novel neurobiological mechanisms
that regulate cocaine seeking. In conclusion, the data in this dissertation supports clinical
studies examining the efficacy of GLP-1R agonists in treating cocaine use disorder, as
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well as the development of pharmacotherapies aimed at increasing GLP-1R signaling in
the brain to prevent cocaine craving-induced relapse.
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Figures

Figure 5.1 Circuitry influenced by the GLP-1 system to regulate cocaine-seeking
behavior
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